C LI NI C A L S T U D Y P R O T O C O L 
I D P- [ADDRESS_686457] u d y C o m pari n g t he 
Efficac y a n d Safet y of I D P -1 2 1 a n d I D P -1 2 1 Ve hicle L oti o n i n t he 
Treat me nt of Ac ne V ul garis  
De vel o p me nt  P h ase:  [ADDRESS_686458] u d y  Desi g n:  M ulti -ce nter, r a n d o mize d, d o u ble- bli n d, ve hicle - c o ntr olle d 
efficac y a n d s afet y st u d y  
D ate:  0 4 J u ne 2 0 1 5 
S p o ns or:  D o w P har mace utical Sci e nces, a Di visi o n of Valea nt 
P har mace uticals N ort h A merica,  L L C  
1 3 3 0 Re d w o o d Wa y  
Petal u ma, C A  9 4 9 5 4 
C O N FI D E N TI A L  
N ot hi n g herei n is t o be discl ose d wit h o ut pri or a p pr o v al of t he s p o ns or.  N C T #: N C T 0 2 9 6 5 4 5 6 
Pr ot oc ol  V 0l -1 2 1 A -3 0 2.  I D P -lll  Valca nt Researc h & De vel o p me nt  
 
Pr ot oc ol R e vie w a n d  A p pr o vals  
 
A P h as e 3, M ulti -C e nte r, R a n d o miz e d, D o u ble -Bli n d, V e hicle -C o ntr olle d, [ADDRESS_686459] u d y  C o m p a ri n g  t h e  Effic a c y  a n d  S afet y  of  I D P -1 2 1  a n d 
I D P -1 2 1 V e hicle L oti o n i n t h e T r e at m e nt of A c n e  V ul g a ris  
 
Re vie we d a n d a p pr o ve d:  
 
 
 
 
Valea nt P har mace uticals N ort h A merica, L L C   
 
; 2t, -::r  -;l, o,s - 
Date  
Valea nt P har mace uticals N ort h A merica, L L C  
 
 
 
 
 
 
Valea nt P har mace uticals N ort h A merica, L L C  -Z 6/ J W 1  ( // 1 J( -J 
Dat e  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Versi o n I, 0 4  J u ne  2 0 1 5  C O N FI D E N TI A L  
2 
Protocol V01 -121A -302, IDP -121 Valeant Research & Development  
Version 1, [ADDRESS_686460] 
[COMPANY_002]lle Park, NJ [ZIP_CODE]  
 
 

Pr ot oc ol V 0 1 -1 2 1 A -3 0 2, I D P -1 2 1  Valea nt Researc h & De vel o p me nt  
Versi o n 1, 0 4 J u ne 2 0 1 5  C O N FI D E N TI A L  
4  
  
I a gree:  Pri nci p al I n vesti g at or Pr ot oc ol A gree me nt P a ge  
• T o ass u me res p o nsi bilit y f or t he pr o per c o n d u ct of t his cli nical st u d y at t his site a n d t o 
c o n d uct t he st u d y i n c o m plia nce wit h t his pr ot oc ol, a n y f ut ure a me n d me nts, a n d wit h 
a n y ot h er st u d y c o n d uct pr oce d ur es pr o vi de d b y t he  s p o ns or.  
• T hat I a m a w are of, a n d will c o m pl y wit h, t he i nter nati o nall y  rec o g nize d c o de of G o o d 
Cli nical Practices ( G C P) a n d all ot her a p plica ble r e g ul at or y re q uir e me nts t o o btai n 
writte n a n d date d a p pr o v al fr o m t he I nstit uti o nal Re vie w B o ar d (I R B) or I n de pe n de nt 
Et hics C o m mittee (I E C) f or t he st u d y pr ot oc ol, writte n i nf or me d  c o nse nt, c o nse nt  f or m 
u p dates, s u bject -r ecr uit m e nt pr oce d ures ( e. g., a d v ertise me nts), a n d a n y ot her writte n 
i nf or mati o n t o be pr o vi de d t o t he s u bjects, bef ore i nitiati n g t his cli nical  st u d y.  
• N ot t o i m ple me nt a n y c h a n ges t o, or de viati o ns fr o m t he pr ot oc ol  wit h o ut pri or 
a gree m e nt fr o m t he s p o ns or a n d re vie w a n d d o c u me nte d a p pr o val fr o m t he I R B/I E C, 
e x ce pt t o eli mi nate a n i m me diate hazar d t o t he st u d y s u bjects, or w he n c ha n ge(s) 
i n v ol ves o nl y l o gistical or a d mi nistrati ve as pects of t he cli nical  st u d y.  
• T o per mit direct m o nit ori n g a n d a u diti n g b y t he s p o ns or or s p o ns or’s  re pres e ntati ves 
a n d i ns pecti o n b y t h e a p pr o priate r e g ulat or y  a ut h orit y(ies).  
• T hat I a m t h or o u g hl y fa miliar wit h t he a p pr o priate use of t he i n vesti gati o nal 
pr o d ucts(s), as d escri be d i n t his pr ot oc ol, a n d a n y ot her i nf or mati o n pr o vi d e d b y t h e 
s p o ns or or desi g nee, i n cl u di n g, b ut n ot li mite d t o, t he c urr e nt I n vesti gat or Br oc h ure or 
e q ui vale nt d oc u me nt a n d a p pr o ve d pr o d u ct la bel (if  a p plica ble).  
• T o pr o vi de s ufficie nt ti m e, a n d a d e q uate n u m bers of  q ualifie d staff a n d f acilities f or t he 
f oresee n d urati o n of t he cli nical st u d y t o c o n d uct t he st u d y pr o p erl y, et hicall y, a n d 
safel y.  
• T o e ns ure t hat all pers o ns assisti n g i n t his st u d y are a de q u atel y i nf or me d a b o ut t he 
pr ot oc ol, i n vesti gati o nal pr o d uct(s), a n d t h eir cli nical st u d y -relat e d d uties a n d 
f u ncti o ns.  
 
 
 
 
Pri nci pal I n v esti gat or ( pri nt na me)  
 
 
Pri nci pal  I n vesti gat or  (si g nat ur e)  Date  
Pr ot oc ol V 0 1 -1 2 1 A -3 0 2, I D P -1 2 1  Valea nt Researc h & De vel o p me nt  
Versi o n 1, 0 4 J u ne 2 0 1 5  C O N FI D E N TI A L  
5  
  
2 S y n o psis  
 
N a me of S p o ns or/ C o m p a n y: D o w P h ar m ace utic al Scie nc es, a di visi o n of Valea nt P har mace uticals 
N ort h A merica, L L C  
N a me of I n vesti g ati o n al Pr o d uct: I D P -1 2 1 L oti o n  
N a me of Acti ve I n gre die nts: Treti n oi n 0. 0 5 % l oti o n  
Title of St u d y: A P hase 3, M ulti -Ce nter, Ra n d o mize d, D o u ble -Bli n d, Ve hicle -C o ntr olle d, [ADDRESS_686461] u d y C o m pari n g t he Efficac y a n d Safet y of I D P -1 2 1 L oti o n a n d I D P -1 2 1 Ve hicle 
L oti o n i n t he Treat me nt of Ac ne V ul garis  
N u m ber of cli nic al ce nters: M ultice nter, a p pr o xi matel y 3 2 -5 0 i n vesti gati o nal ce nters i n N ort h A merica  
O bjecti ve:  
T he pri mar y o bj ecti ve of t his st u d y is t o c o m pare t he efficac y, safet y a n d t olera bilit y of I D P -1 2 1 L oti o n 
a n d ve hicle i n t he treat me nt of s u bj ects wit h ac ne v ul garis.  
M et h o d ol o g y:  
T his is a m ultice nter, ra n d o mi ze d, d o u ble -bli n d, parallel gr o u p, ve hicle -c o ntr olle d, [ADDRESS_686462] u d y t o 
e val uate relati ve c ha n ges i n i nfla m mat or y a n d n o n -i nfla m mat or y lesi o n c o u nts, as well as treat me nt 
s uccess usi n g a n E val uat or’s Gl o bal Se verit y Scale ( E G S S) i n s u bj ects wit h m o derate t o s e vere ac ne. 
S u bj ects m ust be at least 9 years of a ge a n d ol der wit h m o der ate t o se vere ac ne v ul garis (a s c ore of 3 or 4 
[ m o derate t o se vere] o n t he E G S S scale), prese nti n g wit h 2 0 -4 0 i nfla m mat or y facial lesi o ns ( pa p ules, 
p ust ules, a n d n o d ules), 2 0 -1 0 0 n o n -i nfla m mat or y fac ial lesi o ns ( o pe n a n d cl ose d c o me d o nes), a n d < 2 
facial  n o d ules.  
A p pr o xi matel y ei g ht h u n dre d ( 8 0 0) s u bj ects will be ra n d o mi ze d t o t he f oll o wi n g treat me nt gr o u ps:  
• 4 0 0 S u bj ects t o I D P -1 2 1 L oti o n, o nce -dail y  a p plicati o n  
• [ADDRESS_686463] a n ne d:  
A p pr o xi matel y 8 0 0 s u bj ects will be ra n d o mize d t o t he f oll o wi n g treat me nt gr o u ps:  
• 4 0 0 S u bj ects t o I D P -1 2 1 L oti o n, o nce -dail y  a p plicati o n  
• 4 0 0 S u bj ects t o I D P -1 2 1 Ve hicle L oti o n, o nce -dail y  a p plicati o n  
I ncl usi o n criteri a:  
1.  Male or fe male at least 9 years of a ge a n d ol der;  
2.  Writte n a n d ver bal i nf or me d c o nse nt m ust be o btai ne d. S u bj ects less t ha n a ge of c o nse nt m ust si g n a n 
asse nt f or t he st u d y a n d a pare nt or a le gal g uar dia n m ust si g n t he i nf or me d c o nse nt (if s u bj ect reac hes 
a ge o f c o nse nt d uri n g t he st u d y t he y s h o ul d be re -c o nse nte d at t he ne xt st u d y  visit);  
3.  S u bj ect  m ust  ha ve  a sc ore  of  3 ( m o derate)  or  4 (se vere)  o n  t he  E val uat or’s  Gl o bal  Se verit y  assess me nt 
at t he scree ni n g a n d baseli ne  visit;  
4.  S u bj ects wit h facial ac ne i nfla m mat or y lesi o n ( pa p ules, p ust ules, a n d n o d ules) c o u nt n o less t ha n 2 0 
b ut n o m ore t ha n  4 0;  
5.  S u bj ects wit h facial ac ne n o n -i nfla m mat or y lesi o n ( o pe n a n d cl ose d c o me d o nes) c o u nt n o less t ha n 2 0 
b ut n o m ore t ha n  1 0 0;  
6.  S u bj ects wit h t w o or fe wer facial  n o d ules;  
Protocol V01 -121A -302, IDP -121 Valeant Research & Development  
Version 1, [ADDRESS_686464] be willing to practice 
effective contraception for the duration of the study. (Effective contraception is defined as stabilized 
on oral contraceptive for at least 3 months, IUD, condom with spermicidal, diaphragm with 
spermicidal, implant, Nuvaring, injection, transdermal patch or abstinence.) Females on birth control pi[INVESTIGATOR_528808]. Those who have used birth control pi[INVESTIGATOR_220110]. Women who use birth control for acne control only should be  excluded.  
8. Pre-menses females and women of childbearing potential must have a negative urine pregnancy test at 
the screening and baseline visits;  
9. Subjects must be willing to comply with study instructions and return to the clinic for required visits. Subjects under the age of consent must be accompanied by [CONTACT_85168]/consent  signing;  
10. If a cleanser, moisturizer or sunscreen is needed during the study, Subjects must be willing to use only 
allowed cleansers, moisturizers, sunscree ns, or moisturizer/sunscreen combination products (see 
Appendix 2). If the subject wears makeup they must agree to use non -comedogenic  makeup.  
Exclusion criteria:  
1. Use of an investigational drug or device within 30 days of enrollment or participation in a research 
study concurrent with this  study;  
2. Any dermatological conditions on the face that could interfere with clinical evaluations such  as acne 
conglobata, acne fulminans, secondary acne, perioral dermatitis, clinically significant rosacea, gram - 
negative  folliculitis;  
3. Any underlying disease(s) or some other dermatological condition of the face that requires the use of 
interfering topi[INVESTIGATOR_500768];  
4. Subjects with a facial beard or mustache that could interfere with the study  assessments;  
5. Subjects with more than two (2) facial  nodules;  
6. Evidence or history of cos metic -related  acne;  
7. Subject has a history of experiencing significant burning or stinging when applying any facial treatment (eg, make -up, soap, masks, washes, sunscreens, etc) to their  face;  
8. Female  subjects  who are pregnant,  nursing mothers,  planning  a pregnancy  during  the course  of the 
trial, or become pregnant during the  study;  
9. Use of estrogens (eg, Depogen, Depo -Testadiol, Gynogen, Valergen, etc) for less than 12 weeks 
immediately preceding study entry; Subjects treated with estrogens [ADDRESS_686465] expects to change dose, drug 
or discontinue estrogen use during the  study;  
10. If female, subject has a history of hirsutism, polycystic ovarian disease or clinically significant 
menstrual  irregularities;  
11. Treatment of any type of cancer within the last 6  months;  
12. Subject uses medications and/or vitamins during the study which are reported to exacerbate acne 
(azothiaprim, haloperidol, Vitamin D, Vitamin B12, halogens such as iodides or bromides, lithium, 
systemic or mid -to super -high potency corticosteroids, phenytoin and phenobarbital); Daily vitamins 
at the prescribed amounts are acceptable;  
13. History of hypersensitivity or allergic reactions to any of the stu dy preparations as described in the 
Investigator’s Brochure, including known sensitivities to any dosage form of  tretinoin;  
14. Concomitant use of potentially irritating over -the-counter products that contain ingredients such as 
benzoyl peroxide, alpha- hydroxy  acid, salicylic acid, retinol or glycolic  acids;  
Protocol V01 -121A -302, IDP -121 Valeant Research & Development  
Version 1, [ADDRESS_686466] not undergone the specified washout period(s) for the following topi[INVESTIGATOR_500769]:  
Topi[INVESTIGATOR_500770] [ADDRESS_686467] requires topi[INVESTIGATOR_85129] (e.g., chest and/or back), the 
investigator may prescribe a product that does not contain tretinoin and must be noted in source 
documents and eCRF.  
16. Subjects that have not undergone the specified washout period(s) for the following systemic 
medications  or subjects  who require  the concurrent  use of any of the following  systemic  medications:  
Corti costeroids (including intramuscular injections)  
(inhaled  corticosteroids  allowed)  [ADDRESS_686468], dosage and mode of administration:  
Investigational Product: IDP -121 (tretinoin 0.05%) Lotion, applied topi[INVESTIGATOR_500771], once daily for [ADDRESS_686469]: IDP -121 Vehicle Lotion, applied topi[INVESTIGATOR_500771], once daily for 12 weeks.  
Duration of treatment:  
12 weeks for all subjects.  
Reference therapy, dosage and mode of administration:  
See comparator product above.  
Criteria for evaluation:  
Co-Primary efficacy:  
IDP-121 Lotion versus IDP -121 Vehicle Lotion  
Co-primary endpoints are:  
(1) Superiority in absolute change from Baseline to Week 12 in mean inflammatory lesion  counts  
(2) Superiority in absolute change from Baseline to Week 12 in mean non -inflammatory lesion counts, 
and, 
(3) Percent of subjects who achieve at least a two -grade reduction from baseline and are Clear - or Almost 
Clear at Week 12 in the Evaluator’s Global Severity  Score.  
Secondary efficacy variables:  
Mean percent change in inflammatory and non -inflammatory lesion counts from baseline as well as 
proportion of subjects with at least a two grade improvement in the Evaluator’s Global Severity Score 
from baselin e will be evaluated at Weeks 4, 8 and 12.  
Protocol V01 -121A -302, IDP -121 Valeant Research & Development  
Version 1, 04 June 2015  CONFIDENTIAL  
8  
 Efficacy Measurements:  
Lesion Counts  
At each visit the Evaluator will count the total number of inflammatory lesions (papules, pustules, and 
nodules) on the subject’s face. Nodules will be count ed separately but will be included in the total 
inflammatory lesion count. At baseline, eligible subjects may have no more than two nodules. Nodules 
will be included in the statistical analysis of inflammatory lesion counts. All inflammatory lesions will b e 
counted at the same time rather than counting papules and pustules separately. The Evaluator will also 
count the total number of non- inflammatory lesions (open and closed comedones). The same blinded 
evaluator should perform the lesion counts and EGSS ev aluations at all visits from baseline to week [ADDRESS_686470].  
Inflammatory lesions are defined as follows:  
Papule – a small, solid elevation less than [ADDRESS_686471] of the lesion is above the surface of the 
skin.  
Pustule – a small, circumscribed elevation less than 5 mm in diameter that contains yellow -white exudate. 
Nodule – a subcutaneous lesion greater than or equal to 5 mm in diameter  
Non-inflammatory lesions are defined as follows:  
Open comedones (black head) -  a lesion in which  the follicle opening is widely dilated with the contents 
protruding out onto the surface of the skin.  
Closed comedones (white head) – a lesion in which the follicle opening is closed, but the sebaceous gland 
is enlarged by [CONTACT_500799] u p, which in turn causes the skin around the follicle to thin 
and become elevated with a white appearance.  
Evaluator’s Global Severity Score (EGSS)  
At each visit the severity will be determined based on evaluator -blinded evaluations of the signs and 
symptoms of acne vulgaris. Evaluations will be scored on a scale of [ADDRESS_686472] clear  Rare non -inflammatory lesions present, with rare non -inflamed papules (papules must 
be resolving and may be hyperpi[INVESTIGATOR_49194], though not pi[INVESTIGATOR_8745] -red) 
2  
Mild  Some non -inflammatory lesions are present, with few inflammatory lesions  
(papules/pustules only; no nodulo -cystic lesions)  
 
3  
Moderate  Non-inflammatory lesions predominate, with multiple inflammatory lesions evident: 
several to many comedones and papules/pustules, and there may or may not be one  
nodulo -cystic lesion  
4  
Severe  Inflammatory lesions are more apparent, many comedones and papules/pustules, there  
may or may not be up to 2 nodulo -cystic lesions  
 
Cutaneous safety and tolerability will be evaluated by [CONTACT_500800] (scaling, erythema, itching, burning, and stinging) to be assessed at 
each study visit. Itching, burning and stinging (Cutaneous tolerability) will be reviewed with the subject at 
each study visit as an average over the perio d since the previous visit. Scaling and erythema (Cutaneous 
Safety) will be assessed by [CONTACT_500801].  
Cutaneous tolerability signs and symptoms that result in the subject requiring a concomitant therapy, interruption of treatment, or discontinuation from the study will be reported as an AE.  
At selected sites, standardized photography of the face will be performed.  
Pr ot oc ol V 0 1 -1 2 1 A -3 0 2, I D P -1 2 1  Valea nt Researc h & De vel o p me nt  
Versi o n 1, [ADDRESS_686473] atistic al met h o ds:  
All statistical pr ocessi n g will be perf or me d usi n g S A S ® versi o n 9. [ADDRESS_686474] ors of treat me nt a n d a nal ysis ce nter a n d t he res pecti ve B aseli ne lesi o n c o u nt as a 
c o variate. T he pri mar y met h o d of ha n dli n g missi n g efficac y data will be base d o n esti mati o n usi n g t he 
met h o d of Mar k o v C hai n M o nte Carl o ( M C M C) i m p utati o n. A d diti o nall y, a m o del -base d m ulti ple 
i m p utati o n pr ocess will be use d as a se nsiti vit y a nal ysis t o t he M C M C i m p utati o n. Fi nall y, t he a bs ol ute 
c ha n ge i n lesi o n c o u nt will be a nal yze d usi n g a re peate d meas ures A N C O V A f or lesi o n c o u nt data or a 
re peate d meas ures l o gistic re gressi o n m o del ( ge neralize d esti mati n g e q uati o ns) f or t he dic h ot o mize d 
E G S S.  
T he c o -pri mar y a nal ysis of t he dic h ot o mize d E G S S will be base d o n t he l o gistic re gressi o n test stratifie d 
b y a nal ysis ce nter.  
P o p ul ati o ns A n alyze d a n d Tre at me nt Gr o u ps:  
I nfla m mat or y a n d n o n -i nfla m mat or y lesi o n c o u nts will be rec or de d f or eac h S u bj ect at B aseli ne a n d at 
W ee ks 4, 8, a n d [ADDRESS_686475]. T he E G S S will be dic h ot o mize d i nt o “s uccess” a n d “fail ure” 
wit h a S u bj ect c o nsi dere d a s uccess if t he E val uat or’s Gl o bal Se verit y Sc ore at W ee k 4, 8, a n d [ADDRESS_686476] Clear.  
A n i nte nt -t o -treat (I T T) a nal ysis will be c o n d ucte d o n all st u d y s u bj ects. T he I T T p o p ulati o n will c o nsist 
of all ra n d o mize d s u bj ects w h o recei ve d st u d y me dicati o n.  
T he safet y p o p ulati o n will be c o m prise d of all ra n d o mize d s u bj ects w h o are pres u me d t o ha ve use d t he 
st u d y me dicati o n at least o nce a n d w h o pr o vi de at least o ne p ost -baseli ne e val uati o n. A per -pr ot oc ol ( P P) 
a na l ysis will als o be c o n d ucte d. S u bj ects will be eli gi ble f or t he P P a nal ysis if t he y c o m pl ete t he [ADDRESS_686477] u d y pr ot oc ol vi olati o ns (i.e., a n y S u bj ect or i n vesti gat or acti vit y t hat 
c o ul d ha ve p ossi bl y i nterfere d wit h t he t hera p e utic a d mi nistrati o n of t he treat me nt or t he precise 
e val uati o n of treat me nt efficac y). T he P P p o p ulati o n will i ncl u de s u bj ects i n t he I T T p o p ulati o n w h o d o 
n ot meet a n y of t he f oll o wi n g criteria:  
• Faile d a n y of t he i ncl usi o n/e xcl usi o n  criteria;  
• Ha ve ta ke n a n y i nterferi n g c o nc o mita nt  me dicati o ns;  
• Di d n ot atte n d t he W ee k [ADDRESS_686478];  
• Misse d b ot h t he wee k 4 a n d wee k 8  visits;  
• Ha ve n ot bee n c o m plia nt wit h t he d osi n g re gi me n (i.e. S u bj ects ma y n ot miss m ore t ha n 
fi ve  c o nsec uti ve  da ys  of  d osi n g  a n d m ust  ta ke  8 0 -1 2 0 %  of  e x pecte d  d oses.  T he  n u m ber  of 
e x pecte d d oses will be deter mi ne d f or eac h s u bj ects base d o n t he le n gt h of t heir 
partici pati o n i n t he  st u d y);  
• O ut of visit wi n d o w at t he [ADDRESS_686479] u d y pr ot oc ol 
vi olati o ns.  
A p pr o xi matel y ei g ht h u n dre d ( 8 0 0) s u bj ects will be ra n d o mi ze d t o t he f oll o wi n g treat me nt gr o u ps:  
• 4 0 0 S u bj ects t o I D P -1 2 1 L oti o n, o nce -dail y  a p plicati o n  
• 4 0 0 S u bj ects t o I D P -1 2 1 Ve hicle L oti o n, o nce -dail y  a p plicati o n  
Protocol V01 -121A -302, IDP -121 Valeant Research & Development  
Version 1, 04 June 2015  CONFIDENTIAL  
10  
  
Efficacy:  
Primary:  
Co-primary efficacy analyses of the absolute change in inflammatory and in non -inflammatory lesions 
will be conducted on the ITT population. The pre -specified time point will be Week 12. Descriptive 
statistics  will be presented by [CONTACT_500802]- inflammatory lesions as well 
as the absolute change in inflammatory and in non- inflammatory lesions. All of the testing relating to the 
analysis of inflammatory and non -inflammatory lesions  will use the methods introduced in Section 12.  
The co -primary analysis of the dichotomized EGSS (success being at least a [ADDRESS_686480] Clear) for the ITT population will be based on the logistic regression test 
stratif ied by [CONTACT_85229].  
Secondary:  
Mean percent change in inflammatory and non -inflammatory lesion counts from baseline, as well as 
proportion of subjects with at least a two grade improvement in the Evaluator’s Global Severity Score from baseline, will be evaluated at Weeks 4, 8 and 12.  
Safety Evaluation:  
All subjects who receive medication and provide at least one post -baseline evaluation will constitute the 
safety population.  
Safety will be evaluated by [CONTACT_220131] (AE s), Cutaneous Tolerability Evaluations. 
Cutaneous Safety Evaluation scores (erythema and scaling) and Tolerability (itching, burning, and stinging) will be presented with descriptive statistics at Baseline and at Weeks 4, 8, and 12 for each 
treatment group . Frequencies and percentages for each outcome category will be included in these 
statistics. Mean values will be presented graphically by [CONTACT_85223].  
Vital signs and an abbreviated physical exam will be conducted on all subjects at specified  visits. For 
females of child -bearing potential (FOCBP), urine pregnancy testing and serum pregnancy testing will 
occur at specified visits.  
All adverse events occurring during the study will be recorded and classified on the basis of MedDRA terminology. Descriptions of AEs will include the date of onset, the date the AE ended, the severity of the 
AE, the relationship to study medication, the action taken regarding study medication usage, the action taken regarding to treat the AE, and the out come.  
Adverse events will be summarized by [CONTACT_85225]. Each subject will be counted only once within a system organ class or a preferred term by [CONTACT_500803].  
Adverse events will be summarized by [CONTACT_220160]. Each 
subject will be counted only once within a system organ class or a preferred term by [CONTACT_220161].  
Comparisons among  treatment groups will be made by [CONTACT_220132] (classified into MedDRA terms) during the study. The Fisher’s Exact test will be used to compare the proportion of subjects in each treatment group who report any a dverse event at a significance 
level of 0.05. The specific system organ classes and preferred terms analyzed will be those that are reported by [CONTACT_220133].  
All information pertaining to AEs noted during the  study will be listed by [CONTACT_1130], detailing verbatim 
given by [CONTACT_093], preferred term, system organ class, start date, stop date, severity, actions taken, and drug relatedness. The AE onset will also be shown relative (in number of days) to the day of initial 
dose of the randomized study medication.  
Serious adverse events (SAEs) will be tabulated by [CONTACT_85177].  
In addition, a list of subjects who discontinued from the study and a list of subjects who experienced SAEs will also be provided.  
Protocol V01 -121A -302, IDP -121 Valeant Research & Development  
Version 1, [ADDRESS_686481] Self -Assessments  
An exploratory patient self assessment questionnaire and satisfaction survey will also be administered 
during the study.  
Subjects will be asked to complete three questionnaires during the study: th e Subject Self Assessment 
scale, the Patient Satisfaction Survey and the Acne -Specific Quality of Life Questionnaire. The 
Investigator assessments (EGSS, lesion counts) will be conducted independently of these subject self assessments. The EGSS should alwa ys be completed prior to the lesion counts. Inferential statistical 
analysis will not be performed on these questionnaires; the subjective responses will be compared between 
treatment groups for trends.  
 
This study will be performed in compliance with GCP including the archiving of essential study 
documents. This protocol follows guidelines outlined by [CONTACT_8639] 
(ICH). All data furnished to the investigator and his/her staff, and all data obtained thro ugh this stud, will 
be regarded as confidential and proprietary in nature and will not be disclosed to any third party, except 
for the [LOCATION_002] Food and Drug Administration or other regulatory body, without written consent 
from the sponsor.  
Pr ot oc ol V 0 1 -1 2 1 A -3 0 2, I D P -1 2 1  Valea nt Researc h & De vel o p me nt  
Versi o n 1, 0 4 J u ne 2 0 1 5  C O N FI D E N TI A L  
1 2   
  
3 T a ble of  C o nte nts  
1 TI T L E  P A G E  ................................ ................................ ................................ ........... 1 
2 S Y N O P SI S  ................................ ................................ ................................ ............... 5# 
3 T A B L E  O F  C O N T E N T S  ................................ ................................ ....................... 1 2 # 
4 LI S T O F A B B R E VI A TI O N S A N D D E FI NI TI O N S  O F  T E R M S  ........................ 1 5 # 
5 I N T R O D U C TI O N  ................................ ................................ ................................ .1 6 # 
6 S T U D Y O BJ E C TI V E S  A N D  P U R P O S E  ................................ .............................  1 7 # 
7 I N V E S TI G A TI O N A L  P L A N  ................................ ................................ ...............  1 7 # 
7. [ADDRESS_686482] u d y Desi g n a n d  Pla n:  Descri pti o n  ................................ .............  1 7 # 
8 S E L E C TI O N A N D WI T H D R A W A L  O F  S U BJ E C T S  ................................ ........  2 1 # 
8. [ADDRESS_686483]  I n cl usi o n  Criteri a ................................ ................................ ..........  2 1 # 
8. [ADDRESS_686484]  E x cl usi o n  Criteria  ................................ ................................ ........  2 2 # 
8. [ADDRESS_686485]  Wit h dra wal  Criteria  ................................ ................................ ....... 2 3 # 
9 T R E A T M E N T  P L A N  ................................ ................................ ............................ 2 5 # 
9. 1  Met h o ds of Assi g ni n g S u bjects t o  Treat me nt  Gr o u ps  ............................... 2 5 # 
9. 2  Ra n d o mizati o n  a n d Bli n di n g  ................................ ................................ ..... 2 5 # 
9. 3  U n -bli n di n g  ................................ ................................ ...............................  2 5 # 
9. 4  Pri or a n d Pr o hi bite d C o nc o mita nt Me dicati o n  or  T hera p y  ........................ 2 6 # 
9. 5  Treat me nt  C o m plia nce  ................................ ................................ ............... 2 7 # 
9. 6  Pr ot oc ol De viati o ns  a n d  Vi olati o ns  ................................ ..........................  2 7 # 
1 0  S T U D Y D R U G M A T E RI A L S  A N D  M A N A G E M E N T  ................................ ......  2 8 # 
1 0. 1  I D P -1 2 1 L oti o n a n d I D P -1 2 1  Ve hicle  L oti o n  ................................ ...........  2 8 # 
1 0. 1. 1  Pac ka gi n g  a n d La b eli n g  ................................ ................................ .2 8 # 
[ADDRESS_686486] u g  ...........................  2 9 # 
1 0. 1. 3  A d mi nistrati o n  ................................ ................................ ..............  2 9 # 
[ADDRESS_686487] u g  Acc o u nta bilit y  ................................ ................................ ........ 3 0 # 
1 1  S T U D Y P R O C E D U R E S  A N D  E V A L U A TI O N S ................................ ................  3 1 # 
1 1. 1  Sc he d ule of E val u ati o ns  a n d  Pr oce d ur es  ................................ ..................  3 1 # 
1 1. 1. 1  Visit 1:  Scree ni n g  Visit  ................................ ................................ . 3 1 # 
1 1. 1. 2  Visit 2: Baseli ne Visit  ( D a y  0)  ................................ ....................... 3 2 # 
1 1. 1. 3  Visit 3 a n d 4: Wee k 4 ( Da y 2 8 ± 3 Da ys) a n d Wee k 8 ( Da y  5 6  
± 3  Da ys)  Visits ................................ ................................ .............  3 3 # 
1 1. 1. 4  Visit 5: Wee k 1 2 ( Da y 8 4  -3/ + 5  Da ys)  Visit  –  E n d  of  St u d y 
Visit  ................................ ................................ ...............................  3 4 # 
1 1. 2  E val uati o n of  Efficac y  ................................ ................................ ............... 3 4 # 
1 1. 2. 1  E val uat or’s Gl o bal Se v erit y  Sc or e ( E G S S) ................................ .... 3 5 # 
Pr ot oc ol V 0 1 -1 2 1 A -3 0 2, I D P -1 2 1  Valea nt Researc h & De vel o p me nt  
Versi o n 1, 0 4 J u ne 2 0 1 5  C O N FI D E N TI A L  
1 3   
 1 1. 2. 2  Lesi o n  C o u nts  ................................ ................................ ................ 3 5 # 
1 1. 2. 3  Ot her  Ass ess me nts  ................................ ................................ ........  3 6 # 
1 1. 3  E val uati o n of  Safet y  ................................ ................................ ................... 3 6 # 
1 1. 3. 1  C uta ne o us  Safet y  E val u ati o ns  ................................ ........................ 3 6 # 
1 1. 3. 2  T olera bilit y  E val uati o ns  ................................ ................................ . 3 7 # 
[ADDRESS_686488] or y a n d A b bre viate d  P h ysical  E x a mi nati o n  ..............  3 7 # 
1 1. 3. 4  Pre g n a nc y  T ests  ................................ ................................ ............. 3 8 # 
1 1. 4  A d verse  E ve nts  ................................ ................................ .........................  3 8 # 
1 1. 4. 1  Defi niti o n of  A d vers e  E v e nt  ................................ .........................  3 8 # 
1 1. 4. 2  D oc u me nti n g  A d vers e  E x perie nces  ................................ ............... 3 8 # 
1 1. 4. 3  Seri o us  A d vers e  E ve nts  ................................ ................................  3 9 # 
1 1. 4. 4  Assess me nt  of  Se verit y  ................................ ................................ . 4 0 # 
1 1. 4. 5  Assess me nt  of  Ca usalit y  ................................ ................................ 4 0 # 
1 1. 4. 6  Re p orti n g of Seri o us  A d verse  E ve nts  ................................ ............ 4 0 # 
1 1. 4. 7  E x pe dite d Seri o us A d verse  E ve nt  Re p orts ................................ ..... 4 1 # 
1 1. 4. 8  Pre g n a nc y  ................................ ................................ ......................  4 2 # 
1 2  S T A TI S TI C S  ................................ ................................ ................................ ........  4 3 # 
1 2. 1  Assess me nt  of  Efficac y  ................................ ................................ .............. 4 3 # 
1 2. 1. 1  Pri mar y  Effi cac y  ................................ ................................ ...........  4 4 # 
1 2. 1. 2  Sec o n dar y  Efficac y  ................................ ................................ .......  4 4 # 
[ADDRESS_686489] of S u peri orit y f or Lesi o n  C o u nt  Varia bles  ............................  4 4 # 
1 2. 1. 4  Statistical H y p ot hesis Testi n g a n d C o ntr ol  of M ulti plicit y  ........... 4 5 # 
1 2. 1. 5  Descri pti ve  Statistics  ................................ ................................ .....  4 6 # 
1 2. 1. 6  P o oli n g  A nal ysis  ................................ ................................ ...........  4 6 # 
1 2. 1. 7  Missi n g Efficac y  Dat a  I m p utati o ns  ................................ ................ 4 8 # 
1 2. 1. 8  Se nsiti vit y  Efficac y  A n al ys es ................................ ........................  4 9 # 
1 2. 1. 9  S u b gr o u p  A nal ys es  ................................ ................................ .......  5 0 # 
1 2. 2  Assess me nt  of  Safet y  ................................ ................................ ................. 5 0 # 
1 2. 2. 1  A d verse  E ve nts  ................................ ................................ .............  5 1 # 
1 2. 2. 2  Vital  Si g n  Meas ur e me nts  ................................ ............................... 5 1 # 
1 2. 2. 3  C o nc o mita nt  Me dicati o ns  ................................ .............................  5 2 # 
[ADDRESS_686490]  Self -Assess me nts  ................................ .............................  5 2 # 
[ADDRESS_686491]  Dis p ositi o n  ................................ ................................ .................... 5 2 # 
1 2. 4  De m o gra p hics a n d  Baseli ne  C haracteristics  ................................ .............. 5 2 # 
1 2. 5  Pr ot oc ol  De viati o ns  ................................ ................................ ...................  5 2 # 
1 2. 6  C o m plia nce  ................................ ................................ ................................ 5 2 # 
1 2. 7  I nteri m  A nal yses  ................................ ................................ .......................  5 2 # 
1 2. 8  A d diti o nal  Statistical  C o nsi derati o ns  ................................ ........................  5 2 # 
1 2. 8. 1  A nal ysis  P o p ulati o ns  ................................ ................................ .....  5 2 # 
Pr ot oc ol V 0 1 -1 2 1 A -3 0 2, I D P -1 2 1  Valea nt Researc h & De vel o p me nt  
Versi o n 1, 0 4 J u ne 2 0 1 5  C O N FI D E N TI A L  
1 4   
 1 2. 8. 2  Sa m ple  Size  Deter mi nati o n.  ................................ ..........................  5 3 # 
1 2. 8. 3  Ha n dli n g of  Missi n g  Dat a  ................................ .............................. 5 4 # 
1 2. 8. 4  M ultice nter  Iss ues  ................................ ................................ .........  5 4 # 
1 2. 8. 5  M ulti plicit y  Iss ues  ................................ ................................ .......... 5 4 # 
1 2. 8. 6  Wi n d o wi n g  R ules.  ................................ ................................ .......... 5 5 # 
1 3  Q U A LI T Y C O N T R O L A N D  Q U A LI T Y  A S S U R A N C E  ................................ ..... 5 5 # 
[ADDRESS_686492] u d y  M o nit ori n g  ................................ ................................ ....................... 5 5 # 
1 3. 2  A u dits  a n d I ns pecti o ns  ................................ ................................ ............... 5 5 # 
1 3. 3  Data  Q u alit y  Ass ura nce  ................................ ................................ ............. 5 6 # 
1 4  E T HI C S A N D  A D MI NI S T R A TI V E I S S U E S  ................................ .....................  5 6 # 
[ADDRESS_686493] u d y  ................................ ................................ ..... 5 6 # 
1 4. 2  Et hics Re vie w  ................................ ................................ ............................ 5 6 # 
1 4. 3  Writte n  I nf or me d  C o nse nt  ................................ ................................ ......... 5 6 # 
[ADDRESS_686494]  Data  Pr otecti o n  ................................ ................................ .............  5 7 # 
1 4. 5  Data  M o nit ori n g  C o m mittee  ................................ ................................ ...... 5 7 # 
1 4. 6  Fi na ncial  Discl os ur e  ................................ ................................ ................... 5 7 # 
1 4. 7  I n v esti gat or  O bli gati o ns  ................................ ................................ ............  5 8 # 
1 4. 8  C ha n ges t o  t he  Pr ot oc ol  ................................ ................................ ............. 5 8 # 
1 4. 9  C o nfi de ntialit y/ P u blicati o n of  t he  St u d y ................................ .................... 5 8 # 
1 5  D A T A H A N D LI N G A N D  R E C O R D  K E E PI N G  ................................ ................. 5 8 # 
1 5. 1  I ns p ecti o n  of  Rec or ds  ................................ ................................ ...............  5 8 # 
1 5. 2  Rete nti o n  of  Rec or ds  ................................ ................................ .................. 5 9 # 
1 6  R E F E R E N C E S  ................................ ................................ ................................ ...... 6 0 # 
1 7  A P P E N DI C E S  ................................ ................................ ................................ ....... 6 1 # 
[ADDRESS_686495]  I nstr u cti o n  S heet  ................................ ................................ ........... 6 1 # 
[ADDRESS_686496] urizers a n d S u nscree n  Use  G ui deli nes  ...........................  6 3 # 
[ADDRESS_686497] Self Assess me nt  Sc ori n g  Scal e  ................................ ..................... 6 4 # 
1 7. 4  Patie nt Satisfacti o n  S ur ve y  ( P S S)  ................................ .............................. 6 5 # 
1 7. 5  Ac ne -S pecific Q u alit y of Lif e  Q uesti o n nair e  ( Ac n e -Q o L)  ........................ 6 6 # 
 
LI S T O F T A B L E S  
Ta ble  1.  St u d y Desi g n a n d Sc h e d ule  of  Assess me nts  ................................ ................... [ADDRESS_686498] u g  S u bsta nces  I d e ntificati o n … ................................ ................................ ..  [ADDRESS_686499]  I d e ntificati o n …  ................................ ................................ ........  2 8  
Ta ble  4.  E val uat or’s Gl o bal  Se verit y  S c ore …  ................................ .............................  3 5  
Protocol V01 -121A -302, IDP -121 Valeant Research & Development  
Version 1, [ADDRESS_686500] Research  Organization  
cGCP  Current Good Clinical Pratice  
EGSS  Evaluator’s Global Severity  Score  
ET Early  termination  
FDA 
FOCBP [LOCATION_002] Food and Drug Administration 
Female of Childbearing Potential 
g Gram  
GCP  Good Clinical Practice  
IATL  Investigator’s Assessment of Total  Lesions  
ICH International Conference on  Harmonization  
IEC Independent Ethics  Committee  
IRB Institutional Review  Board  
ITT Intent -to-treat 
IWRS  Interactive Web Response System  
LOCF  Last observation carried  forward  
MedDRA  Medical Dictionary for Regulatory  Affairs  
mL Milliliter  
OTC  Over -the-counter  
PP Per protocol  
PSS Patient Satisfaction  Survey  
QoL Quality of  Life 
SAE  Serious adverse event  
SSA Subject Self Assessment  
UPT  Urine Pregnancy  Test 
WHO World Health  Organization  
 
In this protocol, “sponsor duties” refer to responsibilities that will be performed by [CONTACT_103], the sponsor’s designee, or the sponsor’s designated contract research organization. 
In this protocol, “investigator” refers to the principal investigator [INVESTIGATOR_022]/her designee, who is responsible for performing the study procedures and assessments.  
Pr ot oc ol V 0 1 -1 2 1 A -3 0 2, I D P -1 2 1  Valea nt Researc h & De vel o p me nt  
Versi o n 1, [ADDRESS_686501] o ge n pr o d ucti o n occ urri n g i n a d olesce n ce [ 1]. T he disease is m ost 
pre vale nt a m o n gst tee na gers, b ut it d oes occ ur l ater i n life, partic ularl y i n t h e t hir d a n d f o urt h 
deca d e. T he pat h o ge nesis is c o m ple x a n d i n v ol ves a n a n dr o ge n -sti m ulate d i ncreas e i n se b u m 
pr o d ucti o n, ass ociate d wit h f ollic ular h y p er kerati nizati o n a n d o bstr ucti o n of t he se bace o us 
f ollicles. T his res ults i n a b n or mal des q ua mati o n of t he f ollic ular e pit heli u m, a n d is ass ociate d 
wit h bacterial pr olif erati o n (es peci all y Pr o pi o ni b a cteri u m ac nes ( P. ac nes) ) a n d c hr o nic 
i nfla m mati o n ass ociate d wit h ac ne. T hes e c h a n ges i n ac ne s u bjects r es ult i n e nlar ge d 
se bace o us gl a n ds; o bstr ucti o n of t he f ollic ular ca n al wit h ass ociate d se b u m rete nti o n a n d 
diste nti o n of t he f ollicle b y ti g htl y p ac ke d h or n y cells t hat lea d t o t he f or mati o n cli nical 
i nfla m mat or y l esi o ns i ncl u di n g s u perficial p ust ules s uc h as c o me d o n es ( p o p ularl y k n o w n as 
“ blac k hea ds” or “ w hite h ea ds”); a n d m ore dee pl y l ocate d pa p ules, n o d ules a n d c ysts [ 1]. T he 
areas m ost affecte d b y t h e disease i ncl u d e t he pil ose bace o us f ollicles of t he hea d a n d u p p er 
tr u n k, w here t h e se bace o us gla n ds are p artic ularl y acti v e [ 2].  
C urre ntl y, t hera p e utic treat me nt of ac n e is directe d a gai nst [ADDRESS_686502] t he c ol o nizati o n of bacteria ( P. a c nes ) i n f ollicles has 
ma de use of a nti -i nfecti v es s uc h as t o pi[INVESTIGATOR_500772] o yl per o xi de ( 2. 5 % -1 0 %), cli n da m yci n, a n d 
er yt hr o m yci n a n d s yste mic tetrac ycli n es; h o we ver, k n o w n disa d va nta ges t o t his treat me nt 
m o dalit y i ncl u de irritati o n a n d li mite d use d ue t o pat h o ge n resista nce [ 2-5]. Effecti ve 
treat me nt direct e d t o war ds i n hi biti n g se bace o us gla n d acti vit y h as i ncl u de d oral 
c ortic oster oi ds, s pir o n olact o ne, a n d is otr eti n oi n i n a d diti o n t o a nti -a n dr o ge ns  
(e g, c y pr ot er o ne acet ate). K n o w n disa d va nta ges t o t his treat me nt m o dalit y i ncl u de bei n g 
li mite d t o use i n fe males (a nti -a n dr o ge ns), a n d li mite d t o s h ort ter m use f or safet y ( or al 
c ortic oster oi ds). Fi nall y, effecti ve tr eat me nt direct e d a gai nst i ntraf ollic ular 
h y perc or nifi cati o n has m a de use of reti n oi ds s uc h as oral is otreti n oi n a n d t o pi[INVESTIGATOR_500773] n oi n or 
is otreti n oi n t o re g ulate t h e i ntraf ollic ular k erati nizati o n pr ocess, i n hi biti n g f ollic ular 
h y per ker ati nizati o n a n d f oll ic ular o bstr ucti o n [ 6]. I n ge ner al, t he k n o w n us ef ul ness of or al 
reti n oi ds (ie, oral is otreti n oi n) is li mite d b y t heir si de eff ects, w hic h r a n ge fr o m relati vel y 
mi n or effects (e g, dr y n ess of m uc osa a n d s ki n, s ki n irritati o n, a n d s ki n scali n g) t o maj or 
t o xi cit y s y n dr o mes (r e versi ble hair l oss, b o ne t o xicit y a n d t erat o ge ni cit y) a n d ma y i ncl u d e 
var yi n g d e gr ees of s y m pt o ms ass ociate d wit h h y p er vita mi n osis A s y n dr o m e [ 2, 7, 8].  
Li ke wis e, t he efficac y of t o pi[INVESTIGATOR_332063] n oi ds s uc h as treti n oi n or is otreti n oi n ma y b e li mite d b y 
t he k n o w n si de effects, w hic h i ncl u de si g nifi ca nt er yt he m a, dr y ness, p eeli n g, scali n g, a n d 
irritati o n [ 9].  
Pr ot oc ol V 0 1 -1 2 1 A -3 0 2, I D P -1 2 1  Valea nt Researc h & De vel o p me nt  
Versi o n 1, 0 4 J u ne 2 0 1 5  C O N FI D E N TI A L  
1 7   
 Treti n oi n (all -tra ns -reti n oic -aci d) is a m e m ber of t he reti n oi d fa mil y of c o m p o u n ds a n d is a 
meta b olite of Vita mi n A t hat occ urs nat ur all y i n a ni mal a n d h u ma n tiss ues. W hile oral 
reti n oi ds (e g, is otreti n oi n) are reser ve d f or treat me nt of se vere n o d ular ac ne or se ver e ac n e 
resista nt t o oral a nti bi otics, t o pi[INVESTIGATOR_332063] n oi ds (e g, tr eti n oi n or is otreti n oi n) a p plie d dail y are 
use d t o i n hi bit t he f or mati o n of c o me d o nes a n d us uall y cl ear e ve n se v ere c o me d o nal ac n e 
wit hi n a fe w m o nt hs [ 6]. T o pi[INVESTIGATOR_2855] f or mati o ns of tr eti n oi n ha ve bee n use d t o treat ac n e i n t he 
U nite d States ( U S) a n d t he E ur o pea n U ni o n f or m ore t ha n [ADDRESS_686503]. Treti n oi n acti vates 
3 me m bers of t he r eti n oi d aci d ( R A R) n uclear r ece pt ors ( R A R α, R A R β, a n d R A Rγ) w hic h 
act t o m o dif y ge ne e x pressi o n, s u bse q ue nt pr otei n s y nt hesis, a n d e pit helial cell gr o wt h a n d 
differe ntiati o n; h o we v er, it has n ot bee n esta blis h e d w het her t he cli nical eff ects of treti n oi n 
are me diat e d t hr o u g h acti vati o n of reti n oic aci d rece pt ors, ot her mec ha nis ms, or b ot h.  
Alt h o u g h t he e x act m o de of acti o n of treti n oi n is u n k n o w n, c urr e nt e vi de nce s u g gests t hat 
t o pi[INVESTIGATOR_500773] n oi n decreases c o hesi ve ness of f ollic ular e pit helial cells wit h decreas e d 
micr oc o me d o f or m ati o n. A d diti o nall y, treti n oi n sti m ulates mit otic acti vit y a n d i ncreas e d 
t ur n o ver of f ollic ular e pit helial cells ca usi n g e xtr usi o n of t he c o me d o nes.  
I D P -1 2 1 is a l oti o n c o ntai ni n g 0. 0 5 % t reti n oi n f or t he t o pi[INVESTIGATOR_500774]. T his 
pr o p ose d pr o d uct is t he first l oti o n f or m ulati o n de vel o pe d f or tr eti n oi n a n d will be e val uate d 
f or effecti ve n ess i n treati n g ac ne v ul garis.  
 
[ADDRESS_686504] u d y is t o e val uat e t he efficac y, s afet y a n d t olera bilit y of a o nce -dail y 
t o pi[INVESTIGATOR_2855] a p plicati o n of I D P -1 2 1 L oti o n c o m par e d t o its ve hicle (I D P -1 2 1 V e hicle L oti o n) i n 
s u bjects wit h m o derate t o se vere ac n e v ul garis (a sc ore of 3 or 4 [ m o derate t o se vere] o n t he 
E G S S scale).  
 
[ADDRESS_686505] a n:  Descri pti o n  
T his is a m ultice nter, ra n d o mize d, d o u ble -bli n d, parallel -gr o u p st u d y d esi g ne d t o assess t he 
safet y, efficac y a n d t oler a bilit y of I D P -[ADDRESS_686506] 9 years of a ge a n d ol der a n d ha ve a cli nical 
dia g n osis of m o derate t o se vere ac n e v ul garis (a s c ore of 3 or 4 [ m o der ate t o se vere] o n t he 
E G S S scale).  
A p pr o xi matel y 8 0 0 s u bj ects will be e nr olle d i nt o t his s t u d y a n d r a n d o mize d i nt o o ne ( 1) of 
t w o ( 2) treat me nt gr o u ps: 4 0 0 s u bjects i n t he I D P -1 2 1 L oti o n, o nce d ail y a p plicati o n gr o u p,  
Protocol V01 -121A -302, IDP -121 Valeant Research & Development  
Version 1, 04 June 2015  CONFIDENTIAL  
18  
 and 400 subjects in the IDP -121 Lotion Vehicle, once daily application group. Subjects will 
be enrolled at a minimum of 32 and maximum of 50 independent study centers. The duration 
of treatment will be 12 weeks. Subjects will be evaluated at Screening, Baseline and at subsequent follow -up visits (Weeks 4, 8, and 12).  
An interactive web based response system (IWRS) wil l be employed to facilitate 
randomization of study patients. Treatment assignments and study drug kit numbers will be generated centrally by [CONTACT_246011]. At each clinical site, subject numbers will be assigned consecutively at the screening visit starti ng with 001.  
The assigned study drug will be applied topi[INVESTIGATOR_85130] [ADDRESS_686507] -baseline study visits 
(Weeks 4, 8 and 12) the subjec ts will be asked to return their used tubes of study drug and 
will be dispensed new tubes of study drug (only Weeks 4 and 8; Week 12 will be final visit). 
During the study, each subject will only be permitted to use approved non- medicated 
cleansers, moistu rizers and  sunscreens.  
Subjects will be asked to complete three questionnaires during the study: the Subject Self 
Assessment scale (SSA, Appendix 17.3), the Patient Satisfaction Survey (PSS, Appendix 17.4) and the Acne -Specific Quality of Life Questionnair e (Acne- QoL, Appendix 17.5). The 
Investigator assessments (EGSS, lesion counts) will be conducted independently of these subject self assessments. The EGSS should be completed prior to the lesion counts. Subjects will assess the severity of their acne at t he baseline visit and at Weeks 2 (at home), 4, 8, and 
[ADDRESS_686508] at the baseline visit with instructions to complete it two weeks later and return it the Week 4 visit; sites should call th e Subject at Week 2 to remind them to complete the SSA. Subjects will 
complete the PSS related to prior therapy at baseline, and at Week 12 will complete the PSS related to current study medication. The Acne- QOL will be completed at baseline and Week  
12. Inferential statistical analysis will not be performed on these questionnaires; the 
subjective responses will be compared between treatment groups for trends. 
Information on reported and observed adverse events (AEs) will be obtained at each visit. An 
abbreviated physical examination will be performed at Baseline and Week 12 (end of treatment, final visit) for all subjects.  
For all female subjects of childbearing potential, urine pregnancy testing will be performed at Screening and confirmed at Baseline with a urine pregnancy test prior to randomization, and at Weeks 4, 8 and 12. Serum pregnancy tests will also be conducted at Screening and Week 12. 
Protocol V01 -121A -302, IDP -121 Valeant Research & Development  
Version 1, 04 June 2015  CONFIDENTIAL  
19  
 Subjects who terminate study participation early will be asked to complete all Week 12 
assessments, as appropriate. Subjects who discontinue from the study during the treatment 
period will not be replaced. 
 
 Protocol  V01-121A -302, IDP-121 Valeant Research &  Development  
 
Table  1. Study Design and Schedule of  Assessments  
 
 
 
PROCEDU RES  VISIT 11 
Screening 
Visit  VISIT 22 
Baseline 
Day 0  VISIT 32 
Week 4  
(Day 28 ±3 days)  VISIT 42 
Week 8  
(Day 56 ± 3 days)  VISIT 52,3 
Week  12 
(Day 84 -3/+5 days)  
Informed consent/Assent  X     
Obtain Subject Number from IWRS  X     
Demographics  X     
Medical history  X X    
Inclusion/Exclusion criteria  X X    
Previous therapi[INVESTIGATOR_014]  X     
PSS & Acne -QoL  X   X 
SSA4  X X X X 
Urine Pregnancy Test (UPT) (FOCBP)  X X X X X 
Serum Pregnancy Test (FOCBP)  X    X 
Abbreviated physical examination   X   X 
Oily/shiny skin assessment   X   X 
Lesion Counts  X X X X X 
EGSS  X X X X X 
Photographs (select sites only)   X   X 
Cutaneous Safety Evaluation   X X X X 
Tolerability Evaluation   X X X X 
Randomization in IWRS (obtain kit #)   X X X  
Administer Subject Instructions (Appendix 17.1)   X    
Dispense Study Drug5  X X X  
Weigh Study Drug   X X X X 
Study Drug applied at investigational center   X    
Study Drug Collected    X X X 
Subject Diary Calendar dispensed   X X X  
Subject Compliance Reviewed / Diary    X X X 
Adverse Events  X X X X X 
Concomitant Therapy and Prohibited Therapi[INVESTIGATOR_365435]  X X X X X 
End of Study      X 
[ADDRESS_686509] occur after the appropriate washout period.  
2 All visit dates are in reference to baseline, e.g., Visit 4 occurs 8 weeks +/ - [ADDRESS_686510] during the baseline visit (Visit 2) with instructions to complete it at two weeks and return it at 
the Week [ADDRESS_686511]  material at the Baseline, Week 4 and Week 8 visits.  
 
Version 1, 04 June 2015  CONFIDENTIAL  
20 
Protocol V01 -121A -302, IDP -121 Valeant Research & Development  
Version 1, [ADDRESS_686512] Inclusion Criteria  
Subjects meeting all of the following criteria will be eligible for study entry:  
1. Male or female at least 9 years of age and  older;  
2. Written and verbal informed consent must be obtained. Subjects less than age of 
consent must sign an assent for the study and a parent or a legal guardian must sign the informed  consent  (if subject  reaches  age of consent  during  the study  they should 
be re- consented at the next study  visit);  
3. Subject must have a score of 3 (moderate) or 4 (severe) on the Evaluator’s Global Severity assessment at the screening and baseline visit;  
4. Subjects with f acial acne inflammatory lesion (papules, pustules, and nodules) count 
no less than 20 but no more than 40; 
5. Subjects with facial acne non -inflammatory lesion (open and closed comedones) 
count no less than 20 but no more than 100; 
6. Subjects with two or fewer facial  nodules;  
7. Females of childbearing potential
[ADDRESS_686513] be willing to 
practice effective contraception for the duration of the study. (Effective contraception is defined as stabilized on oral contraceptive for at least 3 months, IUD, condom with spermicidal, diaphragm with spermicidal, implant, Nuvaring, injection, transdermal patch or abstinence.) Females on birth control pi[INVESTIGATOR_500793]. Those who have used birth control pi[INVESTIGATOR_220110]. Women who use birth control for acne control only should be  excluded.  
8. Pre-menses femal es and females of childbearing potential must have a negative urine 
pregnancy test
2 at the screening and baseline visits; 
9. Subjects must be willing to comply with study instructions and return to the clinic  for 
required visits. Subjects under the age of consent must be accompanied by [CONTACT_85184]/consent  signing;  
10. If a cleanser, moisturizer or sunscreen is needed during the study, Subjects must be willing to use only allowed cleansers, moisturizers, sunscreens, or 
 
 
1 Pre-menses females and Females of Child Bearing Potential (FOCBP) include any female who has not undergone 
successful surgical sterilization (hysterectomy, bilateral tubal ligation or bilateral oophorectomy) or is not 
postmenopausal [defined as amenorrhea >12 consecutive months; or women on hormone replacement therapy 
(HRT) with documented plasma follicle -stimulating hormone (FSH) level >35mLU/mL]. Even women who are 
using oral, implanted or, injectable contraceptive hormones, an intrauterine device (IUD), barrier methods 
(diaphragm, condoms, spermicidal) to prevent pregnancy, practicing abstinence or where partner is sterile (e.g., vasectomy), should be considered to be of child bearing potential.  
[ADDRESS_686514] a minimum sensitivity of 2 5mIU -HCG/mL of urine and must be performed 
within 72 hours prior to the start of study medication. Kits will be provided by [CONTACT_2024].  
Protocol V01 -121A -302, IDP -121 Valeant Research & Development  
Version 1, 04 June 2015  CONFIDENTIAL  
22  
  
 
moisturizer/sunscreen combination products (see Appendix 2). If the subject wears 
makeup they must agree to use non- comedogenic makeup.  
 
8.[ADDRESS_686515] Exclusion Criteria  
Subjects meeting any of the following criteria will be excluded from the study:  
1. Use of an investigational drug or device within 30 days of enrollment or  participation 
in a research study concurrent with this  study;  
2. Any dermatological conditions on the face that could interfere with clinical evaluations  such as acne conglobata,  acne fulminans, secondary  acne,  perioral 
dermatitis, clinically significant rosacea, gram- negative  folliculitis;  
3. Any underlying disease(s) or some other dermatological condition of the face that requires  the use of interfering  topi[INVESTIGATOR_500776];  
4. Subjects with a facial beard or mustache that could interfere with the study assessments;  
5. Subjects with more than two (2) facial  nodules;  
6. Evidence or history of cosmeti c-related  acne;  
7. Subject has a history of experiencing significant burning or stinging when applying any facial  treatment  (eg, make- up, soap, masks,  washes,  sunscreens, etc) to their  face;  
8. Female subjects  who are pregnant, nursing  mothers, planning  a pregnancy  during the 
course of the trial, or become pregnant during the  study;  
9. Use of estrogens (eg, Depogen, Depo- Testadiol, Gynogen, Valergen, etc) for less than 
12 weeks immediately preceding study entry; Subjects treated with estrogens [ADDRESS_686516]  expects  to change dose,  drug or discontinue  estrogen  use during the study;  
10. If female, subject has a history of hirsutism, polycystic ovarian disease or clinically significant menstrual  irregularities;  
11. Treatment of any type of cancer within the last 6  months;  
12. Subject uses medications and/or vitamins during the study which are reported to exacerbate acne (azothiaprim, haloperidol, Vitamin D, Vitamin B12, halogens such as 
iodides or bromides, lithium, systemic or mid -to super -high potency corticosteroids, 
phenytoin and phenobarbital); Daily vitamins are  acceptable;  
13. History of hypersensitivity or allergic reactions to any of the study preparations as 
described in the Investi gator’s Brochure, including known sensitivities to any  dosage 
form of tretinoin; 
14. Concomitant use of potentially irritating over -the-counter products that contain 
ingredients such as benzoyl peroxide, alpha -hydroxy acid, salicylic acid, retinol or 
glycolic acids;  
Pr ot oc ol V 0 1 -1 2 1 A -3 0 2, I D P -1 2 1  Valea nt Researc h & De vel o p me nt  
Versi o n 1, 0 4 J u ne 2 0 1 5  C O N FI D E N TI A L  
2 3   
  
 
1 5.  S u bjects t hat ha ve n ot u n der g o ne t he s pecifi e d was h o ut peri o d(s) f or t he f oll o wi n g 
t o pi[INVESTIGATOR_199252] p arati o ns us e d o n t he face or s u bjects w h o re q uir e t he c o n c urr e nt use of 
a n y of t he f oll o wi n g t o pi[INVESTIGATOR_2855] a ge nts i n t he tr eat me nt area  : 
 
T o pi[INVESTIGATOR_500777] n ge nts a n d a brasi ves  o n  face  [ADDRESS_686517] re q uires t o pi[INVESTIGATOR_200369] f or ac ne o n areas ot her t ha n t he face (e. g., 
c hest a n d/ or b ac k), t h e i n vesti gat or m a y pres cr i be a pr o d uct t hat d o es n ot c o ntai n 
treti n oi n a n d m ust be n ote d i n s o urce d o c u me nts a n d e C R F.  
 
1 6.  S u bjects t hat ha ve n ot u n der g o ne t he s p ecifie d w as h o ut peri o d(s) f or t h e f oll o wi n g 
s yste mic me dicati o ns or s u bjects w h o re q uir e t he c o nc urr e nt use of a n y of t he 
f oll o wi n g s yste mic  me di cati o ns:  
 
C ortic oster oi ds (i ncl u di n g i ntra m usc ul ar i njecti o ns)  
(i n hale d c ortic oster oi ds  are  all o we d)  [ADDRESS_686518] a w al  Criteri a  
Reas o ns f or wit h dra wal ma y i ncl u d e, b ut are n ot li mite d t o, t he f oll o wi n g:  
• Ac ne  flare,  as  deter mi ne d  b y  t he  i n vesti g at or,  w hic h  re q uir es  treat me nt  wit h  a 
disall o we d  t hera p y.  
• Eit her at t he i n vesti gat or's re q uest, f or t olera bilit y reas o ns ( e g, se vere  a d verse 
reacti o ns), or at t he s u bject’s  re q u est.  
• W he n t he re q uire me nts of t he pr ot oc ol ar e n ot  f oll o we d.  
• W he n a c o nc o mita nt t her a p y li kel y t o i nterfer e wit h t he res ults of t he st u d y is 
re p orte d, or re q uir e d b y t he s u bject (t he i n vesti gat ors will re p ort all s uc h  i nf or mati o n  
Pr ot oc ol V 0 1 -1 2 1 A -3 0 2, I D P -1 2 1  Valea nt Researc h & De vel o p me nt  
Versi o n 1, 0 4 J u ne 2 0 1 5  C O N FI D E N TI A L  
2 4   
  
 
o n t he s o urce d o c u me nts/case r e p ort f or ms ( C R Fs) a n d deci de, i n acc or da nce wit h t he 
s p o ns or, w het her t he s u bj ect is t o be wit h dra w n).  
• W he n a s u bject is l ost t o f oll o w -u p. T he i n vesti gat ors will tr y t wice t o reac h t he 
s u bject b y tel e p h o ne a n d will se n d a f oll o w -u p letter b y certifie d mail bef or e 
c o nsi deri n g  t hat  t he  s u bject  is  l os t t o  f oll o w -u p.  T hese  acti o ns  will  be  re p orte d  o n  t he 
E n d of St u d y C R F a n d a c o p y of t he f oll o w -u p lett er mai ntai ne d i n t he i n vesti gat or's 
file.  
All pre mat ure disc o nti n u ati o ns a n d t heir reas o ns m ust be caref ull y d o c u me nte d b y t he 
i n vesti gat or o n t he fi nal C R F, a n d, if nee d b e, o n t he A E f or m. I n a n y cas e, n o s u bject w h o has 
bee n i ncl u de d a n d has a st u d y n u m ber assi g n e d ca n be re place d b y a n ot h er if t he y disc o nti n ue 
pre mat urel y f or w hat e ver reas o n. All data gat her e d o n t he s u bject pri or t o ter mi nati o n will b e 
ma de a vaila ble t o t he s p o ns or.  
Reas o ns f or st u d y c o m pl eti o n/ disc o nti n uati o n as liste d o n t he fi nal re p ort f or m are d efi ne d as 
f oll o ws:  
N or m al St u d y C o m pleti o n – S u bject c o m pletes t he st u d y as pla n ne d i n t h e pr ot oc ol.  
A d verse E ve nt – C o m plete A E f or m.  
De a t h – C o m plete S A E f or m.  
S u bject Re q uest – C o nse nt wit h dra wal, s u bject m o ve d, sc he d ule c o nflicts. 
Pr ot oc ol Vi ol ati o n – C o ntact t he S p o ns or or desi g nee bef ore ma ki n g d ecisi o n. 
L ost t o F oll o w -U p – D o c u me nt wit h 2 p h o ne calls a n d a certifie d letter.  
Pre g n a nc y – S u bject will disc o nti n ue st u d y dr u g i m me diatel y, b ut will be f oll o we d t o ter m. 
C o m plete pre g na nc y f or m.  
W orse ni n g C o n diti o n – S u bject re q uires alter nate treat me nt f or ac ne b ef or e t he e n d of t he 
st u d y a n d t he i n vesti gat or deter mi nes it is n ot d ue t o lac k of efficac y.  
L ac k of Effic ac y – S u bject re q uir es alter n ate treat me nt f or ac n e after at least [ADDRESS_686519] a w al b y P ar e nt/ G u ar di a n – A n i n dicati o n t hat t he st u d y partici pa nt has bee n 
re m o ve d fr o m t he st u d y b y t he p are nt or l e gal g uar dia n. C o nse nt wit h dra w al, s u bject m o ve d, 
sc he d ule c o nflicts.  
St u d y Ter mi n ate d b y S p o ns or – A n i n dicati o n t hat a cli nical st u d y was st o p pe d b y its 
S p o ns or.  
Ot her – S pecif y i n c o m me nts secti o n of fi nal C R F.  
S u bjects w h o ter mi nate treat me nt earl y will be as ke d t o c o m plete all Wee k 1 2 assess me nts a n d 
pr oce d ur es pri or t o c o m me nce me nt of a n y alter n ati ve t hera p y f or ac ne (if p ossi ble). S u bje cts 
w h o disc o nti n ue fr o m t he st u d y d uri n g t he tr eat m e nt peri o d will n ot be re place d.  
Protocol V01 -121A -302, IDP -121 Valeant Research & Development  
Version 1, [ADDRESS_686520] or whenever clinically necessary as determined by [CONTACT_9682].  
 
9 Treatment  Plan  
9.1 Methods of Assigning Subjects to Treatment  Groups  
This is a double -blinded study, in which the identity of the study drug will be unknown to 
investigator/evaluator and subjects, as well as all individuals closely associated with the study.  
Subjects will be randomized  to 1 of the 2 study drug groups in a ratio of 1:1 (IDP -121 [tretinoin 
0.05%] Lotion : IDP -121 Vehicle Lotion). Each screened subject will be assigned a unique 6-  
digit study subject number assigned by [CONTACT_118250], which will consist of the 3-  
digit investigational center/site number (pre -assigned by [CONTACT_3211]/designee) and the 3 digit 
chronological screening order number, starting with 001 (eg, 101001, 101002). The study drug kit will be assigned to subjects based on a randomization code and kit will be dispensed to the subjects at Baseline by [CONTACT_500804], and at Week [ADDRESS_686521] all used and unused study drug tubes as scheduled.  
 
9.3 Un-blinding  
The treatment assignments for all enrolled subjects will be unblinded only after the conclusion of the study. Specifically, the blind will be broken only after all data are verified, entered into the database, and validated; subject evaluability assessments are performed and entered into the database; and the database is locked.  
In the case of a med ical emergency, the investigator can break the blind for the subject involved 
preferably by [CONTACT_220142] (or designee) immediately. After confirmation, the investigator will be contact[CONTACT_528818] V01 -121A -302, IDP -121 Valeant Research & Development  
Version 1, [ADDRESS_686522]’s source documents. 
 
9.[ADDRESS_686523] for acne vulgaris:  
Topi[INVESTIGATOR_500778] [ADDRESS_686524] requires topi[INVESTIGATOR_85129] (eg, chest or back), the investigator may prescribe a product that does not contain tretinoin and noted in source documents and eCRF.  
In addition there is a mandatory wash out period and restrictions during the study for the following systemic drugs: 
Corticosteroids (including intramuscular injections,  
inhale d corticosteroids  are allowed)  4 weeks  
Antibiotics  4 weeks  
Other systemic  acne treatments  4 weeks  
Systemic  retinoids  6 months  
 
Subjects using concomitant therapi[INVESTIGATOR_85145] (including but not limited to those listed above) should not be withdrawn, but the use of the concomitant product should be discontinued. No other topi[INVESTIGATOR_35786] (except as noted above) other than the study drug will be permitted for acne.  
Information on concomitant therapi[INVESTIGATOR_528809]. Any therapy used by [CONTACT_500823] (eg, aspi[INVESTIGATOR_248], Tylenol, birth control pi[INVESTIGATOR_3353], vitamins, moisturizers, sunscreens). 
Every attempt should be made to keep concomitant therapy dosing constant during the study.  
Any change to concomitant therapy should be noted on the Concomitant Therapy source document and eCRF.  
Protocol V01 -121A -302, IDP -121 Valeant Research & Development  
Version 1, [ADDRESS_686525]’s compliance with applying the study drug. A s ubject who deviates 
significantly from the prescribed application amount will be counseled. Any missed applications of study drug will be noted by [CONTACT_85196], which will be collected and placed in the appropriate source document. Missed appli cations will be documented in the CRF. The subject 
will also be sent home with a Subject Self Assessment (SSA) survey at the Baseline visit, with instructions to complete it at home at two (2) weeks after their baseline visit, and return it at the Week [ADDRESS_686526] follow the instructions exactly.  
A deviation from the protocol is an unintended and/or unanticipated departure from the procedures and/or processes approved by [CONTACT_135785]/IEC and agreed to by [CONTACT_093]. Deviations usually have an impact on individual patients or a small group of patients and do not involve inclusion/exclusion or primary endpoint criteria. 
A protocol viola tion occurs when there is nonadherence to the protocol that results in a 
significant, additional risk to the patient, when the patient or investigator has failed to adhere to 
significant protocol requirements (inclusion/exclusion criteria) and the patient was enrolled without prior sponsor approval, or when there is nonadherence to FDA regulations and/or ICH GCP guideline.  
The investigator or designee must document and explain in the patients’ source documentation any deviation from the approved protocol. T he investigator may implement a deviation from, or 
a change of, the protocol to eliminate an immediate hazard to study patients without prior IRB/IEC approval. As soon as possible after such an occurrence, the implemented deviation or change, the reasons f or it, and any proposed protocol amendment(s) should be submitted to the  
Protocol V01 -121A -302, IDP -121 Valeant Research & Development  
Version 1, 04 June 2015  CONFIDENTIAL  
28  
  
 
IRB/IEC for review and approval, to the sponsor for agreement, and to the regulatory authorities, 
if required.  
 
10 Study Drug Materials and  Management  
The study drug will be dispensed by [CONTACT_500807].  
 
10.1 IDP-121 Lotion and IDP -121 Vehicle  Lotion  
Chemical structure and formula for the active ingredients in IDP -121 Lotion and vehicle are 
listed in the tables below: 
Table  2. Drug Substances  Identification  
 
Active Ingredient  Tretinoin 0.05%  
Chemical Name  (2E,4E,6E,8E) -3,7-dimethyl -9-(2,6,6 -trimethylcyclohexen -1-yl)nona - 
2,4,6,8- tetraenoic acid  
Chemical Class  Retinoid  
Molecular Formula  C20H28O2 
CAS Registry Number  302-79-[ADDRESS_686527]  Vehicle  
Name [CONTACT_500833], EP / USP  N/A 
Drug Name/Formulation/  
Concentration  IDP-121 Lotion [Tretinoin 0.05%]  IDP-[ADDRESS_686528] 
Laval (Quebec), Canada H7L 4A8  
Packaging  45 g tube  45 g tube  
Storage Requirements  Store at 20°C to 25°C (68°F to 
77°F)  Store at 20°C to 25°C (68°F 
to 77°F)  
Appearance  Opaque pale yellow lotion  Opaque pale yellow lotion  
Dosing Schedule  Once daily x [ADDRESS_686529] at each visit: Baseline, Week 4 and Week 8. The subjects will be dispensed one kit at Baseline as ass igned in the IWR system. The tube will be  
Pr ot oc ol V 0 1 -1 2 1 A -3 0 2, I D P -1 2 1  Valea nt Researc h & De vel o p me nt  
Versi o n 1, [ADDRESS_686530] u d y visit ( Wee k 4), 
w here it will be c ollecte d a n d wei g he d; o ne n e w t u be will be dis pe nse d a gai n b y t he I W R s yste m 
at Wee k 4, wei g he d a n d pr o vi de d t o t he s u bject. T he sa me will occ ur at t h e Wee k [ADDRESS_686531] l oses a t u be (l ost or da ma ge d t u be), a n ot her kit will be dis pe nse d via I W R S. Eac h t u be 
dis pe nsi n g will be d oc u me nte d o n t he dr u g acc o u nta bilit y l o g.  
Eac h s u bject kit (a n d t u b e) will ha ve a si n gle p a nel la bel. La bels will c o ntai n t he f oll o wi n g 
i nf or mati o n:  
• Pr ot oc ol  N u m ber  
• Kit N u m ber  
• C o nte nts  
• S pace f or e ntr y of t he s u bject  i nitials  
• S pace f or e ntr y of d ate  dis pe nse d  
• T he s p o ns or na me, D o w P har mace utical Scie nce s, a di visi o n of  Valea nt 
P har mace uticals N. A.,  L L C  
• T he q ua ntit y of pr o d uct ( 4 5  gra ms)  
• A state me nt rea di n g, “ F or e xter nal use o nl y. A v oi d c o ntact wit h e yes a n d  li ps”  
• A state me nt rea di n g, “ St ore at c o ntr olle d r o o m te m perat ure 2 0° C t o 2 5° C ( 6 8° F t o 
7 7° F) wit h e x c ursi o ns per mitte d bet wee n 1 5° C t o 3 0° C ( 5 9° F t o  8 6° F) .”  
• A state me nt rea di n g, “ Ca uti o n: Ne w Dr u g Li mite d b y Fe deral La w t o  I n vesti gati o nal 
Use”  
• A state me nt rea di n g, “ Ret ur n t his pr o d uct t o y o ur i n vesti gati o nal site at y o ur ne xt 
visit.”  
[ADDRESS_686532] ore d at c o ntr olle d r o o m te m perat ure 2 0° C t o 2 5° C ( 6 8° F t o 7 7° F) wit h 
e xc ursi o ns per mitte d bet wee n 1 5° C t o 3 0° C ( 5 9° F t o 8 6° F) , a n d s h o ul d n ot be refri gerate d. All 
u n use d st u d y dr u g will be se nt bac k t o t he S p o ns or or S p o ns or desi g nee u p o n st u d y c o m pleti o n 
f or d oc u me nte d dis p osal.  
[ADDRESS_686533] 
material will be a p plie d as a t hi n c oati n g (a da b t h e size of a lar ge p ea) t hat is ge ntl y r u b be d i n t o 
t he s ki n. T he test material use s h o ul d be li mite d t o t he face.  
T he I n vesti gat or a n d/ or trai ne d i n vesti gati o nal c e nter staff me m b er will i nstr uct t he s u bject o n 
t he pr o per a p plicati o n pr oce d ure of t he st u d y dr u g t o t he treat me nt ar ea at t he Bas eli ne visit (see 
A p pe n di x 1 7. 1). All s u bjects will be i nstr ucte d t o a p pl y t he t est material at a p pr o xi matel y t he  
Protocol V01 -121A -302, IDP -121 Valeant Research & Development  
Version 1, 04 June 2015  CONFIDENTIAL  
30  
  
 
same time every day for 12 weeks after cleansing. On study visit days subjects should be 
instructed to wait until after their study visit to apply study medication. No time interval between dosing and meals or any other activity is specified. Subjects will be instructed to gently wash their face with a Sponsor approved cleanser and warm (not hot) water. After washing, the subjects will be asked to thoroughly rinse and gently pat their face dry. The subjects should use the tube to dispense a pea -sized am ount of study drug to their fingertip. This dose should then be 
dotted on to 6 areas (chin, left cheek, right cheek, nose, left forehead, right forehead) on the face. After distributing the dose in this manner the subject should gently rub the lotion into the skin.  
This amount of drug should be sufficient to cover the entire face excluding the mouth, eyes, inside the nose, and lips. It is important for the subject to treat their entire face (excluding the mouth, eyes and lips) and they should be instructed NOT to treat only specific lesions. They should gently smooth the test material over the face evenly. The test material should become invisible almost immediately following application with gentle rubbing. If this does not happen, the Investigator should i nstruct the subject on the use of a smaller dosage. The subject should 
wash his/her hands after applying the investigational product to the face.  
The subjects will be instructed to continue using the same Sponsor approved facial cleanser and moisturizer and not to change products during the study. At each visit, subjects are to be asked if they have changed their cleansing routine. Facial makeup may be applied according to the subject’s normal daily routine; however, subjects should be instruc ted not to wear make- up 
during study visits as it may interfere with the evaluator’s assessments. Subjects must also agree to use non- comedogenic makeup during the study if they use makeup. No other products should 
be used on the face.  
Subjects should be i nstructed to store the test material at room temperature.  
 
10.[ADDRESS_686534] will be made available to the sponsor’s monitor for the purpose of accounting for all clinical supplies. Any significant discrepancy and/or deficiency must be recorded with an explanation. 
All sup plies sent to the Investigators will be accounted for and, in no case, used in any 
unauthorized situation. Tubes will be weighed (with the cap on) before dispensing to and upon return by [CONTACT_748], and weights will be recorded on the pharmacy log and appropriate CRF. All used and unused supplies will be returned to sponsor/designee for destruction at the conclusion of the study.  
Protocol V01 -121A -302, IDP -121 Valeant Research & Development  
Version 1, [ADDRESS_686535] appropriate, documented experience and training, or obtain approval from 
the sponsor based on experience (or through additional training organized by [CONTACT_456]).  
At each study visit, every attempt should be made to ensure that the same investigator / evaluator assesses the same subject.  
 
11.1 Schedule of Evaluations and  Procedures  
11.1.1  Visit 1: Screening  Visit  
The following procedures will be conducted at this visit:  
1. Obtain written informed consent prior to performing any study procedures. Subjects less 
than [ADDRESS_686536] of the 
3-digit site number (pre -assigned to your site) and the 3- digit chronological order 
screening number, assigned by [CONTACT_500808] 101 (eg, 101 001, 101 002, etc; in this example site number is  101). 
3. Record the  subject’s demographic  information.  
4. Record the subject’s medical  history.  
5. Record all previous medications (including acne medications) for the past 4 weeks (past 6 months for systemic retinoids). Record any therapi[INVESTIGATOR_500780].  
6. Perform Evaluator’s Global Assessment followed by [CONTACT_220148]-  
inflammatory lesion count to determine  eligibility.  
7. Perform a Urine Pregnancy Test and Serum Pregnancy Test for all females that are pre-  
menses  and females  of childbearing  potential.  The urine  pregnancy  tests will be supplied 
by [CONTACT_500809].  
8. Discuss allowed moisturizers and sunscreens and record any cleanser, moisturizer and 
sunscreen use. (Appendix  17.2).  
9. If subject wears makeup, remind the subject not to wear make- up during any future  visits.  
10. Verify that the subject meets the applicable inclusion/exclusion criteria as outlined in 
Sections 8.[ADDRESS_686537] medication on day of next study visit prior to the clinic visit.  
Protocol V01 -121A -302, IDP -121 Valeant Research & Development  
Version 1, [ADDRESS_686538] to return for the Baseline/Day [ADDRESS_686539] requires a washout, 
schedule the Baseline/Day 0 visit to occur after the washout is  complete.  
NOTE : At the Screening and Week [ADDRESS_686540] be completed at 
Screening and at the Baseline visit prior to randomization, and at Weeks 4, 8 and 12. The 
decision may be made by [CONTACT_249293].  
11.1.2  Visit 2: Baseline Visit (Day  0) 
If a washout is not needed, this visit may occur on the same day as the Screening Visit (Visit 1). If a washout is needed, Visit [ADDRESS_686541] occur after the appropriate washout period based on the criteria provided in Section 8.2. 
The following procedures will be conducted at this visit:  
1. The baseline Subject Self Assessment (SSA), Patient Satisfaction Survey (PSS) and the 
Acne- Specific Quality of Life Questionnaire (Acne- QoL) will be completed by [CONTACT_528819] -related procedures. The Week [ADDRESS_686542] continues to meet the applicable inclusion/exclusion criteria as outlined in Sec tions 8.[ADDRESS_686543] regarding how oily/shiny their facial skin has been in the past  week.  
7. The Evaluator will perform Baseline efficacy evaluations including the Evaluator’s 
Global Severity Score (EGSS), inflammatory lesion counts and non- inflammatory lesion 
counts. The EGSS is performed prior to the lesion counting. Every effort should be made for the same qualified, validated Evaluator to perform the efficacy evaluations at all visits from Baseline to Week [ADDRESS_686544]. 
8. The Evaluator will perform Cutaneous Safety and Tolerability  Evaluations. 
Protocol V01 -121A -302, IDP -121 Valeant Research & Development  
Version 1, [ADDRESS_686545] the presented kit number (this number will be generated from the 
Interactive Web Response system,  (IWRS)).  
10. The study coordinator or designee will weigh the tube within the assigned kit and 
dispense to the subject. A study diary calendar will also be dispensed and the subject will 
be instructed to bring it in for their subsequent  visits.  
11. The study coordinator or designee will instruct t he subject on the proper application 
procedure for the study drug per Section 10.1.3, and will provide written subject use instructions to the subject (Appendix 17.1). For the first application, the subject will apply the study drug at the investigational center under the direction of the study 
coordinator or designee. The study drug should be applied after all clinical assessments. 
The study coordinator or designee will instruct the subjects to apply the study drug once daily at  home.  
12. Record any AEs or changes in AEs since the screening visit and/or reported 
spontaneously by [CONTACT_19578].  
13. Selected Sites only - Obtain representative photographs of the  face.  
14. Schedule the next study visit at Week 4 (Day 28 ± 3 days). Remind the subject to not apply test medi cation on day of next study visit, prior to the clinic  visit.  
11.1.3  Visit 3 and 4: Week 4 (Day 28 ± 3 Days) and Week 8 (Day 56 ± 3 Days)  Visits  
The following procedures will be conducted at this visit (if a subject terminates early, all final 
visit (Week 12/Fina l Visit) procedures must be performed):  
1. The take- home Week 2 SSA will be collected during the Week 4 study  visit.  
2. The Week 4 or Week 8 SSA will be conducted and collected.  
3. The Evaluator will perform the efficacy evaluations including the Evaluator’s Global 
Severity Score (EGSS), inflammatory lesion counts and non- inflammatory lesion counts. 
The EGSS is performed prior to the lesion counting. Every effort should be made for the 
same qualified and validated evaluator to perform the efficacy evaluations at all visits 
from Baseline to Week [ADDRESS_686546] another kit number  (this number will be generated from the Interactive Web 
Response system, (IWRS) and dispense a new subject kit of test material. The tube will be weighed on a calibrated scale. Record the weight to the nearest 0.1  gram.  
Protocol V01 -121A -302, IDP -121 Valeant Research & Development  
Version 1, [ADDRESS_686547] 
medication on the day of the next study visit, prior to the clinic  visit.  
11.1.4  Visit 5: Week 12 (Day 84 - 3/+5 Days) Visit – End of Study  Visit  
The following procedures will be conducted at this visit:  
1. The Week [ADDRESS_686548] regarding how oily/shiny their facial skin has been in the past  week.  
4. The Evaluator will perform the efficacy evaluations including the Evaluator’s Global 
Severity Score (EGSS), inflammatory lesi on counts and non- inflammatory lesion counts. 
The EGSS is performed prior to the lesion counting. Every effort should be made for the same qualified and validated Evaluator to perform the efficacy evaluations at all visits from Baseline to Week [ADDRESS_686549]- certified/board -eligible dermatologist or 
have appropriate documented experience and training, and be present for formal study training 
Protocol V01 -121A -302, IDP -121 Valeant Research & Development  
Version 1, 04 June 2015  CONFIDENTIAL  
35  
  
 
and validation at the Investigator Meeting (and/or Site Initiation Visit), or obtain a waiver from 
the Sponsor based on experience (or through additional training organized by [CONTACT_1034]).  
The EGSS scores and lesion counts will be performed at each study visit. The EGSS scores will be collected before the Lesion Counts. All Subject assessments will be performed by a trained and validated Evaluator. Every effort should be made to have the same evaluator assess the same 
Subject at each visit. If this is not possible, the same Evaluator must assess the Subject at both the baseline and Week 12 visits.  
11.2.1  Evaluator’s Global Severity Score  (EGSS)  
The Evaluator’s Global Severity Score will be a static assessment that is independent of the baseline score. The investigator will make the assessment without referring to the baseline value. Every effort should be made for the same evaluator to perform each study assessment for the same study subject, for consistency in evaluations. 
Subjects are eligible if they have acne with a global severity of a 3 (moderate) or a 4 (severe) on 
the EGSS at the baseline visit. The following scores will be used to describ e the severity grade 
and subsequent score:  
Table 4. Evaluator’s Global Severity Score  
Score  Grade  Description  
[ADDRESS_686550] 
Clear  Rare non -inflammatory lesions present, with rare non-inflamed papules (papules must 
be resolving and may be hyperpi[INVESTIGATOR_49194], though not pi[INVESTIGATOR_8745]- red 
2 Mild  Some non -inflammatory lesions are present, with few inflammatory lesions 
(papules/pustules only; no nodulocystic lesions)  
 
3  
Moderate  Non-inflammatory lesions predominate, with multiple inflammatory lesions evident: 
several to many comedones and papules/pustules, and there may or may not be one 
nodulocystic lesion  
4 Severe  Inflammatory lesions are more apparent, many comedones and papules/pustules, there 
may or may not be up to [ADDRESS_686551]’s face. The lesion count groups will 
be inflammatory and non -inflammatory. Facial inflammatory lesions (pustules, papules, and 
nodules) will be counted as follows: pustules and papules will be counted and recorded together, not separately; nodular lesions will be counted and recorded separately. Non- inflammatory 
lesions (open and closed comedones) w ill be counted and recorded together. The lesions counts 
will be collected at each visit and/or upon discontinuation. The following are definitions of each lesion type counted:  
Protocol V01 -121A -302, IDP -121 Valeant Research & Development  
Version 1, 04 June 2015  CONFIDENTIAL  
36  
  
 
Inflammatory lesions are defined as follows:  
 
Papule – a solid, elevated lesion less than 5 mm  
Pustule – an elevated lesion containing pus less than 5 mm  
Nodule – palpable subcutaneous lesion greater than 5 mm; has depth, not necessarily elevated  
Non- inflammatory lesions are defined as follows:  
 
Open comedones (blackhead) – plugged hair follicle with dilated/open orifice; black in color  
Closed comedones (whitehead) – plugged hair follicle: small opening at skin surface  
 
11.2.3  Other Assessments 
Oily/Shiny Face Assessment  
The subject will be asked at Baseline and Week [ADDRESS_686552] week by [CONTACT_500810]:  
Oily/Shiny skin assessment  
0 – None  No oily or shiny skin on face  
1 – Mild  Mild oily or shiny skin on face 
2 – Moderate Definite oily or shiny skin on face 
3 – Severe Extremely oily or shiny skin on face 
If subject answers 1, [ADDRESS_686553] week with scale below:  
0 – Not bothered at all 1 – A little bothered  
2 – Moderately bothered 3 – Very bothered  
4 – Extremely bothered  
Photography  
At select sites, photographs of the face will be taken at Baseline and Week 12, at a minimum. 
Only subjects who provide written photographic consent for facial photographs will be inc luded 
in photography.  
 
11.[ADDRESS_686554] ug-application site: itching, burning and stinging at the time of the visit.  
Cutaneous tolerability signs and symptoms that result in the subject’s requiring a concomitant therapy, interruption of treatment, or discontinuation from the study, will be repor ted as an AE.  
Protocol V01 -121A -302, IDP -121 Valeant Research & Development  
Version 1, 04 June 2015  CONFIDENTIAL  
37  
  
 
(Note: To be assessed by [CONTACT_220154].)  
Scaling:  
0 – None  No scaling  
1 – Mild  Barely perceptible, fine scales present on limited areas of the  face 
2 – Moderate Fine scale generalized to all areas of the face 
3 – Severe  Scaling and peeling of skin over all areas of the face 
 
Erythema:  
0 – None  No evidence of erythema present 
1 – Mild  Slight pi[INVESTIGATOR_500781] 
2 – Moderate Definite redness  
3 – Severe  Marked erythema, bright red to dusky dark red in color 
 
11.3.[ADDRESS_686555] at the study visit as average over the period since the previous 
visit.  
Itching:  
0 – None  No itching  
1-  Mild  Slight itching, not really  bothersome  
2 – Moderate Definite itching that is somewhat  bothersome  
3 – Severe  Intense itching that may interrupt daily activities and/or  sleep  
 
Burning:  
0 – None  No burning 
1 – Mild  Slight burning sensation; not really  bothersome  
2 – Moderate Definite warm, burning sensation that is somewhat bothersome 
3 – Severe Hot burning sensation that causes definite discomfort and may 
interrupt daily activities and/or sleep  
 
Stinging:  
0 – None  No stinging  
1 – Mild  Slight stinging sensation, not really  bothersome  
2 – Moderate Definite stinging sensation that is somewhat bothersome  
3 – Severe  Stinging sensation that causes definite discomfort and may interrupt daily 
activities and/or  sleep  
11.3.3  Medical History and Abbreviated Physical  Examination  
A medical history will be taken at Screening, and confirmed and revised if needed, at Baseline. 
Medical histories having resolved two or more years before Baseline need not be collected unless 
considered relevant by [CONTACT_093].  
An abbreviated physical examination including measurements of height and weight, and vital signs (blood pressure, heart rate, respi[INVESTIGATOR_1487], and oral temperature) will be performed at  
Pr ot oc ol V 0 1 -1 2 1 A -3 0 2, I D P -1 2 1  Valea nt Researc h & De vel o p me nt  
Versi o n 1, 0 4 J u ne 2 0 1 5  C O N FI D E N TI A L  
3 8   
  
 
Baseli ne a n d Wee k 1 2 ( e n d of treat me nt/st u d y). A n y a b n or mal p h ysical e x a m fi n di n gs will be 
rec or d e d.  
[ADDRESS_686556] u g(s) u n der st u d y. A Es i ncl u d e a n y ill ness, si g n, s y m pt o m, 
or o ut -of -r a n ge a n d cli nicall y si g nifica nt la b orat or y fi n di n g t hat h as a p pear e d or w ors e ne d d uri n g 
t he c o urse of t h e cli nical trial, r e gar dl ess of ca usal relati o ns hi p t o t he st u d y. T he c ollecti o n of 
n o n -seri o us A Es a n d s eri o us a d verse e ve nts ( S A Es) will be gi n f oll o wi n g t h e s u bject's 
c o m pleti o n of t he c o nse nt pr ocess t o partici pat e i n t he  st u d y.  
[ADDRESS_686557] u d y. T he A Es s h o ul d be d oc u me nte d as a si n gle me dical dia g n osis. W he n t his is n ot p ossi ble, 
t he A E s h o ul d be d oc u m e nte d i n ter ms of si g ns a n d/ or s y m pt o ms o bser ve d b y t he i n vesti gat or or 
re p orte d b y t he s u bject at eac h st u d y visit. Eac h A E w hic h a p pears t o be i n de pe n de nt of a n y pri or 
e ve nt will be re p orte d se paratel y.  
All A Es occ urri n g after t he s u bject si g ns t he i nf or me d c o nse nt t hr o u g h t he last st u d y visit m ust 
be re p ort e d, re gar dless of w het her or n ot t he A Es are c o nsi der e d dr u g -relat e d. All A Es, w het her 
i n res p o nse t o a q uer y, o bser ve d b y t he st u d y site pers o n nel, o r r e p orte d s p o nta ne o usl y b y t he 
s u bject, will be rec or de d.  
At eac h visit d uri n g t he st u d y, t he s u bject will be assesse d f or t h e occ urre n ce of ne w a n d o n g oi n g 
A Es. C uta ne o us t olera bilit y si g ns a n d s y m pt o ms t hat res ult i n t he s u bject’s re q uiri n g a 
c o nc o mita n t t hera p y or disc o nti n uati o n fr o m t he st u d y will be re p orte d as a n A E. T he f oll o wi n g 
data will be c ollecte d o n all A Es a n d rec or de d o n t he a p pr o pri ate C R F:  
• E ve nt na me ( dia g n osis pr eferre d, if u n k n o w n, rec or d t he  si g ns/s y m pt o ms)  
Pr ot oc ol V 0 1 -1 2 1 A -3 0 2, I D P -1 2 1  Valea nt Researc h & De vel o p me nt  
Versi o n 1, 0 4 J u ne 2 0 1 5  C O N FI D E N TI A L  
3 9   
  
 
• O nset date a n d e n d  date  
• Ma xi m u m i nte nsit y  (se v erit y)  
• Seri o us ness  
• Acti o n ta ke n re gar di n g st u d y  dr u g  
• C orrecti ve tr eat me nt, if  gi ve n  
• O utc o me  
I n a d diti o n, t he i n vesti gat or’s assess me nt of ca usalit y will be rec or de d.  
Vital si g n a b n or m alities are t o be rec or de d as A Es  o nl y if t he y are cli nicall y si g nifica nt (f or 
e x a m ple: are s y m pt o mati c, re q uiri n g c orrecti ve treat me nt, lea di n g t o disc o nti n uati o n or f ulfilli n g 
a seri o us ness criteri o n).  
1 1. 4. 3  Seri o us A d verse  E ve nts  
All A Es will be assesse d as eit her seri o us or n o n -s eri o us.  
A n S A E or seri o us a d v erse e ve nt is defi ne d as a n y u nt o war d me dical o cc urre nce t h at at a n y 
d ose:  
• Res ults i n  deat h  
• Is i m me diatel y life t hr eat e ni n g, (t h e ter m "life t hr eate ni n g" i n t he d efi niti o n of 
"seri o us" r efers t o a n e v e nt i n w hic h t he s u bje ct is at ris k of deat h at t he ti m e of t he 
e ve nt; it d oes n ot refer t o a n e ve nt w hic h h y p ot h eticall y mi g ht ha ve ca use d deat h if it 
were m or e  se vere)  
• Re q uires i n patie nt h os pi[INVESTIGATOR_1314] o n or pr ol o n gati o n of e xisti n g h os pi[INVESTIGATOR_1314] o n 
( h os pi[INVESTIGATOR_1314] o n  f or  electi v e s ur ger y  f or  a bas eli ne  c o n diti o n  is  n ot  c o nsi der e d  a n  A E)  
• Res ults i n persiste nt or si g nifica nt disa bilit y/i n ca p acit y ( per m a ne nt or s u bst a ntial 
disr u pti o n of a pers o n’s a bilit y t o c o n d u ct n or mal life  f u ncti o ns)  
• Is a c o n ge nital a n o mal y/ birt h defect  
• Is a me dicall y i m p orta nt e ve nt t hat ma y n ot be i m me diatel y lif e t hreat e ni n g or res ult 
i n deat h or h os pi[INVESTIGATOR_1314] o n, b ut ma y je o p ar dize t he s u bject a n d ma y r e q uire me dical or 
s ur gical i nter ve nti o n t o pre ve nt o ne of t he a b o v e liste d o utc o mes. E x a m ples of s uc h 
e ve n ts i ncl u de, b ut ar e n ot li mite d t o, aller gic br o nc h os pas m re q uiri n g i nte nsi ve 
treat me nt i n a n e mer ge nc y r o o m or at h o me; bl o o d d yscrasias or c o n v ulsi o ns t hat d o 
n ot res ult i n i n patie nt  h os pi[INVESTIGATOR_1314] o n.  
N ote: A s p o nta ne o us a b orti o n will be c o nsi dere d a n S A E , a n d m ust be re p orte d per Re p orti n g of 
S A Es u n der Secti o n 1 1. 4. 6.  
Pr ot oc ol V 0 1 -1 2 1 A -3 0 2, I D P -1 2 1  Valea nt Researc h & De vel o p me nt  
Versi o n 1, 0 4 J u ne 2 0 1 5  C O N FI D E N TI A L  
4 0   
  
 
1 1. 4. 4  Assess me nt of  Se verit y  
T he se verit y assi g ne d t o a n A E s h o ul d be deter mi ne d b y t h e ma xi m u m se verit y of t he A E. T h e 
cate g ories d escri b e d bel o w s h o ul d be use d t o esti mate t he se verit y of A Es:  
• Mil d: Tra nsie nt or mil d disc o mf ort; n o li mitati o n i n acti vit y; n o  me di cal 
i nter ve nti o n/t hera p y re q uire d  
• M o derate: Mil d t o m o der ate li mitati o n i n acti vit y; s o me assista nce ma y b e nee de d; n o 
or mi ni mal me dical i nter ve nti o n/t hera p y  re q uire d  
• Se vere: Mar k e d li mitati o n i n acti vit y; s o me assista nce us uall y r e q uire d; m e dical 
i nter ve nti o n/t hera p y r e q uire d; h os pi[INVESTIGATOR_1314] o n or pr ol o n gati o n of c urre nt 
h os pi[INVESTIGATOR_1314] o n p ossi ble; ma y b e i nca p acitati n g or life  t hreate ni n g  
[ADDRESS_686558] u g as eit her 
“ Relate d” or “ N ot Relate d”. T he f oll o wi n g s h o ul d be ta ke n i nt o acc o u nt w he n assessi n g S A E 
ca usalit y:  
Relate d: T here is at least a reas o n a ble p ossi bilit y t hat t he A E/ S A E is relate d t o t he st u d y dr u g. 
Reas o na ble p ossi bilit y m ea ns t hat t her e is e vi de nce t o s u g gest a ca us al relati o ns hi p bet wee n t he 
dr u g a n d t he A E. 
 
N ot Relate d: T here is little or n o reas o na ble p ossi bilit y t hat t he A E/ S A E is relate d t o t he st u d y 
dr u g. T his assess me nt i m plies t hat t he A E/ S A E has little or n o te m p oral relati o ns hi p t o t he st u d y 
dr u g a n d/ or a m or e li kel y or cert ai n alter nati ve eti ol o g y e xists.  
 
1 1. 4. 6  Re p orti n g of Seri o us A d verse  E ve nts  
A d verse e ve nts classifie d as “seri o us” re q uir e e x pe diti o us ha n dli n g a n d r e p orti n g t o s p o ns or or 
desi g nee wit hi n [ADDRESS_686559] be i m me diatel y re p orte d t o t he 
me dic al m o nit or wit hi n 2 4 h o urs of t he i n vesti gat or’s a w are n ess of t he e v e nt. All S A Es m ust be 
re p orte d via c o nfir me d facsi mile a n d e mail tra ns missi o n a n d m ust be s u b mitte d o n a writte n S A E 
re p ort f or m si g ne d b y t he i n vesti gat or wit hi n 2 4 h o urs of t he i n vesti ga t or’s a war e ness of t he 
e ve nt.  
T he c o ntact(s) f or re p orti n g a n S A E are:  
 
 Me dical M o nit or 
 
Protocol V01 -121A -302, IDP -121 Valeant Research & Development  
Version 1, 04 June 2015  CONFIDENTIAL  
41  
  
 
& 
 
  Program Manager [TKL Research, Inc.] 
 
 
Investigators should not wait to receive additional information to fully document the event 
before notifying Medical Monitor and Sponsor of an SAE. If only limited information is initially available, follow-up reports are required. Additional relevant information such as hospi[INVESTIGATOR_85154]. Should the investigator become aware of an SAE (regardless of its relationship to investigational product) that occurs within [ADDRESS_686560] be reported in accordance w ith procedures specified in this protocol. 
All deaths of subjects, regardless of cause, and which are known to the Investigator will be reported on the appropriate CRF for up to 30 days after the administration of study drug, regardless of the Investigator's opi[INVESTIGATOR_85155]. Documentation of the subject’s cause of death and a copy of the autopsy or hospi[INVESTIGATOR_85156]. The Medical Monitor must be notified within 24 hours of knowledge of the event by [CONTACT_756] (and/or fa csimile/email) of all subject deaths. Written follow -up must be received by [CONTACT_500811] (5) calendar days of initial notification.  
 
The investigator should take all appropriate measures to ensure the safety of the subjects, notably he/she should follow a subject with an SAE until the event has resolved or the condition has stabilized. This may imply that follow -up will continue after the subject has left the study, and 
that additional investigations may  be requested by [CONTACT_1034], and that additional investigations 
may be requested by [CONTACT_1034]. When a SAE persists at the end of the study, the Investigator will conduct follow-up contacts with the subject until the Investigator/Sponsor agree the event is satisfactorily resolved and/or stabilized. If at any time after 30 days after administration of study drug, the investigator becomes aware of an SAE which he/she feels is related to study drug or procedure, this must also be reported immediately (within 24 hours of knowledge of occurrence) by [CONTACT_220155]/email to the Medical Monitor and Sponsor 
11.4.7  Expedited Serious Adverse Event  Reports  
An AE, whether serious or non-serious, is designated unexpected (unlabeled) if it is not reported 
in the clinical safety section of the Investigator Brochure or if the event is of greater frequency, specificity or severity.  
Expedited SAE reports are those that are both unexpected based on the reference document (Investigator Brochure or Package Insert) and are related (ie, the relationship cannot be ruled out) to the study drug. These expedited reports are subject to reporting timelines of 7 and/or 15 

Pr ot oc ol V 0 1 -1 2 1 A -3 0 2, I D P -1 2 1  Valea nt Researc h & De vel o p me nt  
Versi o n 1, 0 4 J u ne 2 0 1 5  C O N FI D E N TI A L  
4 2   
  
 
cale n dar da ys t o t he r e g ulat or y re p orti n g a ge nc y(i es). T he S p o ns or will n otif y r e g ulat or y 
a ut h orities of t hese A Es a n d all partici pati n g i n vesti gati o nal ce nt ers i n writi n g f or s u b missi o n b y 
t he i n vesti gat or t o t he I R B/I E C. T his n otificati o n will be i n t he f or m of a S afet y U p dat e t o t he 
I n v esti gat or Br oc h ur e (ie, “ 1 5 -da y letter”).  
U p o n recei vi n g s u c h n otices, t he i n vesti gat or m ust re vie w a n d retai n t he n otice wit h t he 
I n v esti gat or Br oc h ur e a n d i m me diatel y s u b mit a c o p y of t his i nf or mati o n t o t he res p o nsi ble 
I R B/I E C acc or di n g t o l ocal re g ulati o ns. T he i n v esti gat or a n d I R B/I E C will deter mi ne if t he 
i nf or me d c o nse nt r e q uires re visi o n. T he i n vesti gat or s h o ul d als o c o m pl y wit h t he I R B/I E C 
pr oce d ur es f or re p orti n g a n y ot h er saf et y i nf or mati o n.  
[ADDRESS_686561] u d y partici pati o n:  
• I nf or me d c o ns e nt  re q uir e me nts  
• C o ntrace pti ves i n c urre nt use  
F oll o wi n g re vie w of t his i nf or mati o n a n d a p pr o priate s u bject c o u ns eli n g, t h e i n vesti gat or or 
desi g nee a n d t he s u bj ect m ust si g n t he i nf or me d c o nse nt bef ore st u d y e nr oll me nt.  
D uri n g t h e st u d y, all fe m ale s u bjects of c hil d beari n g p ote ntial s h o ul d be i nstr ucte d t o c o ntact t he 
i n vesti gat or i m me diatel y if t he y s us p ect t he y mi g ht be pre g na nt ( e g, misse d or late me nstr ual 
peri o d).  
If a s u bject or i n vesti gat or s us pects t hat t he s u bject ma y b e pre g n a nt pri or t o st u d y e nr oll me nt, 
t he st u d y dr u g m ust be wit h hel d u ntil t he res ults of la b orat or y pre g na n c y testi n g ar e a vaila ble. If 
pre g na nc y is c o nfir me d, t he s u bject m ust n ot recei ve st u d y dr u g a n d m ust n ot be e nr olle d i n t he 
st u d y. If pre g na n c y is s us pecte d w hile t he s u bject is recei vi n g st u d y treat me nt, t he st u d y dr u g 
m ust i m me diatel y b e wit h hel d u ntil t he  res ult of pre g na nc y t esti n g is k n o w n. If pre g n a nc y is 
c o nfir me d, t he st u d y dr u g will be per ma ne ntl y dis c o nti n ue d a n d t he s u bject will be f oll o we d 
u ntil t he pre g n a nc y c o m es t o ter m. A Pre g na nc y R e p ort f or m will be s u b mitte d t o t he s p o ns or, 
i nitiall y a n d at  t he e n d of t he pre g na n c y, w hic h i n cl u des t he o utc o me of t h e pre g na n c y a n d a n y 
c o m plicati o ns occ urri n g d uri n g t he pre g na n c y or t he deli ver y.  
All c o nfir me d pre g n a nci es m ust be i m me diatel y r e p orte d t o t he me dical m o nit or wit hi n 2 4 h o urs 
of t he i n vesti gat or’s  a war e ness of t he pre g n a nc y. All c o nfir me d pre g na nci es m ust be re p orte d via 
c o nfir me d f acsi mile/e mail tra ns missi o n a n d m ust be s u b mitte d o n a S A E f or m wit hi n 2 4 h o urs of  
Protocol V01 -121A -302, IDP -121 Valeant Research & Development  
Version 1, 04 June 2015  CONFIDENTIAL  
43  
  
 
the investigator’s awareness of the pregnancy using the same reporting  as procedure for an SAE 
under Section 11.4.6.  
 
12 Statistics  
All statistical processing will be performed using SAS® version 9.3 or later unless otherwise 
stated. Statistical significance will be based on two -tailed tests of the null hypothesis resulting in 
p-values of 0.05 or less. 
The primary method of handling missing efficacy data will be based on estimation using the 
method of Markov Chain Monte Carlo (MCMC) imputation. This method provides robust estimation when the pattern of missingness is arbitrary. Additionally, the estimation will be done for each treatment group separately so that the pattern of missingness for one group does not influence the estimation of missing data for another group. Groups of complete datasets following the estimation will be  concatenated to form analysis datasets for the comparative 
analyses and subsequent imputation result inference with SAS PROC MIANALYZE. Descriptive statistics will also be derived from the multiply imputed  datasets.  
Additionally, a model -based multiple imputation process will be used as a sensitivity analysis to 
the MCMC imputation. Finally, the absolute change in lesion count will be analyzed using a repeated measures ANCOVA for lesion count data or a repeated measures logistic regression model (generaliz ed estimating equations) for the dichotomized EGSS.  
 
 
A statistical analysis plan (SAP), describing all statistical analyses will be provided as a separate document. The SAP will be finalized prior to unblinding of the study treatments. 
Evaluations and Analyses  
Inflammatory lesions and non- inflammatory lesions will be recorded for each subject at Baseline 
and at Weeks 4, 8, and 12. The absolute and percent change from baseline of inflammatory lesions and non- inflammatory lesions will be d erived for each subject at Weeks 4, 8, and 12.  
The EGSS will be recorded for each Subject. The EGSS will be dichotomized into “success” and “failure” at Week 4, [ADDRESS_686562] week.  
All assessments will be conducted for both ITT and PP.  
 
12.1 Assessment of  Efficacy  
Pr ot oc ol V 0 1 -1 2 1 A -3 0 2, I D P -1 2 1  Valea nt Researc h & De vel o p me nt  
Versi o n 1, 0 4 J u ne 2 0 1 5  C O N FI D E N TI A L  
4 4   
  
 
All efficac y a n al ys es will be c o n d ucte d o n t h e I T T ( pri mar y) a n d P P (s u p p orti ve) p o p ulati o ns.  
 
1 2. 1. 1  Pri m ar y  Effic ac y  
T here are t hr ee c o -pri mar y efficac y e n d p oi nts:  
• A bs ol ute c ha n ge i n i nfla m mat or y lesi o n c o u nt fr o m baseli ne t o Wee k  1 2  
• A bs ol ute c ha n ge i n n o n -i nfla m mat or y lesi o n c o u nt fr o m baseli ne t o Wee k  1 2  
• Pr o p orti o n of s u bjects w h o ha ve a least a 2 gr a de re d ucti o n at Wee k 1 2 fr o m baseli ne 
i n t he E val uat or's Gl o bal Se verit y Sc ore a n d wer e Clear or Al m ost  Clear  
1 2. 1. 2  Sec o n d ar y  Effic ac y  
T here are t hr ee Wee k 1 2 sec o n dar y effi cac y e n d p oi nts:  
• Perce nt c h a n ge i n i nfla m mat or y lesi o n c o u nt fr o m baseli ne t o Wee k  1 2  
• Perce nt c h a n ge i n n o n -i nfla m mat or y lesi o n c o u nt fr o m baseli ne t o Wee k  1 2  
• Pr o p orti o n of s u bjects w h o ha ve a least a 2 gr a de re d ucti o n at Wee k 1 2 fr o m baseli ne 
i n t he E val uat or's Gl o bal Se verit y  S c ore  
T here are t hr ee Wee k 8 s ec o n dar y effi cac y e n d p oi nts:  
• Perce nt c h a n ge i n i nfla m mat or y lesi o n c o u nt fr o m baseli ne t o Wee k  8 
• Perce nt c h a n ge i n n o n -i nfla m mat or y lesi o n c o u nt fr o m baseli ne t o Wee k  8 
• Pr o p orti o n of s u bjects w h o ha ve a least a 2 gr a de re d ucti o n at Wee k 8 fr o m baseli ne 
i n t he E val uat or's Gl o bal Se verit y  S c ore  
T here are t hr ee Wee k 4 s ec o n dar y effi cac y e n d p oi nts:  
• Perce nt c h a n ge i n i nfla m mat or y lesi o n c o u nt fr o m baseli ne t o Wee k  4 
• Perce nt c h a n ge i n n o n -i nfla m mat or y lesi o n c o u nt fr o m baseli ne t o Wee k  4 
• Pr o p orti o n of s u bjects w h o ha ve a least a 2 gr a de re d ucti o n at Wee k 4 fr o m baseli ne 
i n t he E val uat or's Gl o bal Se verit y  S c ore  
[ADDRESS_686563] will be i ncl u de d i n t he m o del; 
ot her wise it will be re m o ve d.  
Pr ot oc ol V 0 1 -1 2 1 A -3 0 2, I D P -1 2 1  Valea nt Researc h & De vel o p me nt  
Versi o n 1, [ADDRESS_686564], bas e d o n t he met h o ds prese nte d b y J. H. Zar ( 1 9 8 4) [ 1 0 ], will be a p plie d t o t he 
resi d uals res ulti n g fr o m a n A N C O V A. A t w o -si de d p -val ue f or t h e s ke w n ess test si g nifica nt at  
0. [ADDRESS_686565] y t he use of t he n o n -par a metric m et h o d. If a para metri c a nal ysis is i n dicate d, t he 
res ults of t he par a metric a nal ysis will be c o nsi der e d t he pri mar y a nal ysis. S h o ul d a n o n - 
para metri c a nal ysis be i n dicate d, t he a bs ol ute or p erce nt c ha n ges i n i nfla m mat or y a n d n o n - 
i nfla m mat or y l esi o ns will be  ra n k tra nsf or me d pri or t o s u b mitti n g t he m t o t he A N C O V A. 
Res ults of t he ra n k -tra nsf or me d a nal yses t he n will be c o nsi der e d t he pri mar y a n al ysis; h o w e ver, 
res ults of t he n o n -r a n ke d tra nsf or me d a nal yses will als o be prese nte d.  
[ADDRESS_686566] o ys t he met h o ds of Secti o n re gar di n g missi n g v al u es. T he a n al ysis of t he 
dic h ot o mize d E val uat or's Gl o ba l Se verit y Sc ore will be base d o n t he l o gisti c re gr essi o n test 
stratifie d b y a nal ysis ce nt er a n d e m pl o ys t he met h o ds of Secti o n [ADDRESS_686567] f or a ste p is n ot si g nifica nt. All 
s u bse q ue nt tests f or t he r e mai ni n g ste ps will be c o nsi dere d n ot si g nifi ca nt. T he or der of testi n g 
is:  
 
Ste p 
N u m ber  Sec o n d ar y E n d p oi nt  
[ADDRESS_686568] a 2 gr a de re d ucti o n at Wee k 1 2 fr o m  
baseli ne i n t he E val uat or's Gl o bal Se verit y Sc ore  
[ADDRESS_686569] a 2 gr a de re d ucti o n at Wee k 8 fr o m  
baseli ne i n t he E val uat or's Gl o bal Se verit y Sc ore  
[ADDRESS_686570] a 2 gr a de re d ucti o n at Wee k 4 fr o m  
baseli ne i n t he E val uat or's Gl o bal Se verit y Sc ore  
Pr ot oc ol V 0 1 -1 2 1 A -3 0 2, I D P -1 2 1  Valea nt Researc h & De vel o p me nt  
Versi o n 1, [ADDRESS_686571] atistics  
Descri pti ve statistics will be prese nt e d f or t he f oll o wi n g para meters b y treat me nt gr o u p f or b ot h 
t he I T T a n d P P p o p ulati o ns:  
• Fre q u e nc y a n d per ce nt distri b uti o ns of t he E val uat or’s Gl o bal Se verit y Sc or e at 
Baseli ne a n d Wee ks 4, 8, a n d  1 2.  
• Fre q u e nc y a n d per ce nt distri b uti o ns of t he dic h ot o mize d E val uat or’s Gl o bal Se verit y 
Sc ore at Baseli ne a n d Wee ks 4, 8, a n d  1 2.  
• Descri pti ve statistics i ncl u di n g mea n, me dia n, sta n dar d de viati o n, mi ni m u m, a n d 
ma xi m u m will be use d t o s u m marize i nfla m mat or y a n d n o n -i nfla m mat or y lesi o n 
c o u n ts at baseli ne a n d wee ks 4, 8, a n d  1 2.  
• Descri pti ve statistics i ncl u di n g mea n, m e dia n, sta n dar d de viati o n, mi ni m u m, a n d 
ma xi m u m will be use d t o s u m marize t he a bs ol ute a n d perce nt c ha n ge i n 
i nfla m mat or y a n d n o n -i nfla m mat or y lesi o n c o u nts at Wee ks 4, 8, a n d  12.  
• Fre q u e nc y a n d per ce nt distri b uti o ns f or t he Oil y/ S hi n y assess me nts at Wee k  1 2  
Mea ns, sta n dar d d e viati o ns a n d fre q u e nc y c o u nts (r o u n de d t o t he nearest w h ole n u m ber) will be 
c o m p ute d fr o m t he m ulti pl y i m p ute d M C M C data f or t he vari a ble.  
[ADDRESS_686572] u d y e x ec uti o n at eac h i n vesti gati o nal site. T h e s t u d y is i nte n de d t o be c o n d ucte d i n a ma n n er 
s uc h t hat a mi ni m u m of 5 s u bjects will be e nr olle d i n eac h treat me nt ar m f or a n y i n vesti gat or. I n 
t he e ve nt t hat t her e ar e t o o fe w s u bjects i n a tr eat me nt ar m f or a n i n v esti gat or, t he n t his 
i n vesti gat or's dat a w ill be c o m bi ne d t o ac hie v e t he desire d sa m ple size mi ni m u m per ar m. T he 
c o m bi ni n g of i n vesti gat or's d ata will be acc o m plis he d b y t a ki n g t h e i n vesti gat or wit h t he 
s mallest e nr oll me nt a n d c o m bi ni n g it wit h t he i n vesti gat or wit h t he lar gest. If t here is a f ur t her 
nee d t o c o m bi ne dat a, t he n t he data of t h e i n vesti gat or wit h t he sec o n d s m allest e nr oll me nt will 
be c o m bi ne d wit h t he i n v esti gat or's d ata w hic h h a d t he sec o n d lar gest e nr oll me nt, a n d s o  o n.  
T his pr ocess will c o nti n ue f or all i n vesti gat ors w h o di d n ot ha ve a mi ni m u m of 5 s u bjects per 
acti ve treat me nt ar m. T h e pr ocess of c o m bi ni n g i n vesti gat or d ata t hat ha v e i ns ufficie nt s u bjects 
per treat me nt ar m will res ult i n re defi ni n g t he gr o u ps of i n vesti gat ors f or t he p ur p oses of 
statistical a nal ys es. T hes e c o m bi n e d gr o u ps will b e ref err e d t o as "a nal ysis ce nters" i n t he 
statistical a nal ys es base d o n A N C O V A a n d str atifie d l o gistic testi n g.  
Pri or t o i n vesti gati n g t h e treat me nt effect wit hi n t h e a nal ysis ce nt ers, t he ma g nit u de of t he site 
mail effect will be i n vesti g at e d t o deter mi ne if t he mai n site -t o -site varia bilit y is s uc h t hat it 
c o ul d mas k t he a nal ysis ce nter effects. T h us, if c o m p utati o nall y p ossi ble, a o ne -wa y A N C O V A 
(f or lesi o n c o u nt varia bles) or a l o gistic re gr essi o n a nal ysis (f or E G S S) wit h a fact or of si te will 
be c o n d ucte d pri or t o p o oli n g. If t he d ata str uct ur e i nterferes wit h t he l o gistic re gressi o n, a  
Protocol V01 -121A -302, IDP -121 Valeant Research & Development  
Version 1, [ADDRESS_686573] at an alpha level of 0.10. Change from basel ine in inflammatory lesions and non- inflammatory lesions will be analyzed with an 
ANCOVA (unranked or ranked) with factors of treatment, analysis center, and treatment by [CONTACT_85218] a co variate. For 
the purpose of testing consistency of treatment response, the dichotomized EGSS will be analyzed with a logistic regression procedure. Further examination will follow for any variables that have a significant ANCOVA or logistic regression inte raction term. In the event that the 
ANCOVA or logistic regression interaction (referred to henceforth as the "appropriate test") p-  
value is less than or equal to 0.10, a sensitivity analysis that excludes analysis centers with the extreme efficacy result will be performed to determine the robustness of the treatment effect. On the other hand, if the outcome of the appropriate test has a p- value greater than 0.10, then the 
conclusions from the pooled data will be considered to be free of the impact of extre me analysis 
centers.  
The first step in conducting a sensitivity analysis is to identify the extreme analysis center or 
centers that contribute to the statistical significance of the appropriate test. The process involves submitting subsets of analysis cent ers to the appropriate test and observing the appropriate test p-  
value for the subset. Subsets with p- values greater than 0.[ADDRESS_686574] p-  
value exceeds 0.10.  
Protocol V01 -121A -302, IDP -121 Valeant Research & Development  
Version 1, [ADDRESS_686575] -hoc aspects of the process will be given when the results are interpreted. Conclusions 
will be presented by [CONTACT_85220].  
12.1.7  Missing Efficacy Data Imputations  
Lesion Count Variable Missing Data Imputation  
Missing 12 week data will be estimated by [CONTACT_85221]. Missing lesion count data will be derived for the analysis using the method of Markov Chain Monte Carlo (MCMC) multiple imputation which does not rely on the assumption of data missing at random. Additionally, the pattern of missing observations in each treatment group cannot influence the missing value estimation in the other because the imputation is being conducted independently for each treatment group. 
Multiple imputation and subsequent analysis will involve [ADDRESS_686576] phases with these principal 
tasks:  
 
1. Calculated the number of missing values to be estimated by [CONTACT_85222] (nmiss) for 12 week 
value.  
2. Create a data set of subjects, one for each treatment gro up, with observed values and 
those needing estimation by [CONTACT_85222]. The missing lesion count values in each data set will be filled in using the MCMC method ‘5 x nmiss’ times to generate ‘5 x nmiss’ data sets. The resulting data sets for each treatment arm will be combined into one complete 
data set for each  imputation.  
3. For each complete data set, the absolute change in lesion counts for baseline minus the 12 
week value will be computed. Each complete data set will be analyzed as specified for the particular  analysis.  
4. The results from these analyses will be combined into a single inference using SAS 
PROC  MIANALYZE.  
EGSS Missing Data Imputation  
A similar procedure will be used for the analyses based on proportion of EGSS successes wherein the ANCOVA analysis is replaced with a logistic regression analysis. Specifically, missing 12 week EGSS values from which the dichotomized EGSS is derived will be estimated by (MCMC) which does not rely on the assumption of data missing at random. Additionally, the  
Protocol V01 -121A -302, IDP -121 Valeant Research & Development  
Version 1, 04 June 2015  CONFIDENTIAL  
49  
  
 
pattern of missing observations in each treatment group cannot influence the missing value 
estimation in the other because the imputation is being conducted independently for each treatment group.  
The missing 12 week EGSS values will be de rived for the analysis using the method of Markov 
Chain Monte Carlo (MCMC) multiple imputation. Multiple imputation and subsequent analysis will involve 4 principal tasks:  
1. Calculate the number of missing values to be estimated by [CONTACT_85222] (nmiss) for 12 week value.  
2. Create a data set, one for each treatment group, of subjects with observed values and those needing estimation by [CONTACT_85222]. The missing EGSS values in each data set will be filled in using the MCMC method ‘5 x nmiss’ times to generate ‘5 x nmiss’ data se ts. The 
resulting data sets for each treatment arm will be combined into one complete data set by [CONTACT_47915].  
3. For each complete data set, the dichotomous success rate (clear or almost clear with a 2 - 
point change from baseline) will be computed. The 12- week estimated global values  will 
be rounded to the nearest integer value prior to evaluating the success rate. Each complete data set will be analyzed with a logistic regression with factors of treatment group and analysis  center.  
4. The results from thes e analyses will be combined into a single inference using SAS 
PROC  MIANALYZE.  
12.1.[ADDRESS_686577] sensitivity analysis for absolute change in lesion count use a repeated measures ANCOVA, with treatment, analysis center, and visit (ie, Week 4, Week 8) as independent factors and a covariate of baseline lesion count.  In this analysis, data from all post -baseline visits will 
be included with no imputation for missing  data.  
The second sensitivity analysis will use the model based multiple imputation method to impute missing data for the absolute change in lesion counts at Week 12. Multiple imputation will involve 4 principal tasks:  
1. Calculate the number of missing values (nmiss) for absolute change in lesion  count.  
2. Missing values will be filled in ‘5 x nmiss’ times to generate ‘5 x nmiss’ complete data sets. The imputation model used will be an ANCOVA with factors of treatment group and analysis center, and a covariate of baseline lesion count (ie, the imputation model will be the same as the analysis model). Appropriate modifications will be made should the analysis be based on a non- parameteric method. 
Protocol V01 -121A -302, IDP -121 Valeant Research & Development  
Version 1, [ADDRESS_686578] sensitivity analysis for the dichotomized EGSS success will use a repeated measures logistic regression model (generalized estimating equations), with dichotomized EGSS success as the dependent variable and treatment, analysis center, and visit (ie, Week 4, Week 8) as independent factors. In this analy sis, data from all post -baseline visits will be included with no 
imputation for missing data.  
The second sensitivity analysis will use the model based multiple imputation method to impute missing data for the dichotomized EGSS data. Multiple imputation wil l involve 4 principal 
tasks:  
1. Calculate the number of missing values (nmiss) for absolute change in lesion count.  
2. Missing values will be filled in ‘5 x nmiss’ times to generate ‘5 x nmiss’ complete data sets. The imputation model used logistic regression with factors of treatment group and analysis center (ie, the imputation model will be the same as the analysis  model). 
3. Each complete data set will be analyzed with a logistic regression a factors of  treatment 
group and analysis  center.  
4. Results from these analyses will be combined into a single  inference.  
 
12.1.9  Subgroup Analyses  
Subset analyses will be conducted for the ITT populations for the subgroups baseline global severity, gender, age, ethnicity and race. Age will be dichotomized to less than the median age of subjects and greater than or equal to the median age of subjects. An additional analysis will be include with categories of less than 18, 18 to less than the median age and greater than or equal to the median age. Subset analyses will be conducted on the variables absolute change from baseline in inflammatory lesions and non- inflammatory lesions at Week 12 as well as the 
dichotomized global severity score at Week 12. These analyses will contain only descriptive statistics.  
 
12.2 Assessment of  Safety  
Safet y will be evaluated by [CONTACT_220131] (AEs), Cutaneous Safety Evaluation, 
and Tolerability Evaluations. Cutaneous Safety Evaluation scores (erythema and scaling) and Tolerability (itching, burning, and stinging) will be presented with descri ptive statistics at 
Baseline and at Weeks 4, 8, and 12 for each treatment group. Frequencies and percentages for  
Protocol V01 -121A -302, IDP -121 Valeant Research & Development  
Version 1, 04 June 2015  CONFIDENTIAL  
51  
  
 
each outcome category will be included in these statistics. Mean values will be presented 
graphically by [CONTACT_528820]. 
12.2.1  Adverse Events  
All adverse events occurring during the study will be recorded and classified on the basis of MedDRA terminology. Descriptions of AEs will include the date of onset, the date the AE ended, the severity of the AE, the relationship to stud y medication, the action taken regarding 
study medication usage, the action taken regarding to treat the AE, and the outcome. All reported treatment -emergent AEs (TEAEs) will be summarized by [CONTACT_365473], 
system organ class, severi ty, seriousness, and relationship to study medication. TEAEs are those 
AEs with an onset on or after the date of the first study drug application.  
Adverse events will be summarized by [CONTACT_85225]. Each subject will be counted only once within a system organ class or a preferred term by [CONTACT_220159].  
Adverse events will be summarized by [CONTACT_220160]. Each subject will be counted only once within a system organ class or a preferred term by [CONTACT_220161].  
Comparisons among treatment groups will be made by [CONTACT_220162] (classified i nto MedDRA terms) during the study. The Fisher’s Exact test will 
be used to compare the proportion of subjects in each treatment group who report any adverse 
event at a significance level of 0.05. The specific system organ classes and preferred terms analy zed will be those that are reported by [CONTACT_365477].  
All information pertaining to AEs noted during the study will be listed by [CONTACT_1130], detailing verbatim given by [CONTACT_093], preferred term, system org an class, start date, stop date, 
severity, actions taken, and drug relatedness. The AE onset will also be shown relative (in number of days) to the day of initial dose of the randomized study medication. 
Serious adverse events (SAEs) will be tabulated by s ubject within treatment groups.  
In addition, a list of subjects who discontinued from the study and a list of subjects who 
experienced SAEs will also be provided.  
12.2.2  Vital Sign  Measurements  
Changes from Baseline in vital sign measurements will be summarized w ith descriptive statistics 
for each treatment group at all applicable study visits.  
Protocol V01 -121A -302, IDP -121 Valeant Research & Development  
Version 1, [ADDRESS_686579]  Self-Assessments 
Subjects will be asked to complete three questionnaires during the study: the Subject Self Assessment scale, the Patient Satisfaction Survey and the Acne- Specific Quality of Life 
Questionnaire (Appendices 17.3, 17.4 and 17.5). Descriptive statistics will be used to summarize the data reported for each questionnaire. No Inferential analyses will be conducted.  
 
12.[ADDRESS_686580] demo graphic and baseline characteristics will be summarized by [CONTACT_528821]. For continuous variables (e.g. age) comparisons among the two treatment groups will be conducted using a two- way analysis of variance 
(ANOVA) with factors of treatment group and analysis center. Ethnicity and race will be analyzed with a Cochran -Mantel -Haenszel test stratified by [CONTACT_85229]. Past and current 
medical conditions, as well as history of disease will not be compared statistically.  
 
12.[ADDRESS_686581] 9 years of age and older with moderate or severe acne (a score of 3 or 4 [moderate to severe] on the EGSS scale) will be enrolled and randomized in the study. With a 1:1 randomization ratio, it is anticipated that: 
Pr ot oc ol V 0 1 -1 2 1 A -3 0 2, I D P -1 2 1  Valea nt Researc h & De vel o p me nt  
Versi o n 1, 0 4 J u ne 2 0 1 5  C O N FI D E N TI A L  
5 3   
  
 
• 4 0 0 s u bjects will be ra n d o mize d t o recei ve I D P -1 2 1 L oti o n, o nce d ail y  a p plicati o n  
• [ADDRESS_686582] -b aseli ne e val uati o n.  
A n i nte nt -t o -treat (I T T) a nal ysis will be c o n d u cte d o n all st u d y s u bjects. A per -pr ot oc ol ( P P) 
a nal ysis will als o be c o n d ucte d. S u bjects will be eli gi ble f or t he P P a nal ysis if t he y c o m plet e t he 
[ADDRESS_686583] u d y pr ot oc ol vi olati o ns (i.e., a n y s u bject or 
i n vesti gat or acti vit y t hat c o ul d ha ve p ossi bl y i nterfere d wit h t he t hera p e utic a d mi nistrati o n of t he 
treat me nt or t he pr ecise e val uati o n of treat me nt  efficac y). T h e P P p o p ulati o n will i ncl u de 
s u bjects i n t he safet y p o p ulati o n w h o d o n ot meet a n y of t he f oll o wi n g  criteria:  
• Faile d a n y of t he i ncl usi o n/e x cl usi o n  criteria;  
• Ha ve ta k e n a n y i nterferi n g c o n c o mita nt  me dicati o ns;  
• Di d n ot atte n d t he Wee k [ADDRESS_686584];  
• Misse d b ot h t he wee k 4 a n d wee k 8  visits;  
• Ha ve n ot bee n c o m plia nt wit h t he d osi n g re gi me n (i.e. S u bject s ma y n ot miss m ore 
t ha n fi ve c o nsec uti ve da ys of d osi n g a n d m ust ta ke 8 0 -1 2 0 % of e x pecte d d oses. T he 
n u m ber  of  e x pecte d  d oses  will  be  deter mi ne d  f or  eac h  s u bject  b ase d  o n  t he  le n gt h  of 
t heir partici pati o n i n t he  st u d y);  
• O ut of visit wi n d o w at t he [ADDRESS_686585] u d y  2 i n 
Atrali n ™ (treti n oi n) Gel, 0. 0 5 % N D A [ADDRESS_686586] u d y was a t w o -ar m trial of 
Atrali n ™ vers us its ve hicle a n d is felt t o be a rele v a nt st u d y i n N D A [ADDRESS_686587] 9 6 % p o wer t o det ect a st atisticall y si g nifica nt 
differe n ce wit h a si g nifica nce le v el of 0. 0 5. T he esti mate d a bs ol ute c ha n ge fr o m baseli ne  i n  
Protocol V01 -121A -302, IDP -121 Valeant Research & Development  
Version 1, 04 June 2015  CONFIDENTIAL  
54  
  
 
treatment means were 6.5 and 3.5 for Atralin™ versus its vehicle, respectively, with a standard 
deviation of 11.3. 
A sample size of 400 per treatment arm has greater than 99% power to detect a statistically 
significant difference with a significance level of 0.05 using the estimated absolute change from baseline in treatment means of 17.8 and 9.9 for Atralin
™ versus its vehicle, respectively, with a 
standard deviation of 24.7. 
The sample size estimates for the dichotomized EGSS require a substantially larger enrollment in 
order to achieve a power of at least 90%. The success rates observed in the second Atralin™ 
study was 23% for Atralin™ and 14% for its vehicle which is a difference of 9%. Approximately 
90% power is achieved with sample s izes of 400 per treatment group, respectively, using a 1:1 
randomization. 
It is noted that the same differential in success rates was observed in Study 1 (Atralin™ 
(tretinoin) Gel, 0.05% NDA 022070 application). The success rates observed in the first 
Atralin™ study was 13% for Atralin™ and 4% for its vehicle which is also a difference of 9%. 
Using these estimates, more than 99% percent power is achieved with sample sizes of 400 per treatment group.  
The clinical study will be conducted under a common protoc ol at each investigational site and 
every effort will be made to promote consistency in study execution at each investigational site as well as uniform evaluation of the EGSS evaluation for subjects at the various study visits. The experience in clinical t rial execution gained during the execution of several acne studies 
conducted under the guidance of the Sponsor raises the expectation that the differential between the success rates of the two arms will be greater than 9%. Thus, the power of the EGSS is expected to be at least 95% for sample sizes of 400 subjects in each arm.  
Individually and collectively the considerations lead to a choice of randomizing 400 subjects per treatment group.  
12.8.3  Handling of Missing Data 
The method of multiple imputation will be used (see Section 12.1.7).  
 
12.8.4  Multicenter  Issues 
The study will be conducted at multiple investigational centers in North America with  the 
intention of pooling the results for  analysis.  
12.8.5  Multiplicity Issues  
Not applicable.  
Protocol V01 -121A -302, IDP -121 Valeant Research & Development  
Version 1, 04 June 2015  CONFIDENTIAL  
55  
  
 
12.8.6  Windowing  Rules  
The timing of all study visits is relative to Baseline (Day 0). The Week 4 and Week 8 visits 
should occur within ± 3 days of the scheduled times, the Week 12 visit should occur within - 3 / 
+5 days of the scheduled time. 
 
13 Quality Control and Quality Assurance  
13.1 Study  Monitoring  
An Investigator Meeting and/or an initiation visit will be conducted with the principal investigator [INVESTIGATOR_220124]/or its designee. During this meeting, an extensive review and discussion of the protocol, the role of the study technician, all study procedures, source documents, and eCRFs will be conducted. Evaluation scales will be reviewed extensively and documentation of training will be recorded for training of sponsor -approved 
evaluators.  
The study monitors /clinical research associates will be trained prior to study initiation. Following 
this training, an overview of the study disease and study material background will be understood. Specific monitoring guidelines and procedures to be followed during monitor ing visits will also 
be utilized. During the course of the study, all data will be 100% source document verified by [CONTACT_85231]. All subject source records must be made available to the monitors. 
The conduct of the study will be closely monitored by [CONTACT_941] s ponsor following GCP guidelines. 
The reports of these verifications will also be archived with the study report. In addition, 
inspections or on site audits may be carried out by [CONTACT_220165]'s Quality Assurance Department. The invest igators will allow the sponsor's representatives and any 
regulatory agency to examine all study records, corresponding subject medical records, clinical dispensing records and storage area, and any other documents considered source documentation. The inves tigators agree to assist the representative, if required.  
 
13.2 Audits and  Inspections  
The study will be conducted under the sponsorship of Valeant in conformation with all appropriate local and federal regulations, as well as ICH guidelines. Interim and end of study audits of raw data, study files, and final report may be conducted by [CONTACT_220166]’s Quality Assurance Department or designee.  
The sponsor is responsible for implementing and maintaining quality assurance and quality control systems to ensure that studies are conducted and data are generated, documented, and reported in compliance with the protocol, GCP, and applicable regulatory requirements. In addition, the sponsor will be responsible for securing agreement from all involved parties to ensure direct access to all study related investigational centers, source data/documents, CRFs,  
Protocol V01 -121A -302, IDP -121 Valeant Research & Development  
Version 1, [ADDRESS_686588]’s source documents and CRFs. The investigator or designee will enter the information required by [CONTACT_500815]. Subjects will be identified in the CRFs by [CONTACT_119123].  
The investigators must read the protocol thoroughly and must follow the instructions exactly. Any deviations should be agreed to by [CONTACT_85238], with appropriate written protocol amendments made prior to implementing the agreed changes. Any amendment containing major modifications (particularly if it may involve an increased risk to the subjects) will be approved by [CONTACT_85239]. No change in the conduct of the study can be instituted without written approval from the sponsor. 
 
[ADDRESS_686589] (IRB) or Independe nt Ethics Committee (IEC). A signed and dated notification of the 
IRB/IEC approval will be provided to the sponsor and investigator prior to study initiation. The name [CONTACT_85251]/IEC will be supplied to the sponsor. The investigator will provide required progress reports and report all SAEs to the IRB/IEC as required by [CONTACT_36985]/IEC.  
 
14.3 Written Informed  Consent  
Written informed consent/assent, in accordance with local clinical investigation regulations, must be obtained prior to participation in the study. The investigator or designee will discuss the purpose of the study with each subject, and provide a description of the study drug (including any potential and possible side effects) and the study procedures. Informat ion must be given both 
in oral and written form. Subject information will be provided in a language understandable to the subject and may not include any language that appears to waive any of the subject‘s  legal  
Protocol V01 -121A -302, IDP -121 Valeant Research & Development  
Version 1, [ADDRESS_686590] any study related procedures performed before his/her written  informed consent has been obtained. The original signed and dated informed consent 
form will be retained with the study records, and a copy of the signed form will be given to the subject.  
An informed consent template will be supplied by [CONTACT_456]. Any changes to the informed consent form must be agreed to by [CONTACT_500816]/IEC, and a copy of the approved version must be provided to the sponsor or designee after IRB/IEC approval.  
 
14.[ADDRESS_686591] initials, demographics (including birthdates), 
medical histories, and prior concomitant medication uses, along with the name [CONTACT_500834]. Other than where necessary to meet regulatory requirements, all data collected in this study will be presented in tabulated (ie, aggregate) form and listings containing information that could be used to identify an individual subject will not be included in any public disclosures of the study data or the study  results.  
 
14.[ADDRESS_686592].  
Pr ot oc ol V 0 1 -1 2 1 A -3 0 2, I D P -1 2 1  Valea nt Researc h & De vel o p me nt  
Versi o n 1, 0 4 J u ne 2 0 1 5  C O N FI D E N TI A L  
5 8   
  
 
1 4. 7  I n vesti g at or  O bli g ati o ns  
T he i n vesti gat or a gr ees, w he n si g ni n g t he pr ot oc ol, t o a d here t o t he i nstr ucti o ns a n d pr oce d ures 
descri be d i n it a n d t her e b y t o a d h ere t o t he pri nci ples of G o o d Cli nical Practice ( G C P).  
 
[ADDRESS_686593] f oll o w t he i ns tr ucti o ns e x actl y. 
W he ne ver p ossi ble, a n y pla n ne d de viati o ns s h o ul d be a gree d t o b y pri or disc ussi o n bet wee n t he 
s p o ns or a n d t he i n vesti gat or, wit h a p pr o priate d o c u me ntati o n of s p o ns or a p pr o val pri or t o 
effecti n g t h e c ha n ges a gr ee d u p o n. A n y a m e n d me nt t o t he pr ot oc ol c o ntai ni n g maj or 
m o dificati o ns ( partic ularl y if it ma y i n v ol ve a n i ncrease d ris k t o t he s u bjects) will be a p pr o ve d 
b y t he I R B bef ore it ma y be i m ple me nte d. N o c h a n ge i n t he c o n d uct of t he st u d y ca n be 
i nstit ute d wit h o ut writte n a p pr o val fr o m t h e s p o ns or.  
 
1 4. 9  C o nfi de nti alit y/ P u blic ati o n of t he  St u d y  
All t he data f ur nis he d t o t he i n vesti gat or a n d his/ her staff a n d all data o bt ai ne d t hr o u g h t his 
pr ot oc ol will be re gar de d as c o nfi de ntial a n d pr o prietar y i n nat ure a n d will n ot be discl ose d t o 
a n y t hir d p art y, e x ce pt f or t he F D A or ot her re g ulat or y b o d y, wit h o ut writte n c o nse nt fr o m t he 
s p o ns or.  
 
[ADDRESS_686594]’s s o urce d oc u me nts a n d i n a p plica ble 
st u d y l o gs pr o vi de d b y t h e s p o ns or. S o urce d o c u me nts i ncl u de s u bject me di cal rec or ds, h os pi[INVESTIGATOR_307] 
c harts, cli nic c h arts, i n vesti gat or s u bject st u d y files, as well as t he r e s ults of dia g n ostic tests  
(e g, la b or at or y tests). All re q uire d d ata s h o ul d be r ec or de d i n t he st u d y d o c u me ntati o n 
c o m pletel y f or pr o m pt data re vie w. U p o n st u d y c o m pleti o n or at a n y ot h er ti me s pecifie d b y t he 
s p o ns or or desi g nee, t h e a p pr o priate st u d y d oc u m e nts m ust be s u b mitte d.  
T he i n vesti gat or m ust kee p acc urate s e par ate r ec or ds (s o urce d oc u me ntati o n) of all s u bject visits, 
bei n g s ur e t o i ncl u de all perti ne nt st u d y r elate d i nf or mati o n. At a mi ni m u m, t his i ncl u des t he 
f oll o wi n g i nf or mati o n:  
• A state me nt i n dicati n g t h at t he s u bject has bee n e nr olle d i n t he st u d y a n d t h e  s u bject 
n u m ber  
• Date t hat i nf or me d c o nse nt was  o btai ne d  
• E vi de nce t hat t he s u bject meets st u d y eli gi bilit y r e q uire me nts (e g, me dical hist or y, 
scree ni n g  e v al uati o ns)  
Pr ot oc ol V 0 1 -1 2 1 A -3 0 2, I D P -1 2 1  Valea nt Researc h & De vel o p me nt  
Versi o n 1, 0 4 J u ne 2 0 1 5  C O N FI D E N TI A L  
5 9   
  
 
• Dates  of  all  st u d y  r elate d  visits  a n d  res ults  of  a n y  e val uati o ns/ pr oce d ur es  perf or me d, 
i ncl u di n g w h o perf or me d eac h assess me nt at eac h  visit  
• Use of a n y c o nc urre nt m e dicati o ns d uri n g t he  st u d y  
• D oc u me ntati o n of st u d y dr u g  acc o u nta bilit y  
• A n y a n d all si de effe cts a n d A Es m ust be t h or o u g hl y d oc u me nt e d t o  c o ncl usi o n  
• Res ults of a n y dia g n ostic tests c o n d ucte d d uri n g t he  st u d y  
• T he date t he s u bject e xite d t he st u d y a n d a state me nt i n dicati n g t hat t he s u bj ect 
c o m plete d t he st u d y or w as disc o nti n ue d earl y, i ncl u di n g t he reas o n f or 
disc o nti n uati o n  
N otes descri bi n g tele p h o ne c o n vers ati o ns a n d all electr o nic mail wit h t he s u bject or t he s p o ns or 
(s p o ns or’s desi g nee) c o n cer ni n g t he st u d y m ust be rec or de d or k e pt o n file. All s o urce 
d oc u me nts m ust be ma de a vaila bl e t o t he s p o ns or a n d t he s p o ns or’s desi g n ate d m o nit or u p o n 
re q uest.  
 
[ADDRESS_686595] u d y ar e t o be ret ai ne d b y t he i n vesti gat or 
u ntil n otifie d b y t h e s p o ns or i n writi n g t hat t he r ec or ds ma y b e destr o ye d.  
T he i n vesti gat or will all o w re pr ese ntati ves of t he s p o ns or’s m o nit ori n g tea m, t he g o ver ni n g 
I R B/I E C, t he F D A, a n d ot her a p plica ble re g ulat or y a ge nci es t o i ns pect all st u d y rec or ds, C R Fs, 
a n d c orr es p o n di n g p orti o ns of t he s u bject’s cli nic a n d/ or h os pi[INVESTIGATOR_500782] r ec or ds at r e g ular 
i nter vals t hr o u g h o ut t he st u d y. T hes e i ns pecti o ns are f or t he p ur p ose of v erif yi n g a d h er e nce t o 
t he pr ot oc ol, c o m plete ness a n d acc urac y of t he data bei n g e nter e d o nt o t he C R F, a n d c o m plia nce 
wit h F D A or ot her re g ul at or y a ge nc y re g ulati o ns.  
Protocol V01 -121A -302, IDP -121 Valeant Research & Development  
Version 1, 04 June 2015  CONFIDENTIAL  
60  
  
16 References  
1. Leyden JJ, Shalita AR. Rational therapy for acne vulgaris: an update on topi[INVESTIGATOR_71831]. 
J Am Acad Dermatol. 1986;15(4 Pt  2):907- 15. 
 
2. Webster GF. Acne vulgaris. BMJ. 2002;325(7362):475- 9. 
 
3. Eady EA. Bacterial resistance in acne. Dermatology.  1998;196(1):[ADDRESS_686596] antibiotic -sensitive and - resistant skin 
bacteria from acne patients. Br J Dermatol.  1994;131(3):331- 6. 
 
5. Leyden JJ, McGinley KJ, Cavalieri S, Webster GF, Mills OH, Kligman AM. 
Propi[INVESTIGATOR_500783].  J Am Acad  Dermatol. 
1983;8(1):41- 5. 
 
6. Shalita A. The integral role of topi[INVESTIGATOR_85163].  J 
Eur Acad Dermatol Venereol. 2001;[ADDRESS_686597]  3:43- 9. 
 
7. McLane  J. Analysis  of common  side effects  of isotretinoin. J Am Acad  Dermatol. 
2001;45(5):S188- 94. 
 
8. Orfanos  CE, Ehlert  R, Gollnick  H. The retinoids. A review  of their clinical  pharmacology 
and therapeutic use. Drugs.  1987;34(4):459- 503. 
 
9. Lucky AW, Cullen SI, Funicella T, Jarratt MT, Jones T, Reddick ME. Double -blind, 
vehicle- controlled, multicenter comparison of two 0.025% tretinoin creams in patients 
with acne vulgaris. J Am Acad Dermatol.  1998;38(4):S24- 30. 
 
10. Zar, JH. Biostatistical analysis. 2nd Edition. Englewood Cliffs, NJ: Prenti ce-Hall. P. 118- 
119. 1984.  
Protocol V01 -121A -302, IDP -121 Valeant Research & Development  
Version 1, [ADDRESS_686598] Instruction Sheet  
 
Wash your face gently with a mild cleanser approved by [CONTACT_85243] (not hot) 
water. Rinse thoroughly and gently pat dry with a cotton towel. Wait until skin is completely dry before applying the test material.  
 
A thin coating of test material should be applied once daily (about the same time every day)  to 
the entire face for twelve weeks. Use the tube to dispense a pea- sized amount of study drug to 
your finger tip. 
 
This dose should then be dotted on to 6 areas (chin, left cheek, right cheek, nose, left forehead, right forehead) on the face. After distributing the dose in this manner, gently rub the lotion into the skin. This amount should be used to evenly cove r the entire face excluding the mouth, eyes 
and lips. It is important to treat your entire face.  
 
Do NOT treat only specific lesions. DO NOT APPLY MORE THAN THE PRESCRIBED 
AMOUNT.  
Be sure to wash your hands after you apply the product. 
Reminders:  
- On study visit days please wait until after your study visit to apply the study  medication.  
- Avoid contact [CONTACT_68572], inside the nose, mouth and all mucous  membranes.  
- Do not cover the affected areas with any type of dressing, such as  gauze.  
- THE TEST MATERI AL SHOULD BE USED ONLY BY [CONTACT_500817].  
- Store at controlled room temperature 
20°C to 25°C (68°F to 77°F) with excursions permitted 
between 15°C to 30°C (59°F to 86°F) . Do not freeze. Avoid excessive heat or  cold.  
- Tubes of test material must be returned to the study facility, even if they are  empty.  
- If you miss any doses, at your next visit inform the study doctor of the date(s) of the missed 
dose(s).  
- Continue  to use the same,  study  doctor  approved, cleanser,  moisturizer  and sunscreen 
throughout the  study.  
- You must not use any other treatment for your facial acne while you are participating in this 
study.  
- Avoid unnecessary sun exposure and tanning  booths. 
Protocol V01 -121A -302, IDP -121 Valeant Research & Development  
Version 1, 04 June 2015  CONFIDENTIAL  
62  
  
 
- It is important that you inform the study site about any  medications (i.e., prescriptions, over - 
the-counter medications, street drugs, or herbal medications) that you have taken during the 
study.  
 
If you have any questions or have a potential research -related side effect or injury you may 
contact   [INVESTIGATOR_136]  . 
Protocol V01 -121A -302, IDP -121 Valeant Research & Development  
Version 1, [ADDRESS_686599] may use in the treatment area during the study. Subjects may only use Investigator approved products on the treatment area. Information regarding products used should be captured in the source document and recorded on the facial skin care section of the eCRF.  
 
Approved Cleansers:  
· CeraVe cleanser  
· Cetaphil daily cleaner and gentle cleansing  bar 
· Purpose gentle cleansing  wash  
Approved Moisturizers:  · CeraVe Cream or  Lotion  
· Moisturel cream or  lotion  
· Nutraderm  
· Cetaphil lotion or  cream  
· DML  
· Eucerin lotion or  cream  
· Purpose  
Approved Moisturizer/Sunscreen Combination Products:  · CeraVe Lotion A.M.  
· Olay Complete (SPF  15) 
· Neutrogena Health Defense Daily Moisturizer (SPF  30) 
· Cetaphil Daily Facial Moisturizer (SPF  15) 
Approved Sunscreens:  · Banana Boat Sport Sunblock Lotion (SPF 15, 30+ or  50) 
· Neutrogena UVA/UVB (SPF 30 or  45) 
· Neutrogena Sensitive Skin Sunblock Lotion (SPF  17) 
· Neutrogena Healthy Defense Oil -Free Sunblock Lotion (SPF 30 or  45) 
· Coppertone Water Babies UVA/UVB Sunblock Lotion (SPF  45) 
Pr ot oc ol V 0 1 -1 2 1 A -3 0 2, I D P -1 2 1  Valea nt Researc h & De vel o p me nt  
Versi o n 1, [ADDRESS_686600] Q uesti o n  
H o w w o ul d rate t h e c urre nt se verit y of y o ur f acial ac ne c o n diti o n o n a scale of 1 -7?  
( C hec k o nl y o ne b o x)  
1, Clear or al m ost clear s ki n ( > 9 0 %);  
2, M o deratel y cl ear s ki n ( > 8 0 % b ut ≤ 9 0 %);  
3, Fairl y clear s ki n ( > 7 0 % b ut ≤ 8 0 %); 
4, Ac ne c o v ere d a b o ut 5 0 % of t he face;  
5, Fairl y se v ere ac ne ( > 7 0 % b ut ≤ 8 0 % c o ver a ge);  
6, M o deratel y se v ere ac n e ( > 8 0 % b ut ≤ 9 0 % c o vera ge); 
7, Se vere ac ne, wit h al m ost t otal c o vera ge ( > 9 0 %).  
 
Wee k 2 ( at -h o me), 4, 8, a n d [ADDRESS_686601] Q uesti o n  
H o w w o ul d rate t h e c urre nt se verit y of y o ur f acial ac ne c o n diti o n o n a scale of 1 -7?  
( C hec k o nl y o ne b o x)  
1, clear ( 1 0 0 %);  
2, al m ost clear ( 9 0 % t o < 1 0 0 %);  
3, mar ke d i m pr o ve me nt ( 7 5 %  t o < 9 0 %);  
4, m o derate i m pr o ve m e nt ( 5 0 % t o < 7 5 %);  
5, fair i m pr o ve me nt ( 2 5 % t o < 5 0 %);  
6, n o c ha n ge;  
7, w orse  
Protocol V01 -121A -302, IDP -121 Valeant Research & Development  
Version 1, 04 June 2015  CONFIDENTIAL  
65  
  
 
17.4 Patient Satisfaction Survey (PSS)  
 
 
Baseline Question 
 
On a scale of [ADDRESS_686602] satisfied please rate your 
level of satisfaction with your current f acial acne study treatment.  
 
 
 
Pr ot oc ol V 0 1 -1 2 1 A -3 0 2, I D P -1 2 1  Valea nt Researc h & De vel o p me nt  
Versi o n 1, 0 4 J u ne 2 0 1 5  C O N FI D E N TI A L  
6 6   
  
 
1 7. 5  Ac ne -S pecific Q u alit y of Lif e Q uesti o n n aire  ( A c ne -Q o L)  
 
1.  I n t he p ast W E E K, h o w u nattracti ve di d y o u f eel beca use of y o ur f acial  ac ne?  
 e xtre mel y  ver y  m uc h  q uite  a bit  a g o o d  bit  s o me w hat  a little bit n ot at  all  
2.  I n t he p ast W E E K, h o w e m barrasse d di d y o u feel beca use of y o ur f acial  ac ne?  
 e xtre mel y  ver y  m uc h  q uite  a bit  a g o o d  bit  s o me w hat  a little bit n ot at  all  
3.  I n t he p ast W E E K, h o w s elf -c o nsci o us ( u neas y a b o ut o neself) di d y o u feel  a b o ut y o ur facial 
ac ne?  
 e xtre mel y  ver y  m uc h  q uite  a bit  a g o o d  bit  s o me w hat  a little bit n ot at  all  
4.  I n t he p ast W E E K, h o w u pset were y o u a b o ut ha vi n g facial  ac ne?  
 e xtre mel y  ver y  m uc h  q uite  a bit  a g o o d  bit  s o me w hat  a little bit n ot at  all  
5.  I n t he p ast W E E K, h o w a n n o ye d di d y o u feel at h a vi n g t o s pe n d ti me e ver y da y clea ni n g a n d 
treati n g y o ur face b eca us e of y o ur f acial ac ne?  
 e xtre mel y  ver y  m uc h  q uite  a bit  a g o o d  bit  s o me w hat  a little bit n ot at  all  
6.  I n t he p ast W E E K, h o w dissatisfie d wit h y o ur self -a p peara n ce di d y o u f eel beca use of y o ur 
facial  ac n e?  
 e xtre mel y  ver y  m uc h  q uite  a bit  a g o o d  bit  s o me w hat  a little bit n ot at  all  
7.  I n t he p ast W E E K, h o w c o ncer ne d or w orrie d wer e y o u a b o ut n ot l o o ki n g y o ur b est beca use 
of y o ur facial  ac ne?  
 e xtre mel y  ver y  m uc h  q uite  a bit  a g o o d  bit  s o me w hat  a little bit n ot at  all  
8.  I n t he p ast W E E K, h o w c o ncer ne d or w orrie d wer e y o u t h at y o ur ac n e me dicati o n pr o d ucts 
were w or ki n g fast e n o u g h i n cleari n g u p t he ac ne o n y o ur  face?  
 e xtre mel y  ver y  m uc h  q uite  a bit  a g o o d  bit  s o me w hat  a little bit n ot at  all  
9.  I n t he p ast W E E K, h o w b ot here d di d y o u feel a b o ut t he nee d t o al wa ys h a v e me dicati o n or 
c o ver -u p a vaila ble f or t h e ac n e o n y o ur f ace?  
 e xtre mel y  ver y  m uc h  q uite  a bit  a g o o d  bit  s o me w hat  a little bit n ot at  all  
[ADDRESS_686603]  W E E K,  h o w  m uc h  was y o ur  self -c o nfi de nce  (s ure  of  y o urs elf)  n e gati vel y  aff ecte d 
beca use of y o ur f acial  ac ne?  
 e xtre mel y  ver y  m uc h  q uite  a bit  a g o o d  bit  s o me w hat  a little bit n ot at  all  
[ADDRESS_686604]  W E E K,  h o w  c o ncer ne d  or  w orrie d  wer e  y o u  a b o ut  meeti n g  n e w  pe o ple  beca us e 
of y o ur facial  ac ne?  
 e xtre mel y  ver y  m uc h  q uite  a bit  a g o o d  bit  s o me w hat  a little bit n ot at  all  
[ADDRESS_686605] W E E K, h o w c o ncer ne d or w orrie d wer e y o u a b o ut g oi n g o ut i n p u blic beca use of 
y o ur faci al ac n e?  
 e xtre mel y  ver y  m uc h  q uite  a bit  a g o o d  bit  s o me w hat  a little bit n ot at  all  
Pr ot oc ol V 0 1 -1 2 1 A -3 0 2, I D P -1 2 1  Valea nt Researc h & De vel o p me nt  
Versi o n 1, [ADDRESS_686606] W E E K, h o w m uc h was s ocializi n g wit h pe o ple a pr o ble m f or y o u beca use of y o ur 
facial  ac n e?  
 e xtre mel y  ver y  m uc h  q uite  a bit  a g o o d  bit  s o me w hat  a little bit n ot at  all  
[ADDRESS_686607]  W E E K,  h o w  m uc h  was  i nteracti n g  wit h  t he  o p p osite  se x  ( or  sa me  se x  if  ga y  or 
les bia n) a pr o ble m f or y o u beca use of y o ur f acial  ac ne?  
 e xtre mel y  ver y  m uc h  q uite  a bit  a g o o d  bit  s o me w hat  a little bit n ot at  all  
[ADDRESS_686608] W E E K, h o w ma n y b u m ps di d y o u ha v e o n y o ur  face?  
 E xte nsi ve   A w h ole  l ot  A l ot  A m o derate  a m o u nt  S o me Ver y fe w  N o ne  
[ADDRESS_686609] W E E K, h o w ma n y b u m ps f ull of p us di d y o u ha v e o n y o ur  face?  
 E xte nsi ve   A w h ole  l ot  A l ot  A m o derate  a m o u nt  S o me Ver y fe w  N o ne  
[ADDRESS_686610] W E E K, h o w m uc h sca b bi n g fr o m y o ur faci al ac n e di d y o u  ha v e?  
 E xte nsi ve   A w h ole  l ot  A l ot  A m o derate  a m o u nt  S o me Ver y fe w  N o ne  
[ADDRESS_686611] W E E K, h o w c o nce r ne d or w orrie d wer e y o u a b o ut scarri n g fr o m y o ur f acial  ac ne?  
 e xtre mel y  ver y  m uc h  q uite  a bit  a g o o d  bit  s o me w hat  a little bit n ot at  all  
[ADDRESS_686612] W E E K, h o w oil y was y o ur facial  s ki n ?  
 e xtre mel y  ver y  m uc h  q uite  a bit  a g o o d  bit  s o me w hat  a little bit n ot at  all  
 
 
 
 
C o p yri g ht © 1 9 9 7 Merc k & C o., I nc.  
W hite h o use Stati o n, NJ, U S A 
Use d wit h P er missi o n  
Pr ot oc ol V 0 1 -1 2 1 A -3 0 2, I D P -1 2 1  Valea nt Researc h & De vel o p me nt  
Versi o n 1, 0 4 J u ne 2 0 1 5  C O N FI D E N TI A L  
6 8   
 1. D ura nte la S E M A N A pasa da, ¿ q ué ta n p oc o at r acti v o( a) t e se ntiste de bi d o al ac né d e la 
cara?  
2. D ura nte la S E M A N A pasa da, ¿ q ué ta n a ver g o nz a d o( a) te se ntiste de bi d o al ac né d e la cara?  
3. D ura nte la S E M A N A pasa da, ¿ q ué ta n ac o m pl ej a d o( a), [i nc ó m o d o(a) c o nti g o mis m o(a)], te 
se ntiste de bi d o al ac n é de la car a?  
4. D ura nte la S E M A N A pasa da, ¿ q ué ta n dis g ust a d o( a) te se ntiste p or te n er ac n é de la cara?  
5. D ura nte la S E M A N A pasa da, ¿ q ué ta n m ol est o( a) te se ntiste p or t o mar t a nt o tie m p o 
diaria me nte li m piá n d ote y trat á n d ote la cara, d e bi d o al ac né d e la cara?  
6. D ura nte la S E M A N A pasa da, ¿ q ué ta n i ns atisf ec h o( a) te se ntiste c o n t u as pect o pers o nal, 
de bi d o al ac n é de la car a?  
7. D ura nte la S E M A N A pasa da, ¿ q ué ta n i ntr a n q uil o( a) o pre oc u p a d o( a) est u viste de n o verte 
l o mej or p osi ble, de bi d o al ac né d e la cara?   
 
Fec h a:    
 
C uesti o n ari o s o bre l a c ali d a d de vi d a, es pecífic o al ac né  
 
  N o. de  I de ntific aci ó n:   
 
( F av or de m arc ar u n a c asill a p ar a c a d a pre g u nt a)  
 
 
de masia d o  m uc h o  m u y  basta nte  al g o  u n p oc o  na da  
       
 
 
de masia d o  m uc h o  m u y  basta nte  al g o  u n p oc o  na da  
       
 
 
de masia d o  m uc h o  m u y  basta nte  al g o  u n p oc o  na da  
       
 
 
de masia d o  m uc h o  m u y  basta nte  al g o  u n p oc o  na da  
       
 
 
de masia d o  m uc h o  m u y  basta nte  al g o  u n p oc o  na da  
       
 
 
de masia d o  m uc h o  m u y  basta nte  al g o  u n p oc o  na da  
       
 
 
de masia d o  m uc h o  m u y  basta nte  al g o  u n p oc o  na da  
       
Pr ot oc ol V 0 1 -1 2 1 A -3 0 2, I D P -1 2 1  Valea nt Researc h & De vel o p me nt  
Versi o n 1, 0 4 J u ne 2 0 1 5  C O N FI D E N TI A L  
6 9   
 8. D ura nte la S E M A N A pasa da, ¿ q ué ta n i ntr a n q uil o( a) o pre oc u p a d o( a) est u viste de q ue l os 
me dica me nt os y pr o d uct os para el ac né est u viese n f u nci o na n d o l o s uficie nte me nte rá pi d o 
para eli mi nar el ac n é de l a car a?  
9. D ura nte la S E M A N A pasa da, ¿ q ué ta n m ol est o( a) te se ntiste p or la n ecesi da d de te ner 
sie m pre dis p o ni bles me dica me nt os o cr e mas para c u brir el ac né d e la cara?  
1 0. D ura nte la S E M A N A pasa da, ¿ q ué ta n ne g ati v o f ue el efect o d el ac né e n t u c o nfia nza e n ti 
mis m o(a)?  
1 1. D ura nte la S E M A N A pasa da, ¿ q ué ta n i ntr a n q uil o( a) o pre oc u p a d o( a) te se ntiste al 
c o n ocer a n ue v as pers o n as, de bi d o al ac n é de la cara?   
 
( F av or de m arc ar u n a c asill a p ar a c a d a pre g u nt a)  
 
 
de masia d o  m uc h o  m u y  basta nte  al g o  u n p oc o  na da  
       
 
 
de masia d o  m uc h o  m u y  basta nte  al g o  u n p oc o  na da  
       
 
 
de masia d o  m uc h o  m u y  basta nte  al g o  u n p oc o  na da  
       
 
 
de masia d o  m uc h o  m u y  basta nte  al g o  u n p oc o  na da  
       
 
 
de masia d o  m uc h o  m u y  basta nte  al g o  u n p oc o  na da  
       
 
 
de masia d o  m uc h o  m u y  basta nte  al g o  u n p oc o  na da  
       
 
 
 
de masia d o  m uc h o  m u y  basta nte  al g o  u n p oc o  na da  
       1 2. D ura nte la S E M A N A pasa da, ¿ q ué ta n i ntr a n q uil o( a) o pre oc u p a d o( a) te se ntiste al salir y 
estar e ntr e la ge nte, d e bi d o al ac né d e la cara?  
1 3. D ura nte la S E M A N A pasa da, ¿ q ué t a n pr o ble m átic o f ue p ar a ti s oci aliz ar c o n l as 
pers o n as, de bi d o al ac né de la cara?  
1 4. D ura nte la S E M A N A pasa da, ¿ q ué t a n pr o ble m átic o f ue p ar a ti rel aci o n arte c o n 
pers o n as del se x o o p uest o ( o del mis m o se x o, para h o m ose x uales), de bi d o al ac né d e la 
cara?  
Pr ot oc ol V 0 1 -1 2 1 A -3 0 2, I D P -1 2 1  Valea nt Researc h & De vel o p me nt  
Versi o n 1, 0 4 J u ne 2 0 1 5  C O N FI D E N TI A L  
7 0   
  
 
( F av or de m arc ar u n a c asill a p ar a c a d a pre g u nt a)  
 
 
 
a b u n da ntes  u na  gra n  
ca nti da d   
m uc h os  u na ca nti da d  
m o dera da   
al g u n os  m u y  
p oc os   
ni n g u n o  
       
 
u na  gra n  
a b u n da ntes  ca nti da d  
  
 
 
 
a b u n da ntes  u na  gra n  
ca nti da d   
m uc has  u na ca nti da d  
m o dera da   
al g u nas  m u y  
p ocas   
ni n g u na  
       
 
 
de masia d o  m uc h o  m u y  basta nte  al g o  u n p oc o  na da  
       
 
 
de masia d o  m uc h o  m u y  basta nte  al g o  u n p oc o  na da  
       1 5. D ura nte la S E M A N A pasa da, ¿c uá nt os gr a n os te nías e n la cara?  
1 6. D ura nte la S E M A N A pasa da, ¿c uá nt os gr a n os i nf ect a d os te nías e n la cara?  
1 7. D ura nte la S E M A N A pasa da, ¿c uá ntas c ostr as o p ostill as (es pi [INVESTIGATOR_500784]) te nías, de bi d o al 
ac né d e la cara?  
1 8. D ura nte la S E M A N A pasa da, ¿ q ué ta n i ntr a n q uil o( a) o pre oc u p a d o( a) est u viste p or las 
marcas y o cicatrices, q u e q ue dar o n d el ac n é de la cara?  
1 9. D ura nte la S E M A N A pasa da, ¿ q ué ta n gr as os o esta ba el c utis?   
m uc h os  u na ca nti da d  
m o dera da   
al g u n os  m u y  
p oc os   
ni n g u n o  
     
 
S O C, A m 1, [ADDRESS_686613] 2 0 1 5  
A d diti o ns mar ke d i n b ol d , deleti o ns mar ke d i n stri ket hr o u g h . 
Secti o n  P a ge  Descri pti o n of C h a n ge or Cl arific ati o n  R ati o n ale  
As  
a p plica ble  As  
a p plica ble  U p date t o re visi o n c hr o n ol o g y, f o oters  A d mi nistrati ve c ha n ges  
2 1 0  Delete d “ a n d ser u m pre g na nc y testi n g ” Re m o val of re q uire me nt f or  
ser u m pre g na nc y testi n g *  
7. 1  1 8, 2 0  Delete d “ Ser u m pre g na nc y tests will als o be  
c o n d ucte d at Scree ni n g a n d Wee k 1 2 ”; 
Delete d “ Ser u m Pre g na nc y T est ( F O C B P) ” 
li ne ite m i n Sc he d ule of Assess me nts.  Re m o val of re q uire me nt f or 
ser u m pre g na nc y testi n g *  
1 1. 1. 1  3 1, 3 2  Delete d “ a n d Ser u m Pre g na nc y T est ”. 
Delete d “ At t he Scree ni n g a n d Wee k 1 2  
visits, ser u m pre g na nc y testi n g is ma n dat or y  
f or all fe males of c hil d beari n g p ote ntial. I n  
a d diti o n, a ” Re m o val of re q uire me nt f or 
ser u m pre g na nc y testi n g *  
1 1. 1. 4  3 4  Delete d “ c ollect a bl o o d sa m ple f or a ser u m  
pre g na nc y test a n d ”.  Re m o val of re q uire me nt f or 
ser u m pre g na nc y testi n g *  
1 1. 3. 4  3 8  Delete d “ ser u m pre g na nc y testi n g at  
Scree ni n g a n d Wee k 1 2. I n a d diti o n, ”.  Re m o val of re q uire me nt f or 
ser u m pre g na nc y testi n g *  
* Detaile d rati o nale f or re m o val of ser u m pre g na nc y testi n g:  
- I nitial pr ot oc ol (s u b mitte d t o F D A as part of pI N D mt g) di d n ot i ncl u de ser u m pre g na nc y testi n g ( o nl y  U P T)  
- S p o ns or s u bse q ue ntl y a d de d i n ser u m testi n g ( B aseli ne a n d W ee k 1 2), t o be c o nser vati ve i n t he a p pr oac h wit h 
re gar d  t o  reti n oi ds  – t his  versi o n  of  pr ot oc ol  ( V 0 1 -1 2 1 A -3 0 1)  was  s u b mitte d  i n  t he  I N D  p ac ka ge  o n  2 4 -J ul y -1 5  
- S u bse q ue nt re vie w of w h ole pr ot oc ol, a n d I n vesti gat or fee d bac k c o nsi dere d t he f oll o wi n g p oi nts t o all o w f or 
re m o val of t he ser u m pre g na nc y testi n g  re q uire me nt:  
o U P Ts all o w f or se nsiti vit y of  ~ 9 9. 6 %  
o U P Ts will be perf or me d at all st u d y visits ( Scree ni n g, B aseli ne, W ee k 4, W ee k 8 a n d W ee k 1 2). T he 
c ha nce  f or m ulti ple false  ne gati ves  is  l o w.  If  at  a n y  p oi nt  d uri n g  t he  st u d y  a s u bj ect  bec o mes  pre g na nt,  t he 
s u bj ect m ust disc o nti n ue use of t he st u d y  dr u g.  
o T here  are  n o  safet y  la bs  bei n g  c o n d ucte d  i n  t his st u d y,  s o  t his  bl o o d  sa m ple w o ul d  be  t he  o nl y  dra w  f or  t he 
st u d y. T his ma y precl u de fe male s u bj ects fr o m e nteri n g t he st u d y ( partic ularl y  i n t he 1 0 -1 4 a ge ra n ge).  
- T he st u d y dr u g is a t o pi[INVESTIGATOR_332063] n oi d (treti n oi n, 0. 0 5 %), c o nsi dere d Cate g or y  C.  P R O T O C O L V 0 1 -1 2 1 A -3 0 2  
I D P -1 2 1 L oti o n  
Pr ot oc ol V 0 1 -1 2 1 A -3 0 2 (I D P -1 2 1)  
A P hase 3, M ulti -Ce nter, Ra n d o mize d, D o u ble -Bli n d, Ve hicle -C o ntr olle d, [ADDRESS_686614] u d y C o m pari n g t he Efficac y a n d Safet y 
of I D P -1 2 1 a n d I D P -1 2 1 Ve hicle L oti o n i n t he Treat me nt of Ac ne V ul garis  
S p o ns or:  
D o w P h ar m ace utic al Scie nces, a di visi o n of V ale a nt P h ar m ace utic als,  
1 3 3 0 Re d w o o d  W a y  
Pet al u m a, C A  9 4 9 5 4  
P R O T O C O L  V 0 1 -1 2 1 A -3 0 2  
I D P -1 2 1  L oti o n  
P a ge 1 of 3  
  
 
 
 
S U M M A R Y O F C H A N G E S  
Pr ot oc ol V 0 1 -1 2 1 A -3 0 2 
A me n d me nt 2, 2 8 Se pte m ber 2 0 1 5  
A d diti o ns mar ke d i n b ol d , deleti o ns mar ke d i n stri ket hr o u g h. 
Secti o n  P a ge  Descri pti o n of C h a n ge or Cl arific ati o n  R ati o n ale 
As  
a p plica ble  As  
a p plica ble  U p date t o re visi o n c hr o n ol o g y, f o oters  A d mi nistrati ve c ha n ges  
1 
1 1. 4. 6  3 
4 2  A d de d Office p h o ne n u m ber f or me dical m o nit or,  
“Office:  A d diti o nal i nf or mati o n f or  
me dical m o nit or c o ntact  
2 5, 6, 7, 8,  
9 A d de d “ Bl o o d s a m ples will be c ollecte d fr o m 
s u bjects f or s afet y m o nit ori n g at B aseli ne a n d Wee k 
1 2. ”  
Re place d refere nce t o A p pe n di x 2 wit h A p pe n di x 
1 7. 2.  
Re vise d sec o n dar y efficac y varia bles t o i ncl u de:  
( 1)  P erce nt c ha n ge i n i nfla m mat or y lesi o n c o u nt fr o m 
B aseli ne t o W ee k  1 2  
( 2)  P erce nt c ha n ge i n n o n -i nfla m mat or y lesi o n c o u nt 
fr o m B aseli ne t o W ee k  1 2  
A n d a d de d S u p p orti ve Efficac y t o i ncl u de:  
• Pr o p orti o n of s u bj ects w h o ha ve at least a 2 gra de 
re d ucti o n at W ee k 1 2 fr o m B aseli ne i n t he  E val uat or’s 
Gl o bal Se verit y  Sc ore  
• P erce nt c ha n ge i n i nfla m mat or y lesi o n c o u nt fr o m 
B aseli ne t o W ee k  8 
• P erce nt c ha n ge i n n o n -i nfla m mat or y lesi o n c o u nt fr o m 
B aseli ne t o W ee k  8 
• Pr o p orti o n of s u bj ects w h o ha ve at least a 2 gra de 
re d ucti o n at W ee k 8 fr o m B as eli ne i n t he  E val uat or’s 
Gl o bal Se verit y  Sc or e 
• P erce nt c ha n ge i n i nfla m mat or y lesi o n c o u nt fr o m 
B aseli ne t o W ee k  4 
• P erce nt c ha n ge i n n o n -i nfla m mat or y lesi o n c o u nt fr o m 
B aseli ne t o W ee k  4 
• Pr o p orti o n of s u bj ects w h o ha ve at least a 2 gra de 
re d ucti o n at W ee k 4 fr o m B as eli ne i n t he  E val uat or’s 
Gl o bal Se v erit y  Sc ore  Re q ueste d rec o m me n dati o n fr o m 
a ge nc y i n St u d y Ma y Pr ocee d 
letter ( date d 1 0 -Se p - 1 5); 
T y p o fi x; 
Re visi o n per re q ueste d 
rec o m me n dati o n fr o m a ge nc y i n 
St u d y Ma y Pr ocee d letter ( date d 
1 0- Se p - 1 5) Pr ot oc ol V 0 1 -1 2 1 A -3 0 2 (I D P -1 2 1)  
A P hase 3, M ulti -Ce nter, Ra n d o mize d, D o u ble -Bli n d, Ve hicle -C o ntr olle d, [ADDRESS_686615] u d y C o m pari n g t he Efficac y a n d Safet y 
of I D P -1 2 1 a n d I D P -1 2 1 Ve hicle L oti o n i n t he Treat me nt of Ac ne V ul garis  
S p o ns or: 
D o w  P h ar m a ce utic al  Scie nces,  a di visi o n  of V ale a nt P h ar m a ce utic als,  N A 
1 3 3 0 Re d w o o d W a y 
Pet al u m a, C A 9 4 9 5 4 
PROTOCOL  V01-121A -302 
IDP-121 Lotion  
Page 2 of 3  
  
  Added hypo/hyper -pi[INVESTIGATOR_500785];  
Added Changes from baseline in all safety laboratory 
values will be summarized using descriptive statistics 
by [CONTACT_1570] . 
Added: Additional supportive efficacy endpoints 
(including mean percent change in inflammatory and non- inflammatory lesions counts from baseline at 
Weeks [ADDRESS_686616] a two grade improvement in the Evaluator’s 
Global Se verity Score from baseline at Weeks 4, 8 
and 12) will be conducted, as noted above.  
Added Changes from baseline in safety laboratory 
values and vital sign measurements will be 
summarized with descriptive statistics for each 
treatment group at all applicabl e study visits. Shift 
tables will be presented for changes in safety laboratory values to summarize laboratory test results collected at Baseline and Week 12. Normal 
ranges established by [CONTACT_500818]. A listi ng of all out -of- 
range laboratory test results at Week [ADDRESS_686617] results will be provided.  Revision per requested 
recommendation from agency in 
Study May Proceed letter (dated 
10-Sep-15) 
7.1 19, 21  Added and safety  labs 
Added line item for “ Safety labs (hematology, 
CBC/diff, urinalysis)”  Revision per recommendation 
from agency in Study May  
Proceed letter dated 10 -Sep-15 
8.2 23 Added “at the prescribed amounts” to exclusion 
criteria #12  Typo updated for consistency 
with synopsis section  
9.4 28 Added “ non-medicated ” and “ and, sunscreens ” To clarify that skin care product 
use must be nonmedicated  
11.1.1  32 Added “ cleansers ” Clarification of allowed skin care 
products  
11.1.2  
11.1.4  33 
35 Added “ blood pressure, heart rate, respi[INVESTIGATOR_1487], 
and oral temperature ” 
Added line item for: Collect blood samples for  
routine laboratory analysis (CBC/Diff, serum 
chemistry and urinalysis)  Clarification of vital signs; 
Revision per recommendation 
from agency in Study May 
Proceed letter dated 10- Sep-15 
11.3.1  37, 38  Added Cutaneous safety will be evaluated through 
assessment of scaling, erythema, hypo- pi[INVESTIGATOR_220120] -pi[INVESTIGATOR_220121] -application site 
at the time of the visit.  
Added Hypopi[INVESTIGATOR_500786].  Clarification of cutaneous safety 
assessments and recommendation 
from agency in Study May 
Proceed letter dated 10- Sep-15 
11.3.4  39 Added Section for Laboratory Tests  Revision per recommendation  
from agency in Study May 
Proceed letter dated 10 -Sep-15 
11.4.2  40 Added “ Any AEs deemed related to treatment 
reported or observed at the final study/treatment 
visit will be followed until stabilization or resolution  Revision per recommendation  
from agency in Study May 
Proceed letter dated 10 -Sep-15 
PROTOCOL  V01-121A -302 
IDP-121 Lotion  
Page 3 of 3  
  
  (or up to 30 days after final study visit).”   
12.1.2  45 Deleted bullet point “ Proportion of subjects who  
have at least a 2 grade reduction at Week 12 from  
baseline in the Evaluator’s Global Severity Score ” 
from Secondary Efficacy and added it to Section  
12.1.3 Supportive Efficacy endpoints  Revision per recommendation 
from agency in Study May 
Proceed letter dated 10- Sep-15 
12.1.5  47 Edited Secondary Endpoint table to remove step 
numbers 3- 9, and added to a new Secondary 
Supportive Endpoint table; also added: The 
following stepwise process will be conducted for 
testing the supportive efficacy endpoints in order to 
control for multiplic ity. These tests will be 
performed for only the ITT population. In order to 
control for multiplicity failure of any one of the 
secondary efficacy endpoints will invalidate the 
statistical significance of the supportive efficacy 
endpoints. The testing proce ss will terminate 
whenever a statistical test for a step is not  significant.  
All subsequent tests for the remaining steps will be 
considered not significant. The order of testing is:  Revision per recommendation 
from agency in Study May 
Proceed letter dated  10-Sep-15 
12.1.8  50, 51, 52  Added Syntax code;  
Added: A total of [ADDRESS_686618] been pre - 
specified by [CONTACT_2329] a random number generator:  
• Inflammatory Lesion Counts; IDP -121 Lotion: 
Seed=  [PHONE_10385]  
• Inflammatory Lesion Counts; IDP -121 Vehicle: 
Seed=  356782065  
• Non-Inflammatory Lesion Counts; IDP -121 
Lotion: Seed=  [PHONE_10386]  
• Non-Inflammatory Lesion Counts; IDP -121 
Vehicle: Seed=  436373460  
Added : A total of [ADDRESS_686619] been pre -specified by [CONTACT_2329] a 
random number generator:  
• EGSS; IDP -121 Lotion: Seed=  [PHONE_10387]  
• EGSS; IDP -121 Vehicle: Seed=  763715437  Revision per recommendation 
from agency in Study May 
Proceed letter dated 10- Sep-15 
12.1.9  52, 53  Added: Although the full details will be presented in 
the Statistical Analysis Plan (SAP), the multiple ” Revision per recommendation 
from agency in Study May 
Proceed letter dated 10 -Sep-15 
12.2 53 Added “ and hypo/hyper -pi[INVESTIGATOR_371] ” Revision per recommendation 
from agency in Study May  
Proceed letter dated 10 -Sep-15 
12.2.2  54 Added Section for Safety Laboratory Tests  Revision per recommendation  
from agency in Study May 
Proceed letter dated 10 -Sep-15 
App 17.2  66 Deleted “ only”; Added “ as examples of approved  
products ”, “the below set of examples or other ”, 
“non-medicated ” Revision per recommendation  
from agency in Study May 
Proceed letter dated [ADDRESS_686620] o ber 2 0 1 6  
A d diti o ns mar ke d i n b ol d , deleti o ns mar ke d i n stri ket hr o u g h. 
Secti o n  P a ge  Descri pti o n of C h a n ge or Cl arific ati o n R ati o n ale 
As  
a p plica ble  As  
a p plica ble  U p date t o re visi o n c hr o n ol o g y, f o oters  A d mi nistrati ve c ha n ges  
1, 1 1. 4. 6  3, 4 3  U p date t o m o bile p h o ne n u m ber f or me dical 
m o nit or, fr o m  t o “  
 U p date d c o ntact i nf or mati o n f or 
me dical m o nit or  
1; [ADDRESS_686621]  M a n a ger  
 
F a x n u m ber:  N/ A  
 C ha n ge i n C R O Pr oject Ma na ger  
2, 1 2. 8. 4  5, 5 7  A d de d “ a n d L ati n A meric a ”  A d de d Lati n A merica sites t o t he  
st u d y  
2, 7. 1,  
1 0. 1. 3 5, 1 9, 3 1  A d de d Gl o ball y  
1 2 wee ks “ ( u p t o wee k 1 2 visit). ” A d de d f or m ore clarificati o n  
2, 1 1. 3. 4,  
1 1. 3. 5  5, 3 9  A d de d Gl o ball y  
wee k 1 2 “ visits ”  A d de d f or m ore clarificati o n  
[ADDRESS_686622] d A nti o bi otics t o A nti bi otics  C orrecti o n of s pelli n g  
2, 9. 5,  
1 0. 1. 1, 
1 0. 2, 
1 1. 1. 2,  2 1, 2 8, 3 0,  
3 2, 3 4, 3 5 A d de d Gl o ball y  
“( wit h t he c a p o n) t o t he ne arest 0. 1 gr a m ”  A d de d f or m ore clarificati o n a n d 
c o nsiste nc y  Pr ot oc ol V 0 1 -1 2 1 A -3 0 2 (I D P -1 2 1)  
A P hase 3, M ulti -Ce nter, Ra n d o mize d, D o u ble -Bli n d, Ve hicle -C o ntr olle d, [ADDRESS_686623] u d y C o m pari n g t he Efficac y a n d Safet y 
of I D P -1 2 1 a n d I D P -1 2 1 Ve hicle L oti o n i n t he Treat me nt of Ac ne V ul garis  
S p o ns or: 
D o w  P h ar m a ce utic al  Scie nces,  a di visi o n  of V ale a nt P h ar m a ce utic als,  N A 
1 3 3 0 Re d w o o d W a y 
Pet al u m a, C A 9 4 9 5 4 
PROTOCOL V01 -121A -302 
IDP-121 Lotion  
Page 2 of 3  
  
11.1.3,  
11.1.4     
8.3 25 Added  
Pregnancy – Subject will discontinue study drug 
immediately, but will be followed to term.  
Complete pregnancy and SAE form s. Added for more clarification for 
pregnancy reporting  
9.4 27-28 Updated  
Any concomitant medication or therapy stopped 
for washout as indicated below is to be recorded. Subjects using concomitant medications or 
therapi[INVESTIGATOR_220112] 
(including but not limited to those liste d above) 
should not be withdrawn, but the use of the 
concomitant product should be discontinued.  
Information on concomitant medications or 
therapi[INVESTIGATOR_500787]. Any therapy used by [CONTACT_220143] 
(e.g., Facial procedures, surgical procedures, 
investigations and operations) and any medication both over the counter (OTC) or 
prescription used by [CONTACT_500819] (eg, aspi[INVESTIGATOR_248], 
Tylenol, birth control pi[INVESTIGATOR_3353], vitamins, moisturizers, sunscreens). Every attempt should be made to keep 
concomitant medication and therapy dosing 
constant during the study. Any change to concomitant medication or therapy should be 
noted on the Concomitant Medication or Therapy 
source document and eCRF. 
All cleansers and moisturizers and other topi[INVESTIGATOR_528810]  
11.4.[ADDRESS_686624] be reported via 
confirmed facsimile/email transmission and must 
be submitted on a SAE and pregnancy report 
form s within 24 hours of the investigator’s 
awareness of the pregnancy using the same 
reporting as procedure for an SA E under Section 
11.4.6.  Added for more clarification for 
pregnancy reporting  
12.1.10  53 Updated  
Subset analyses will be conducted for the ITT populations for the subgroups baseline global 
severity, gender, age, ethnicity , and race, and 
geographic location. Age will be dichotomized to 
less than the median age of subjects and greater  
than or equal to the median age of subjects. An  Addition of outside US 
Geographic region due to addition 
of Latin America sites.  
PROTOCOL V01 -121A -302 
IDP-121 Lotion  
Page 3 of 3  
  
  additional analysis will be include with categories 
of less than 18, 18 to less than the median age and 
greater than or equal to the median age.  
Geographic region will be dichotomized to US 
and outside US (OUS).   
12.[ADDRESS_686625] u d y C o m pari n g  t he 
Efficac y a n d Safet y of I D P -1 2 1 a n d I D P -1 2 1 Ve hicle L oti o n i n t he 
Treat me nt of Ac ne  V ul garis 
 
 
De vel o p me nt  P h ase:  [ADDRESS_686626] u d y  Desi g n:  M ulti -ce nter, r a n d o mize d, d o u ble- bli n d, ve hicle -c o ntr olle d 
efficac y a n d s afet y st u d y  
 
D ate:  [ADDRESS_686627] o ber 2 0 1 6 ( A me n d me nt 3) 
 
S p o ns or:  D o w P har mace utical Sci e nces, a Di visi o n of Valea nt 
P har mace uticals N ort h A merica, L L C  
1 3 3 0 Re d w o o d Wa y 
Petal u ma, C A  9 4 9 5 4 
 
 
 
 
C O N FI D E N TI A L  
N ot hi n g herei n is t o be discl ose d wit h o ut pri or a p pr o v al of t he s p o ns or.  
 
 
 
 
 
 
 
 
 
 
 
Pr ot oc ol V 0 1 -l 2 1 A -3 0 2, I D P -1 2 1  Valea nt Researc h & De vel o p me nt   
  
 
Pr ot oc ol Re vie w a n d   A p pr o vals  
 
A P hase 3, M ulti -Ce nter, Ra n d o mize d, D o u ble -Bli n d, Ve hicle -C o ntr oll e d, [ADDRESS_686628] u d y C o m pari n g t he Effi c a c y a n d Safet y ofl D P -1 2 1 a n d 
I D P -1 2 1 V e hi cle L oti o n i n t he T r e at me nt of A c ne V ul g a ris  
 
R e vi e w e d a n d a p pr o v e d:  
ll · \ · 2ci  l p   
 
 
Va 1ea nt  P h ar m ac e utic als  N ort h  A m eri ca,  L L C  D ate  
 
 
 
 
 
 
V al ea nt P h ar ma c e uti c als N ort h A m eri c a, L L C  
 
 
 
 
 
 
V al ea nt P h ar ma c e uti c als N ort h A m eri c a, L L C  2 3 -  -0 c. i -k/e,  
D ate  
 
 
 
 
1 1/ 1 /wt b  
D at e  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Versi o n [ADDRESS_686629] o ber  2 0 1 6  C O N FI D E N TI A L  
2 
Protocol V01 -121A -302, IDP -121 Valeant Research & Development  
Version 4, [ADDRESS_686630] Manager  Fax number: N/A  
TKL Research, Inc.   
[ADDRESS_686631]   
[COMPANY_002]lle Park, NJ [ZIP_CODE]   

Pr ot oc ol V 0 1 -1 2 1 A -3 0 2, I D P -1 2 1  Valea nt Researc h & De vel o p me nt  
Versi o n 4, [ADDRESS_686632] o ber 2 0 1 6  C O N FI D E N TI A L  
4  
  
 
 
I a gree:  Pri nci p al I n vesti g at or Pr ot oc ol A gree me nt P a ge  
• T o ass u me res p o nsi bilit y f or t he pr o per c o n d u ct of t his cli nical st u d y at t his site a n d  t o 
c o n d uct t he st u d y i n c o m plia nce wit h t his pr ot oc ol, a n y f ut ure a me n d me nts, a n d wit h 
a n y ot h er st u d y c o n d uct pr oce d ur es pr o vi de d b y t he  s p o ns or.  
• T hat I a m a w are of, a n d will c o m pl y wit h, t he i nter nati o nall y rec o g nize d c o de of G o o d 
Cli nical Practices ( G C P) a n d all ot her a p plica ble r e g ul at or y re q uir e me nts t o o btai n 
writte n a n d date d a p pr o v al fr o m t he I nstit uti o nal Re vie w B o ar d (I R B) or I n de pe n de nt 
Et hics C o m mittee (I E C) f or t he st u d y pr ot oc ol, writte n i nf or me d c o nse nt, c o nse nt  f or m 
u p dates, s u bject -r ecr uit m e nt  pr oce d ures ( e. g., a d v ertise me nts), a n d a n y ot her writte n 
i nf or mati o n t o be pr o vi de d t o t he s u bjects, bef ore i nitiati n g t his cli nical  st u d y.  
• N ot t o i m ple me nt a n y c h a n ges t o, or de viati o ns fr o m t he pr ot oc ol wit h o ut pri or 
a gree m e nt fr o m t he s p o ns or a n d re vie w a n d d o c u me nte d a p pr o val fr o m t he  I R B/I E C, 
e x ce pt t o eli mi nate a n i m me diate hazar d t o t he st u d y s u bjects, or w he n c ha n ge(s) 
i n v ol ves o nl y l o gistical or a d mi nistrati ve as pects of t he cli nical  st u d y.  
• T o per mit direct m o nit ori n g a n d a u diti n g b y t he s p o ns or or s p o ns or’s  r e pres e ntati ves 
a n d i ns pecti o n b y t h e a p pr o priate r e g ulat or y  a ut h orit y(ies).  
• T hat I a m t h or o u g hl y fa miliar wit h t he a p pr o priate use of t he i n vesti gati o nal 
pr o d ucts(s), as d escri be d i n t his pr ot oc ol, a n d a n y ot her i nf or mati o n pr o vi d e d b y t h e 
s p o ns or or desi g nee, i n cl u di n g, b ut n ot li mite d t o, t he c urr e nt I n vesti gat or Br oc h ure  or 
e q ui vale nt d oc u me nt a n d a p pr o ve d pr o d u ct la bel (if  a p plica ble).  
• T o pr o vi de s ufficie nt ti m e, a n d a d e q uate n u m bers of q ualifie d staff a n d f acilities f or t he 
f orese e n d urati o n of t he cli nical st u d y t o c o n d uct t he st u d y pr o p erl y, et hicall y, a n d 
safel y.  
• T o e ns ure t hat all pers o ns assisti n g i n t his st u d y are a de q u atel y i nf or me d a b o ut t he 
pr ot oc ol, i n vesti gati o nal pr o d uct(s), a n d t h eir cli nical st u d y -relat e d d uties a n d 
fu ncti o ns.  
 
 
 
 
Pri nci pal I n v esti gat or ( pri nt na me)    
Pri nci pal I n v esti gat or (si g nat ur e)   Date  
Pr ot oc ol V 0 1 -1 2 1 A -3 0 2, I D P -1 2 1  Valea nt Researc h & De vel o p me nt  
Versi o n 4, [ADDRESS_686633] o ber 2 0 1 6  C O N FI D E N TI A L  
5  
  
 
2 S y n o psis  
 
N a me of S p o ns or/ C o m p a n y: D o w P h ar m ace utic al Scie nc es, a di visi o n of Valea nt P har mace uticals 
N ort h A merica, L L C  
N a me of I n vesti g ati o n al Pr o d uct: I D P -1 2 1 L oti o n  
N a me of Acti ve I n gre die nts: Treti n oi n 0. 0 5 % l oti o n  
Title of St u d y: A P hase 3, M ulti -Ce nter, Ra n d o mize d, D o u ble -Bli n d, Ve hicle -C o ntr olle d, [ADDRESS_686634] u d y C o m pari n g t he Efficac y a n d Sa fet y of I D P -1 2 1 L oti o n a n d I D P -1 2 1 Ve hicle 
L oti o n i n t he Treat me nt of Ac ne V ul garis  
N u m ber of cli nic al ce nters: M ultice nter, a p pr o xi matel y 3 2 -5 0 i n vesti gati o nal ce nters i n N ort h A merica 
a n d Lati n A merica  
O bjecti ve:  
T he pri mar y o bj ecti ve of t his st u d y is t o c o m pare t he efficac y, safet y a n d t olera bilit y of I D P -1 2 1 L oti o n 
a n d ve hicle i n t he treat me nt of s u bj ects wit h ac ne v ul garis.  
M et h o d ol o g y:  
T his is a m ultice nter, ra n d o mi ze d, d o u ble -bli n d, parallel gr o u p, ve hicle -c o ntr olle d, [ADDRESS_686635] u d y t o 
e val uate relati ve c ha n ges i n i nfla m mat or y a n d n o n -i nfla m mat or y lesi o n c o u nts, as well as treat me nt 
s uccess usi n g a n E val uat or’s Gl o bal Se verit y Scale ( E G S S) i n s u bj ects wit h m o derate t o s e vere ac ne. 
S u bj ects m ust be at least 9 years of a ge a n d ol der wit h m o der ate t o se vere ac ne v ul garis (a s c ore of 3 or  4 
[ m o derate t o se vere] o n t he E G S S scale), prese nti n g wit h 2 0 -4 0 i nfla m mat or y facial lesi o ns ( pa p ules, 
p ust ules, a n d n o d ules), 2 0 -1 0 0 n o n -i nfla m mat or y facial lesi o ns ( o pe n a n d cl ose d c o me d o nes), a n d < 2 
faci al  n o d ules.  
A p pr o xi matel y ei g ht h u n dre d ( 8 0 0) s u bj ects will be ra n d o mi ze d t o t he f oll o wi n g treat me nt gr o u ps:  
• 4 0 0 S u bj ects t o I D P -1 2 1 L oti o n, o nce -dail y a p plicati o n  
• 4 0 0 S u bj ects t o I D P -1 2 1 Ve hicle L oti o n, o nce -dail y  a p plicati o n  
All s u bj ects will recei ve o nc e dail y, t o pi[INVESTIGATOR_1306] y -a p plie d treat me nt t o t he face f or 1 2 wee ks ( u p t o wee k 1 2 
visit). S u bj ect visits i ncl u de S cree ni n g, B aseli ne, W ee k 4, W ee k 8, a n d W ee k [ADDRESS_686636] a n ne d:  
A p pr o xi matel y 8 0 0 s u bj ects will be ra n d o mize d t o t he f oll o wi n g treat me nt gr o u ps:  
• 4 0 0 S u bj ects t o I D P -1 2 1 L oti o n, o nce -dail y a p plicati o n  
• 4 0 0 S u bj ects t o I D P -1 2 1 Ve hicle L oti o n, o nce -dail y  a p plicati o n  
I ncl usi o n criteri a:  
1.  Male or fe male at least 9 years of a ge a n d  ol der;  
2.  Writte n a n d ver bal i nf or me d c o nse nt m ust be o btai ne d. S u bj ects less t ha n a ge of c o nse nt m ust si g n a n 
asse nt f or t he st u d y a n d a pare nt or a le gal g uar dia n m ust si g n t he i nf or me d c o nse nt (if s u bj ect  reac hes 
a ge of c o nse nt d uri n g t he st u d y t he y s h o ul d be re -c o nse nte d at t he ne xt st u d y  visit);  
3.  S u bj ect m ust ha ve a sc ore of 3 ( m o derate) or 4 (se vere) o n t he E val uat or’s Gl o bal Se verit y  assess me nt 
at t he scree ni n g a n d baseli ne  visit;  
4.  S u bj ects wit h facial ac ne i nfla m mat or y lesi o n ( pa p ules, p ust ules, a n d n o d ules) c o u nt n o less t ha n  2 0 
b ut n o m ore t ha n 4 0;  
5.  S u bj ects wit h facial ac ne n o n -i nfla m mat or y lesi o n ( o pe n a n d cl ose d c o me d o nes) c o u nt n o less t ha n 2 0 
b ut n o m ore t ha n 1 0 0;  
6.  S u bj ects wit h t w o or fe wer facial  n o d ules;  
Protocol V01 -121A -302, IDP -121 Valeant Research & Development  
Version 4, [ADDRESS_686637] be willing to practice 
effective contraception for the duration of the study. (Effective contraception is defined as stabilized 
on oral contraceptive for at least 3 months, IUD, condom with spermicidal, diaphragm with spermicidal, implant, Nuvaring, injection, transdermal patch or abstinence.) Females on birth  control 
pi[INVESTIGATOR_528811] e taken the same type pi[INVESTIGATOR_528812]. Those who have used birth control pi[INVESTIGATOR_528813]. Women who use birth control 
for acne control only should be  excluded.  
8. Pre-menses females and women of childbearing potential must have a negative urine pregnancy test  at 
the screening and baseline visits;  
9. Subjects must be willing to comply with study instructions and return to the clinic for required  visits. 
Subjects under the age of consent must be accompanied by [CONTACT_85168]/consent  signing;  
10. If a cleanser, moisturizer or sunscreen is needed during the study , Subjects must be willing to use  only 
allowed cleansers, moisturizers, sunscreens, or moisturizer/sunscreen combination products (see 
Appendix 17.2). If the subject wears makeup they must agree to use non -comedogenic makeup.  
Exclusion criteria:  
1. Use of an  investigational drug or device within 30 days of enrollment or participation in a  research 
study concurrent with this  study;  
2. Any dermatological conditions on the face that could interfere with clinical evaluations such as acne conglobata, acne fulminans, secondary acne, perioral dermatitis, clinically significant rosacea, gram - 
negative  folliculitis;  
3. Any underlying disease(s) or some other dermatological condition of the face that requires the use of 
interfering topi[INVESTIGATOR_500790];  
4. Subjects with a facial beard or mustache that could interfere with the study  assessments;  
5. Subjects with more than two (2) facial nodules;  
6. Evidence or history of cosmetic- related  acne;  
7. Subject has a history of experiencing significant burning or stinging when applying any  facial 
treatment (eg, make -up, soap, masks, washes, sunscreens, etc) to their  face;  
8. Female subjects  who are pregnant, nursing mothers,  planning a pregnancy during the course  of the 
trial, or become pregnant during the  study;  
9. Use of estrogens (eg, Depogen, Depo -Testadiol, Gynogen, Valergen, etc) for less than 12 weeks 
immediately preceding study entry; Subjects treated with estrogens [ADDRESS_686638] expects  to change dose, drug 
or discontinue estrogen use during the  study;  
10. If female, subject has a history of hirsutism, polycystic ovarian disease or clinically  significant 
menstrual  irregularities;  
11. Treatment of any type of cancer within the last 6  months;  
12. Subject uses medications and/or vitamins during the study which are reported to exacerbate acne 
(azothiaprim, haloperidol, Vitamin D, Vitamin B12, halogens such as iodides or bromides, lithium, systemi c or mid -to super -high potency corticosteroids, phenytoin and phenobarbital); Daily  vitamins 
at the prescribed amounts are acceptable;  
13. History of hypersensitivity or allergic reactions to any of the study preparations as described in  the 
Investigator’s Brochure, including known sensitivities to any dosage form of  tretinoin;  
14. Concomitant use of potentially irritating over -the-counter products that contain ingredients such as 
benzoyl peroxide, alpha- hydroxy acid, salicylic acid, retinol or gl ycolic  acids;  
Protocol V01 -121A -302, IDP -121 Valeant Research & Development  
Version 4, [ADDRESS_686639] not undergone the specified washout period(s) for the following topi[INVESTIGATOR_500769]:  
Topi[INVESTIGATOR_500770] [ADDRESS_686640] requires topi[INVESTIGATOR_85129] (e.g., chest and/or back), the 
investigator may prescribe a product that does not contain tretinoin and must be noted in source 
documents and eCRF.  
16. Subjects that have not undergone the specified washout period(s) for the following systemic 
medications  or subjects  who require  the concurr ent use  of any of the following  systemic  medications:  
Corticosteroids (including intramuscular injections)  
(inhaled  corticosteroids  allowed)  [ADDRESS_686641], dosage and mode of administration:  
Investigational Product: IDP -121 (tretinoin 0.05%) Lotion, applied topi[INVESTIGATOR_500771], once daily for [ADDRESS_686642]: IDP -121 Vehicle Lotion, applied topi[INVESTIGATOR_500771], once daily for 12 weeks.  
Duration of treatment:  
12 weeks for all subjects.  
Reference therapy, dosage and mode of administration:  
See comparator product above.  
Criteria for evaluation:  
Co-Primary efficacy:  
IDP-121 Lotion versus IDP -121 Vehicle Lotion  
Co-primary endpoints are:  
(1) Superiority in absolute change from Baseline to Week 12 in mean inflammatory lesion  counts  
(2) Superiority in absolute change from Baseline to Week 12 in mean non -inflammatory lesion  counts, 
and, 
(3) Percent of subjects who achieve at least a two -grade reduction from baseline and are Clear - or Almost 
Clear at Week 12 in the Evaluator’s Global Sev erity Score.  
Secondary efficacy:  
(1) Percent change in inflammatory lesion count from Baseline to Week  12 
(2) Percent change in non -inflammatory lesion count from Baseline to Week  12   
  
  
  
  
  
  
 
Pr ot oc ol V 0 1 -1 2 1 A -3 0 2, I D P -1 2 1  Valea nt Researc h & De vel o p me nt  
Versi o n 4, [ADDRESS_686643] o ber 2 0 1 6  C O N FI D E N TI A L  
8  
  
 
S u p p orti ve Effic ac y:  
• Pr o p orti o n of s u bj ects w h o ha ve at least a 2 gra de re d ucti o n at W ee k 1 2 fr o m B aseli ne i n  t he 
E val uat or’s Gl o bal Se verit y S c ore  
• P erce nt c ha n ge i n i nfla m mat or y lesi o n c o u nt fr o m B aseli ne t o W ee k  8 
• P erce nt c ha n ge i n n o n -i nfla m mat or y lesi o n c o u nt fr o m B as eli ne t o W ee k  8 
• Pr o p orti o n of s u bj ects w h o ha ve at least a 2 gra de re d ucti o n at W ee k 8 fr o m B aseli ne i n  t he 
E val uat or’s Gl o bal Se verit y  S c ore  
• P erce nt c ha n ge i n i nfla m mat or y lesi o n c o u nt fr o m B aseli ne t o W ee k  4 
• P erce nt c ha n ge i n n o n -i nfla m mat or y lesi o n c o u nt fr o m B as eli ne t o W ee k  4 
• Pr o p orti o n of s u bj ects w h o ha ve at least a 2 gra de re d ucti o n at W ee k 4 fr o m B aseli ne i n  t he 
E val uat or’s Gl o bal Se verit y  S c ore  
Effic ac y M e as ure me nts:  
Lesi o n C o u nts  
At eac h visit t he E val uat or will c o u nt t he t otal n u m ber of i nfl a m mat or y lesi o ns ( pa p ules, p us t ules, a n d 
n o d ules) o n t he s u bj ect’s face. N o d ules will be c o u nte d se paratel y b ut will be i ncl u de d i n t he t otal 
i nfla m mat or y lesi o n c o u nt. At baseli ne, eli gi ble s u bj ects ma y ha ve n o m ore t ha n t w o n o d ules. N o d ules 
will be i ncl u de d i n t he statistic al a nal ysi s of i nfla m mat or y lesi o n c o u nts. All i nfla m mat or y lesi o ns will be 
c o u nte d at t he sa me ti me rat her t ha n c o u nti n g pa p ules a n d p ust ules se paratel y. T he E val uat or will als o 
c o u nt t he t otal n u m ber of n o n -i nfla m mat or y lesi o ns ( o pe n a n d cl ose d c o me d o nes). T he sa m e bli n de d 
e val uat or s h o ul d perf or m t he l esi o n c o u nts a n d E G S S e val uati o ns at all visits fr o m baseli ne t o wee k [ADDRESS_686644].  
I nfl a m m at ory lesi o ns are defi ne d as f oll o ws:  
P a p ule – a s mall, s oli d ele vati o n less t ha n [ADDRESS_686645] ule – a s mall, circ u ms cri be d ele vati o n less t ha n 5 m m i n dia meter t hat c o ntai ns yell o w -w hite e x u date. 
N o d ule – a s u bc uta ne o us lesi o n greater t ha n or e q ual t o 5 m m i n dia meter  
N o n -i nfl a m m at ory lesi o ns are defi ne d a s f oll o ws:  
O pe n c o me d o nes ( blac k hea d) - a lesi o n i n w hic h t he f ollicle o pe ni n g is wi del y dilate d wit h t he c o nte nts 
pr otr u di n g o ut o nt o t he s urfac e of t he s ki n.  
Cl ose d c o me d o nes ( w hite hea d) – a lesi o n i n w hic h t he f ollicle o pe ni n g is cl ose d, b ut t he se bace o us gla n d 
is e nlar ge d b y t he press ure of t he se b u m b uil d u p, w hic h i n t ur n ca uses t he s ki n ar o u n d t he f ollicle t o t hi n 
a n d bec o me ele vate d wit h a w hite a p peara nce.  
Ev al u at or’s Gl o b al Severity Sc ore ( E G S S)  
At eac h visit t he se verit y will be deter mi ne d  base d o n e val uat or -bli n de d e val uati o ns of t he si g ns a n d 
s y m pt o ms of ac ne v ul garis. E val uati o ns will be sc ore d o n a scale of [ADDRESS_686646] clear  Rare n o n -i nfla m mat or y lesi o ns prese nt, wit h rare n o n -i nfla me d p a p ules ( p a p ules m ust 
b e res ol vi n g a n d ma y b e h y p er pi g me nte d, t h o u g h n ot pi n k -re d)  
2  
Mil d  S o me n o n -i nfla m mat or y lesi o ns are prese nt, wit h fe w i nfla m mat or y lesi o ns  
( p a p ules/ p ust ules o nl y; n o n o d ul o -c ystic lesi o ns)  
 
3  
M o d erate  N o n -i nfla m mat or y lesi o ns pre d o mi n ate, wit h m ulti ple i nfla m mat or y lesi o ns e vi d e nt: 
se ver al t o ma n y c o me d o n es a n d pa p ules/ p ust ules, a n d t h ere ma y or ma y n ot b e o n e 
n o d ul o -c ystic lesi o n  
4  
Se vere  I nfla m mat or y lesi o ns are m ore a p p are nt, ma n y c o me d o n es a n d p a p ules/ p ust ules, t h ere 
ma y or ma y n ot b e u p t o 2 n o d ul o -c ystic lesi o ns  
Pr ot oc ol V 0 1 -1 2 1 A -3 0 2, I D P -1 2 1  Valea nt Researc h & De vel o p me nt  
9  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A L  C uta ne o us safet y a n d t olera bilit y will be e val uate d b y ta b ulati o ns of a d verse e ve nts a n d C uta ne o us Safet y 
a n d T olera bilit y E val uati o n sc ores (scali n g, er yt he ma, h y p o/ h y per -pi g me ntati o n, itc hi n g, b ur ni n g, a n d 
sti n gi n g) t o be assesse d at eac h st u d y visit. Itc hi n g, b ur ni n g a n d st i n gi n g ( C uta ne o us t olera bilit y) will be 
re vie we d wit h t he s u bj ect at eac h st u d y visit as a n a vera ge o ver t he peri o d si nce t he pre vi o us visit.  
Scali n g, er yt he ma a n d h y p o/ h y per -pi g me ntati o n ( C uta ne o us Safet y) will be assesse d b y t he e val uat or at 
eac h visit. C ha n ges fr o m baseli ne i n all safet y la b orat or y val ues will be s u m marize d usi n g descri pti ve 
statistics b y treat me nt gr o u p.  
C uta ne o us t olera bilit y si g ns a n d s y m pt o ms t hat res ult i n t he s u bj ect re q uiri n g c o nc o mita nt t hera p y, 
i nterr u pti o n of treat me nt, or disc o nti n uati o n fr o m t he st u d y will be re p orte d as a n A E. At selecte d sites, 
sta n dar dize d p h ot o gra p h y of t he face will be perf or me d.  
St atistic al met h o ds:  
All statistical pr ocessi n g will be perf or me d usi n g S A S ® versi o n 9. [ADDRESS_686647] ors of treat me nt a n d a nal ysis ce nter a n d t he res pecti ve B aseli ne lesi o n c o u nt as a 
c o variate. T he pri mar y met h o d of ha n dli n g missi n g efficac y data will be base d o n esti mati o n usi n g t he 
met h o d of Mar k o v C hai n M o nte Carl o ( M C M C) i m p utati o n. A d diti o nall y, a m o del -base d m ulti ple 
i m p utati o n pr ocess will be use d as a se nsiti vit y a nal ysis t o t he M C M C i m p utati o n. Fi nall y, t he a bs ol ute 
c ha n ge i n lesi o n c o u nt will be a nal yze d usi n g a re peate d meas ures A N C O V A f or lesi o n c o u nt data or a 
re peate d meas ures l o gistic re gressi o n m o del ( ge neralize d esti mati n g e q uati o ns) f or t he dic h ot o mize d 
E G S S.  
T he c o -pri mar y a nal ysis of t he dic h ot o mize d E G S S will be base d o n t he l o gistic re gressi o n test stratifie d 
b y a nal ysis ce nter.  
P o p ul ati o ns A n alyze d a n d Tre at me nt Gr o u ps:  
I nfla m mat or y a n d n o n -i nfla m mat or y lesi o n c o u nts will be rec or de d f or eac h S u bj ect at B aseli ne a n d at 
W ee ks 4, 8, a n d [ADDRESS_686648]. T he E G S S will be dic h ot o mize d i nt o “s uccess” a n d “fail ure” 
wit h a S u bj ect c o nsi dere d a s uccess if t he E val uat or’s Gl o bal  Se verit y Sc ore at W ee k 4, 8, a n d [ADDRESS_686649] Clear.  
A n i nte nt -t o -treat (I T T) a nal ysis will be c o n d ucte d o n all st u d y s u bj ects. T he I T T p o p ulati o n will c o nsist 
of all ra n d o mize d s u bj ects w h o recei ve d st u d y  me dicati o n.  
T he safet y p o p ulati o n will be c o m prise d of all ra n d o mize d s u bj ects w h o are pres u me d t o ha ve use d t he 
st u d y me dicati o n at least o nce a n d w h o pr o vi de at least o ne p ost -baseli ne e val uati o n. A per -pr ot oc ol ( P P) 
a nal ysis will als o be c o n d ucte d. S u bj ects will be eli gi ble f or t he P P a nal ysis if t he y c o m pl ete t he [ADDRESS_686650] u d y pr ot oc ol vi olati o ns (i.e., a n y S u bj ect or i n vesti gat or acti vit y t hat 
c o ul d ha ve p ossi bl y i nterfere d wit h t he t hera pe utic a d mi nistrati o n of t he treat me nt or t he precise 
e val uati o n of treat me nt efficac y). T he P P p o p ulati o n will i ncl u de s u bj ects i n t he I T T p o p ulati o n w h o d o 
n ot meet a n y of t he f oll o wi n g criteria:  
• Faile d a n y of t he i ncl usi o n/e xcl usi o n  criteria;  
• Ha ve ta ke n a n y i nterferi n g c o n c o mita nt  me dicati o ns;  
• Di d n ot atte n d t he W ee k [ADDRESS_686651];  
• Misse d b ot h t he wee k 4 a n d wee k 8  visits;  
• Ha ve n ot bee n c o m plia nt wit h t he d osi n g re gi me n (i.e. S u bj ects ma y n ot miss m ore t ha n 
fi ve c o nsec uti ve da ys of d osi n g a n d m ust ta ke 8 0 -1 2 0 % of e x pecte d d oses. T he n u m ber  of 
e x pecte d d oses will be deter mi ne d f or eac h s u bj ects base d o n t he le n gt h of t heir 
partici pati o n i n t he  st u d y);  
• O ut of visit wi n d o w at t he [ADDRESS_686652] o ber  2 0 1 6  C O N FI D E N TI  
 
Pr ot oc ol V 0 1 -1 2 1 A -3 0 2, I D P -1 2 1  Valea nt Researc h & De vel o p me nt  
Versi o n 4, [ADDRESS_686653] u d y pr ot oc ol 
vi olati o ns.  
A p pr o xi matel y ei g ht h u n dre d ( 8 0 0) s u bj ects will be ra n d o mi ze d t o t he f oll o wi n g treat me nt gr o u ps:  
• 4 0 0 S u bj ects t o I D P -1 2 1 L oti o n, o nce -dail y a p plicati o n  
• 4 0 0 S u bj ects t o I D P -1 2 1 Ve hicle L oti o n, o nce -dail y  a p plicati o n  
Effic ac y:  
Pri m ary:  
C o -pri mar y efficac y a nal yses of t he a bs ol ute c ha n ge i n i nfla m mat or y a n d i n n o n -i nfla m mat or y lesi o ns 
will be c o n d ucte d o n t he I T T p o p ulati o n. T he pre -s pecifie d ti me p oi nt will be W ee k 1 2. Descri pti ve 
statistics will be prese nte d b y treat me nt gr o u p f or i nfla m mat or y a n d f or n o n -i nfla m mat or y lesi o ns as well 
as t he a bs ol ute c ha n ge i n i nfla m mat or y a n d i n n o n -i nfla m mat or y lesi o ns. All of t he testi n g relati n g t o t he 
a nal ysis of i nfla m mat or y a n d n o n -i nfla m mat or y lesi o ns will use t he met h o ds i ntr o d uce d i n Secti o n 1 2.  
T he c o -pri mar y a nal ysis of t he dic h ot o mize d E G S S (s uccess bei n g at least a  [ADDRESS_686654] Cle ar) f or t he I T T p o p ulati o n will be base d o n t he l o gistic re gressi o n test 
stratifie d b y a nal ysis ce nter.  
Sec o n d ary:  
Mea n perce nt c ha n ge i n i nfla m mat or y a n d n o n -i nfla m mat or y lesi o n c o u nts fr o m baseli ne t o  W ee k 1 2.  
S u p p ortive:  
A d diti o nal s u p p orti ve efficac y e n d p oi nts (i ncl u di n g mea n perce nt c ha n ge i n i nfla m mat or y a n d n o n - 
i nfla m mat or y lesi o ns c o u nts fr o m baseli ne at W ee ks [ADDRESS_686655] 
a t w o gra de i m pr o ve me nt i n t he E val uat or’s Gl o bal Se verit y Sc ore fr o m baseli ne at W ee ks 4, 8 a n d 1 2) 
will be c o n d ucte d, as n ote d a b o ve.  
S afet y E v al u ati o n:  
All s u bj ects w h o recei ve me di cati o n a n d pr o vi de at least o ne p ost -baseli ne e val uati o n will c o nstit ute t he 
safet y  p o p ulati o n.  
Safet y will be e val uate d b y ta b ulati o ns of a d verse e ve nts ( A Es), C uta ne o us T olera bilit y E val uati o ns. 
C uta ne o us Safet y E val uati o n s c ores (er yt he ma, scali n g, a n d h y p o/ h y per -pi g me ntati o n) a n d T olera bilit y 
(itc hi n g, b ur ni n g, a n d sti n gi n g) will be prese nte d wit h descri pti ve statistics at B aseli ne a n d at W ee ks 4, 8, 
a n d 1 2 f or eac h treat me nt gr o u p. Fre q ue ncies a n d perce nta ges f or eac h o utc o me cate g or y will be i ncl u de d 
i n t hese statistics. Mea n val ues will be prese nte d gra p hicall y b y wee k a n d treat me n t gr o u p.  
Vital si g ns a n d a n a b bre viate d p h ysical e xa m, a n d safet y la bs will be c o n d ucte d o n all s u bj ects at s pecifie d 
visits. F or fe males of c hil d -be ari n g p ote ntial ( F O C B P), uri ne pre g na nc y testi n g will occ ur at s pecifie d 
visits. C ha n ges fr o m baseli ne i n s afet y la b orat or y val ues a n d vital si g n meas ure me nts will be s u m marize d 
wit h descri pti ve statistics f or eac h treat me nt gr o u p at all a p plica ble st u d y visits. S hift ta bles will be 
prese nte d f or c ha n ges i n safet y la b orat or y val ues t o s u m marize la b orat or y test res ults c olle cte d at B aseli ne 
a n d W ee k [ADDRESS_686656] u d y me dicati o n usa ge, t he acti o n 
ta ke n re gar di n g t o treat t he A E, a n d t he o utc o me.  
Protocol V01 -121A -302, IDP -121 Valeant Research & Development  
Version 4, [ADDRESS_686657] relationship within each category.  
Comparisons among treatment groups will be made by [CONTACT_220162] (classified into Med DRA terms) during the study. The Fisher’s Exact test will be used to 
compare the proportion of subjects in each treatment group who report any adverse event at a significance 
level of 0.05. The specific system organ classes and preferred terms analyzed wil l be those that are 
reported by [CONTACT_220133].  
All information pertaining to AEs noted during the study will be listed by [CONTACT_1130], detailing verbatim 
given by [CONTACT_093], preferred term, system organ clas s, start date, stop date, severity, actions taken, 
and drug relatedness. The AE onset will also be shown relative (in number of days) to the day of initial dose of the randomized study medication.  
Serious adverse events (SAEs) will be tabulated by [CONTACT_85177].  
In addition, a list of subjects who discontinued from the study and a list of subjects who experienced 
SAEs will also be provided.  
Subject Self -Assessments  
An exploratory patient self assessment questionnaire and satisfaction survey will also be administered 
during the study.  
Subjects will be asked to complete three questionnaires during the study: the Subject Self Assessment 
scale, the Patient Satisfaction Survey and the Acne -Specific Quality of Life Questionnaire . The 
Investigator assessments (EGSS, lesion counts) will be conducted independently of these subject self 
assessments. The EGSS should always be completed prior to the lesion counts. Inferential statistical 
analysis will not be performed on these question naires; the subjective responses will be compared between 
treatment groups for trends.  
 
This study will be performed in compliance with GCP including the archiving of essential study 
documents. This  protocol follows guidelines outlined by [CONTACT_8639] 
(ICH).  All data furnished  to the investigator  and his/her  staff,  and all data obtained  through  this stud,  will 
be regarded as confidential and proprietary in nature and will not be disclosed to any third party, except 
for the [LOCATION_002] Food and Drug Administration or other regulatory body, without written  consent  
from the sponsor.  
Pr ot oc ol V 0 1 -1 2 1 A -3 0 2, I D P -1 2 1  Valea nt Researc h & De vel o p me nt  
Versi o n 4, [ADDRESS_686658] u d y Desi g n a n d  Pla n:  Descri pti o n  ................................ ............. [ADDRESS_686659] u g  Acc o u nta bilit y  ................................ ................................ ........ 3 1  
1 1  S T U D Y P R O C E D U R E S  A N D  E V A L U A TI O N S  ................................ ................ 3 2  
1 1. 1  Sc he d ule of E val u ati o ns  a n d  Pr oce d ures  ................................ ................... 3 2  
1 1. 1. 1  Visit 1:  Scree ni n g  Visit  ................................ ................................ .. 3 2  
1 1. 1. 2  Visit 2: Baseli ne Visit  ( D a y  0)  ................................ ....................... 3 3  
1 1. 1. 3  Visit 3 a n d 4: Wee k 4 ( Da y 2 8 ± 3 Da ys) a n d Wee k 8 ( Da y  5 6  
± 3  Da ys)  Visits  ................................ ................................ ............. 3 4  
1 1. 1. 4  Visit 5: Wee k 1 2 ( Da y 8 4 -3/ + 5 Da ys) Visit  –  E n d  of  St u d y 
Visit  ................................ ................................ ................................ 3 5  
1 1. 2  E val uati o n  of Efficac y  ................................ ................................ ............... 3 6  
Pr ot oc ol V 0 1 -1 2 1 A -3 0 2, I D P -1 2 1  Valea nt Researc h & De vel o p me nt  
Versi o n 4, [ADDRESS_686660] o ber 2 0 1 6  C O N FI D E N TI A L  
1 3   
 1 1. 2. 1  E val uat or’s Gl o ba l Se v erit y  Sc or e  ( E G S S)  ................................ ... [ADDRESS_686661] ics  ................................ .............. 5 5  
Pr ot oc ol V 0 1 -1 2 1 A -3 0 2, I D P -1 2 1  Valea nt Researc h & De vel o p me nt  
Versi o n 4, [ADDRESS_686662]  Data Pr otecti o n  ................................ ................................ .............. 6 0  
1 4. 5  Data  M o nit ori n g  C o m mittee  ................................ ................................ ...... 6 0  
1 4. 6  Fi na ncial  Discl os ure  ................................ ................................ ................... 6 0  
1 4. 7  I n v esti gat or  O bli gati o ns  ................................ ................................ ............. 6 1  
1 4. 8  C ha n ges t o  t he  Pr ot oc ol  ................................ ................................ ............. 6 1  
1 4. 9  C o nfi de ntialit y/ P u blicati o n of  t he St u d y  ................................ ................... [ADDRESS_686663] Self Assess me nt  Sc ori n g  Scale  ................................ ..................... 6 7  
1 7. 4  Patie nt Satisfacti o n  S ur ve y  ( P S S)  ................................ .............................. 6 8  
1 7. 5  Ac ne -S pecific Q u alit y of Lif e  Q uesti o n naire  ( A c n e -Q o L)  ........................ 6 9  
Pr ot oc ol V 0 1 -1 2 1 A -3 0 2, I D P -1 2 1  Valea nt Researc h & De vel o p me nt  
Versi o n 4, [ADDRESS_686664]  I de ntificati o n …  ................................ ................................ ........  2 9  
Ta ble  4.  E val uat or’s Gl o bal  Se verit y  S c ore  ................................ ................................ . 3 6  
Protocol V01 -121A -302, IDP -121 Valeant Research & Development  
Version 4, [ADDRESS_686665] Research Organization  
cGCP  Current Good Clinical Pratice  
EGSS  Evaluator’s Global Severity Score  
ET Early termination  
FDA 
FOCBP  [LOCATION_002] Food and Drug Administration 
Female of Childbearing Potential  
G Gram  
GCP  Good Clinical Practice  
IATL  Investigator’s Assessment of Total Lesions  
ICH International Conference on Harmonization  
IEC Independent Ethics Committee  
IRB Institutional Review Board  
ITT Intent -to-treat 
IWRS  Interactive Web Response System  
LOCF  Last observation carried forward  
MedDRA  Medical Dictionary for Regulatory Affairs  
mL Milliliter  
OTC  Over -the-counter  
PP Per protocol  
PSS Patient Satisfaction Survey  
QoL Quality of Life  
SAE  Serious adverse event  
SSA Subject Self Assessment  
UPT  Urine Pregnancy Test  
WHO  World Health Organization  
 
In this protocol, “sponsor duties” refer to responsibilities that will be performed by [CONTACT_103], the sponsor’s designee, or the sponsor’s designated contract research organization. In this protocol, “investigator” refers to the principal investigator [INVESTIGATOR_022]/her  designee, who is 
responsible for performing the study procedures and assessments. 
Pr ot oc ol V 0 1 -1 2 1 A -3 0 2, I D P -1 2 1  Valea nt Researc h & De vel o p me nt  
Versi o n 4, [ADDRESS_686666] o ge n pr o d ucti o n occ urri n g i n a d olesce n ce [ 1]. T he disease is m ost 
pre vale nt a m o n gst tee na gers, b ut it d oes occ ur l ater i n life, partic ularl y i n t h e t hir d a n d f o urt h 
deca d e. T he pat h o ge nesis is c o m ple x a n d i n v ol ves a n a n dr o ge n -sti m ulate d i ncreas e i n se b u m 
pr o d ucti o n, ass oc iate d wit h f ollic ular h y p er kerati nizati o n a n d o bstr ucti o n of t he se bace o us 
f ollicles. T his res ults i n a b n or mal des q ua mati o n of t he f ollic ular e pit heli u m, a n d is ass ociate d 
wit h bacterial pr olif erati o n (es peci all y Pr o pi o ni b a cteri u m ac nes ( P. ac nes) ) a n d c hr o nic 
i nfla m mati o n ass ociate d wit h ac ne. T hes e c h a n ges i n ac ne s u bjects r es ult i n e nlar ge d 
se bace o us gl a n ds; o bstr ucti o n of t he f ollic ular ca n al wit h ass ociate d se b u m rete nti o n a n d 
diste nti o n of t he f ollicle b y ti g htl y p ac ke d h or n y cells t hat lea d t o t he f o r mati o n cli nical 
i nfla m mat or y l esi o ns i ncl u di n g s u perficial p ust ules s uc h as c o me d o n es ( p o p ularl y k n o w n as 
“ blac k hea ds” or “ w hite h ea ds”); a n d m ore dee pl y l ocate d pa p ules, n o d ules a n d c ysts [ 1]. T he 
areas m ost affecte d b y t h e disease i ncl u d e t he pil ose bace o us f ollicles of t he hea d a n d u p p er 
tr u n k, w here t h e se bace o us gla n ds are p artic ularl y acti ve [ 2].  
C urre ntl y, t hera p e utic treat me nt of ac n e is directe d a gai nst [ADDRESS_686667] t he c ol o nizati o n of bacteria ( P. a c nes ) i n f ollicles has 
ma de use of a nti -i nfecti v es s uc h as t o pi[INVESTIGATOR_19529] l be nz o yl per o xi de ( 2. 5 % -1 0 %), cli n da m yci n, a n d 
er yt hr o m yci n a n d s yste mic tetrac ycli n es; h o we ver, k n o w n disa d va nta ges t o t his treat me nt 
m o dalit y i ncl u de irritati o n a n d li mite d use d ue t o pat h o ge n resista nce [ 2-5]. Effecti ve 
treat me nt direct e d t o war ds i n hi b iti n g se bace o us gla n d acti vit y h as i ncl u de d oral 
c ortic oster oi ds, s pir o n olact o ne, a n d is otreti n oi n i n a d diti o n t o a nti -a n dr o ge ns  
(e g, c y pr ot er o ne acet ate). K n o w n disa d va nta ges t o t his treat me nt m o dalit y i ncl u de bei n g 
li mite d t o use i n fe males (a nti -a n dr o ge ns), a n d li mite d t o s h ort ter m use f or safet y ( or al 
c ortic oster oi ds). Fi nall y, effecti ve treat me nt direct e d a gai nst i ntraf ollic ular 
h y perc or nifi cati o n has m a de use of reti n oi ds s uc h as oral is otreti n oi n a n d t o pi[INVESTIGATOR_500773] n oi n or 
is otreti n oi n t o re g ulate t h e  i ntraf ollic ular k erati nizati o n pr ocess, i n hi biti n g f ollic ular 
h y per ker ati nizati o n a n d f ollic ular o bstr ucti o n [ 6]. I n ge ner al, t he k n o w n us ef ul ness of or al 
reti n oi ds (ie, oral is otreti n oi n) is li mite d b y t heir si de eff ects, w hic h r a n ge fr o m relati vel y 
mi n or effects (e g, dr y n ess of m uc osa a n d s ki n, s ki n irritati o n, a n d s ki n scali n g) t o maj or 
t o xicit y s y n dr o mes (r e versi ble hair l oss, b o ne t o xicit y a n d t erat o ge ni cit y) a n d ma y i ncl u d e 
var yi n g d e gr ees of s y m pt o ms ass ociate d wit h h y p er vita mi n osis A  s y n dr o m e [ 2, 7, 8].  
Li ke wis e, t he efficac y of t o pi[INVESTIGATOR_332063] n oi ds s uc h as treti n oi n or is otreti n oi n ma y b e li mite d b y 
t he k n o w n si de effects, w hic h i ncl u de si g nifi ca nt er yt he m a, dr y ness, p eeli n g, scali n g, a n d 
irritati o n [ 9].  
Pr ot oc ol V 0 1 -1 2 1 A -3 0 2, I D P -1 2 1  Valea nt Researc h & De vel o p me nt  
Versi o n 4, [ADDRESS_686668] o ber 2 0 1 6  C O N FI D E N TI A L  
1 8   
  
 
Treti n oi n (all -tra ns -reti n oic -aci d) is a m e m ber of t he reti n oi d fa mil y of c o m p o u n ds a n d is a 
meta b olite of Vita mi n A t hat occ urs nat ur all y i n a ni mal a n d h u ma n tiss ues. W hile oral 
reti n oi ds (e g, is otreti n oi n) are reser ve d f or treat me nt of se vere n o d ular ac ne or se ver e ac n e  
resista nt t o oral a nti bi otics, t o pi[INVESTIGATOR_332063] n oi ds (e g, tr eti n oi n or is otreti n oi n) a p plie d dail y are 
use d t o i n hi bit t he f or mati o n of c o me d o nes a n d us uall y cl ear e ve n se v ere c o me d o nal ac n e 
wit hi n a fe w m o nt hs [ 6]. T o pi[INVESTIGATOR_2855] f or mati o ns of tr eti n oi n ha ve bee n u se d t o treat ac n e i n t he 
U nite d States ( U S) a n d t he E ur o pea n U ni o n f or m ore t ha n [ADDRESS_686669]. Treti n oi n acti vates 
3 me m bers of t he r eti n oi d aci d ( R A R) n uclear r ece pt ors ( R A R α, R A R β, a n d R A Rγ) w hic h 
act t o m o dif y ge ne e x pressi o n, s u bse q ue nt pr otei n s y nt h esis, a n d e pit helial cell gr o wt h a n d 
differe ntiati o n; h o we v er, it has n ot bee n esta blis he d w het her t he cli nical eff ects of treti n oi n 
are me diat e d t hr o u g h acti vati o n of reti n oic aci d rece pt ors, ot her mec ha nis ms, or b ot h.  
Alt h o u g h t he e x act m o de of acti o n of  treti n oi n is u n k n o w n, c urr e nt e vi de nce s u g gests t hat 
t o pi[INVESTIGATOR_500773] n oi n decreases c o hesi ve ness of f ollic ular e pit helial cells wit h decreas e d 
micr oc o me d o f or m ati o n. A d diti o nall y, treti n oi n sti m ulates mit otic acti vit y a n d i ncreas e d 
t ur n o ver of f ollic ular e pi t helial cells ca usi n g e xtr usi o n of t he c o me d o nes.  
I D P -1 2 1 is a l oti o n c o ntai ni n g 0. 0 5 % treti n oi n f or t he t o pi[INVESTIGATOR_500774]. T his 
pr o p ose d pr o d uct is t he first l oti o n f or m ulati o n de vel o pe d f or tr eti n oi n a n d will be e val uate d 
f or effecti ve n ess i n tre ati n g ac ne v ul garis.  
 
[ADDRESS_686670] u d y is t o e val uat e t he efficac y, s afet y a n d t olera bilit y of a o nce -dail y 
t o pi[INVESTIGATOR_2855] a p plicati o n of I D P -1 2 1 L oti o n c o m par e d t o its ve hicle (I D P -1 2 1 V e hicle L oti o n) i n 
s u bjects wit h m o derate t o se vere ac n e v ul garis (a sc ore of 3 or 4 [ m o derate t o se vere] o n t he 
E G S S scale).  
 
[ADDRESS_686671] a n: Descri pti o n  
T his is a m ultice nter, ra n d o mize d, d o u ble -bli n d, parallel -gr o u p st u d y d esi g ne d t o assess t he 
safet y, efficac y a n d t oler a bilit y of I D P -[ADDRESS_686672] 9 years of a ge a n d ol der a n d ha ve a cli nical 
dia g n osis of m o derate t o se vere ac n e v ul garis (a s c ore of 3 or 4 [ m o der a te t o se vere] o n t he 
E G S S scale).  
A p pr o xi matel y [ADDRESS_686673] u d y a n d r a n d o mize d i nt o o ne ( 1) of 
t w o ( 2) treat me nt gr o u ps: 4 0 0 s u bjects i n t he I D P -1 2 1 L oti o n, o nce d ail y a p plicati o n gr o u p,  
Protocol V01 -121A -302, IDP -121 Valeant Research & Development  
Version 4, 7 October 2016  CONFIDENTIAL  
19  
  
 
and 400 subjects in the  IDP-121 Lotion Vehicle, once daily application group. Subjects will 
be enrolled at a minimum of 32 and maximum of 50 independent study centers. The duration 
of treatment will be 12 weeks. Subjects will be evaluated at Screening, Baseline and at subsequent  follow -up visits (Weeks 4, 8, and 12).  
An interactive web based response system (IWRS) will be employed to facilitate 
randomization of study patients. Treatment assignments and study drug kit numbers will be 
generated centrally by [CONTACT_246011]. At each clinical site, subject numbers will be assigned consecutively at the screening visit starting with 001.  
The assigned study drug will be applied topi[INVESTIGATOR_85130] 12 weeks (up to week 12 visit). The initial application will be made at the investigational center as per instruction from the study coordinator or designee. The subjects will be instructed to avoid exposure to direct sunlight to prevent sunburn. Subjects will apply their daily treatments at home as explained by [CONTACT_500821]. During 
post-baseline study visits (Weeks 4, 8 and 12) t he subjects will be asked to return their used 
tubes of study drug and will be dispensed new tubes of study drug (only Weeks 4 and 8; 
Week 12 will be final visit). During the study, each subject will only be permitted to use approved non- medicated cleanser s, moisturizers and sunscreens.  
Subjects will be asked to complete three questionnaires during the study: the Subject Self Assessment scale (SSA, Appendix 17.3), the Patient Satisfaction Survey (PSS, Appendix 17.4) and the Acne -Specific Quality of Life Que stionnaire (Acne -QoL, Appendix 17.5). The 
Investigator assessments (EGSS, lesion counts) will be conducted independently of these subject self assessments. The EGSS should be completed prior to the lesion counts. Subjects will assess the severity of their acne at the baseline visit and at Weeks 2 (at home), 4, 8, and [ADDRESS_686674] at the baseline visit with instructions to complete it two weeks later and return it the Week 4 visit; sites shoul d call the Subject at Week 2 to remind them to complete the SSA. Subjects will 
complete the PSS related to prior therapy at baseline, and at Week 12 will complete the PSS related to current study medication. The Acne- QOL will be completed at baseline and W eek 
12. Inferential statistical analysis will not be performed on these questionnaires; the subjective responses will be compared between treatment groups for trends. 
Information on reported and observed adverse events (AEs) will be obtained at each visit. An 
abbreviated physical examination and safety labs will be performed at Baseline and Week 12 (end of treatment, final visit) for all subjects.  
For all female subjects of childbearing potential, urine pregnancy testing will be performed at Screening and confirmed at Baseline with a urine pregnancy test prior to randomization, and at Weeks 4, 8 and 12.  
Protocol V01 -121A -302, IDP -121 Valeant Research & Development  
Version 4, 7 October 2016  CONFIDENTIAL  
20  
  
 
Subjects who terminate study participation early will be asked to complete all Week 12 
assessments, as appropriate. Subjects who discontinue from the study during the treatment 
period will not be replaced. 
Version 4, 07 October 2016  CONFIDENTIAL  
21  
 Protocol  V01-121A -302, IDP-121 Valeant Research &  Development  
 
Table 1. Study Design and Schedule of  Assessments  
 
 
 
PROCEDURES  VISIT 11 
Screening 
Visit  VISIT 22 
Baseline  
Day 0  VISIT 32 
Week 4  
(Day 28 ±3 days)  VISIT 42 
Week 8  
(Day 56 ± 3 days)  VISIT 52,3 
Week  12 
(Day 84 -3/+5 days)  
Informed consent/Assent  X     
Obtain Subject Number from IWRS  X     
Demographics  X     
Medical history  X X    
Inclusion/Exclusion criteria  X X    
Previous therapi[INVESTIGATOR_014]  X     
PSS & Acne -QoL  X   X 
SSA4  X X X X 
Urine Pregnancy Test (UPT) (FOCBP)  X X X X X 
Abbreviated physical examination and vital signs   X   X 
Safety labs (hematology, CBC/diff, urinalysis)   X   X 
Oily/shiny skin assessment   X   X 
Lesion Counts  X X X X X 
EGSS  X X X X X 
Photographs (select sites only)   X   X 
Cutaneous Safety Evaluation   X X X X 
Tolerability Evaluation   X X X X 
Randomization in IWRS (obtain kit #)   X X X  
Administer Subject Instructions (Appendix 17.1)   X    
Dispense Study Drug5  X X X  
Weigh Study Drug to the nearest 0.1gram   X X X X 
Study Drug applied at investigational center   X    
Study Drug Collected    X X X 
Subject Diary Calendar dispensed   X X X  
Subject Compliance Reviewed / Diary    X X X 
Adverse Events  X X X X X 
Concomitant Therapy and Prohibited Therapi[INVESTIGATOR_365435]  X X X X X 
End of Study      X 
[ADDRESS_686675] occur after the appropriate washout period.  
2 All visit dates are in reference to baseline, e.g., Visit 4 occurs 8 weeks +/ - [ADDRESS_686676] during the baseline visit (Visit 2) with instructions to complete it at two  weeks and return it at 
the Week [ADDRESS_686677] material at the Baseline, Week 4 and Week 8 visits.  
Protocol V01 -121A -302, IDP -121 Valeant Research & Development  
Version 4, [ADDRESS_686678] Inclusion Criteria  
Subjects meeting all of th e following criteria will be eligible for study entry:  
1. Male or female at least 9 years of age and  older;  
2. Written and verbal informed consent must be obtained. Subjects less than age of 
consent must sign an assent for the study and a parent or a legal guardian must sign 
the informed consent (if subject reaches age of consent during the study they  should 
be re- consented at the next study  visit); 
3. Subject must have a score of 3 (moderate) or 4 (severe) on the Evaluator’s  Global 
Severity assessment at the s creening and baseline visit;  
4. Subjects with facial acne inflammatory lesion (papules, pustules, and nodules)  count 
no less than 20 but no more than 40; 
5. Subjects with facial acne non -inflammatory lesion (open and closed comedones) 
count no less than 20 but no more than 100; 
6. Subjects with two or fewer facial  nodules;  
7. Females of childbearing potential1 and females that are pre- menses must be willing to 
practice effective contraception for the duration of the study. (Effective contraception is defined as st abilized on oral contraceptive for at least 3 months, IUD, condom with 
spermicidal, diaphragm with spermicidal, implant, Nuvaring, injection, transdermal patch or abstinence.) Females on birth control pi[INVESTIGATOR_528814] t hree months prior to entering the study and must not change type during 
the study. Those who have used birth control pi[INVESTIGATOR_220110]. Women who use birth control for acne control only should be  excluded.  
8. Pre-menses females and females of childbearing potential must have a negative urine 
pregnancy test2 at the screening and baseline visits; 
9. Subjects must be willing to comply with study instructions and return to the clinic  for 
required visits. Subjects under the age of consent must be accompanied by [CONTACT_85184]/consent  signing;  
10. If a cleanser, moisturizer or sunscreen is needed during the study, Subjects must be willing to use only allowe d cleansers, moisturizers, sunscreens, or 
 
 
1 Pre-menses females and Females of Child Bearing Potential (FOCBP) include any female who has not undergone 
successful surgical sterilization (hysterectomy, bilateral tubal ligation or bilateral oophorectomy) or is not 
postmenopausal [defined as amenorrhea >12 consecutive months; or women on hormone replacement therapy 
(HRT) with documented plasma follicle -stimulating hormone (FSH) level >35mLU/mL]. Even women who are 
using oral, implanted or, injectable contraceptive hormones, an intrauterine device (IUD), barrier methods (diaphragm, condoms, spermicidal) to prevent pregnancy, practicing abstinence or where partner is sterile (e.g., vasectomy), should be considered to be of child bearing potential.  
[ADDRESS_686679] a minimum sensitivity of 2 5mIU -HCG/mL of urine and must be performed 
within 72 hours prior to the start of study medication. Kits will be provided by [CONTACT_2024].  
Protocol V01 -121A -302, IDP -121 Valeant Research & Development  
Version 4, 7 October 2016  CONFIDENTIAL  
23  
 moisturizer/sunscreen combination products (see Appendix 17.2). If the subject wears 
makeup they must agree to use non- comedogenic makeup.  
 
8.[ADDRESS_686680] Exclusion Criteria  
Subjects meeting any of the following criteria will be excluded from the study:  
1. Use of an investigational drug or device within 30 days of enrollment or  participation 
in a research study concurrent with this  study;  
2. Any dermatological conditions on the face that could interfere with c linical 
evaluations such as acne conglobata, acne fulminans, secondary acne, perioral 
dermatitis, clinically significant rosacea, gram- negative  folliculitis; 
3. Any underlying disease(s) or some other dermatological condition of the face that requires the use  of interfering topi[INVESTIGATOR_500794];  
4. Subjects with a facial beard or mustache that could interfere with the study assessments;  
5. Subjects with more than two (2) facial  nodules;  
6. Evidence or history of cosmetic -related  acne;  
7. Subject has a history of experiencing significant burning or stinging when applying any facial treatment (eg, make- up, soap, masks, washes, sunscreens, etc) to their  face;  
8. Female subjects who are pregnant, nursing mothers, planning a pregnancy during  the 
course of the trial, or become pregnant during the  study;  
9. Use of estrogens (eg, Depogen, Depo- Testadiol, Gynogen, Valergen, etc) for less than 
12 weeks immediately preceding study entry; Subjects treated with estrogens [ADDRESS_686681] expects to change dose, drug or discontinue estrogen use during the  study;  
10. If female, subject has a history of hirsutism, polycystic ovarian disease or clinically significant menstrual irregularities;  
11. Treatment of any type of cancer within the last 6  months;  
12. Subject uses medications and/or vitamins during the study which are reported to exacerbate acne (azothiaprim, haloperidol, Vitamin D, Vitamin B12, ha logens such as 
iodides or bromides, lithium, systemic or mid -to super -high potency corticosteroids, 
phenytoin and phenobarbital); Daily vitamins at the prescribed amounts are acceptable;  
13. History of hypersensitivity or allergic reactions to any of the study  preparations as 
described in the Investigator’s Brochure, including known sensitivities to any  dosage 
form of tretinoin; 
14. Concomitant use of potentially irritating over -the-counter products that contain 
ingredients such as benzoyl peroxide, alpha -hydroxy a cid, salicylic acid, retinol or 
glycolic acids;  
Pr ot oc ol V 0 1 -1 2 1 A -3 0 2, I D P -1 2 1  Valea nt Researc h & De vel o p me nt  
Versi o n 4, [ADDRESS_686682] o ber 2 0 1 6  C O N FI D E N TI A L  
2 4   
 1 5.  S u bjects t hat ha ve n ot u n der g o ne t he s pecifie d was h o ut peri o d(s) f or t he f oll o wi n g 
t o pi[INVESTIGATOR_199252] p arati o ns us e d o n t he face or s u bjects w h o re q uir e t he c o n c urr e nt use of 
a n y of t he f oll o wi n g t o pi[INVESTIGATOR_19529] l a ge nts i n t he tr eat me nt area  : 
 
T o pi[INVESTIGATOR_500777] n ge nts a n d a brasi ves o n face  [ADDRESS_686683] re q uires t o pi[INVESTIGATOR_200369] f or ac ne o n areas ot her t ha n t he face  (e. g., 
c hest a n d/ or bac k), t he i n vesti gat or ma y pr escri b e a pr o d uct t hat d oes n ot c o ntai n 
treti n oi n a n d m ust be n ote d i n s o urce d o c u me nts a n d  e C R F.  
 
1 6.  S u bjects t hat ha ve n ot u n der g o ne t he s p ecifie d w as h o ut peri o d(s) f or t h e  f oll o wi n g 
s yste mic me dicati o ns or s u bject s w h o re q uir e t he c o nc urr e nt use of a n y of t he 
f oll o wi n g s yste mic  me di cati o ns:  
 
C ortic oster oi ds (i ncl u di n g i ntra m usc ul ar i njecti o ns)  
(i n hale d c ortic oster oi ds are all o we d)   
[ADDRESS_686684] a w al  Criteri a  
Reas o ns f or wit h dra wal ma y i ncl u d e, b ut are n ot li mite d t o, t he f oll o wi n g:  
• Ac ne flare, as deter mi ne d b y t he i n vesti gat or, w hic h re q uir es treat me nt wit h  a 
disall o we d  t hera p y.  
• Eit her at t he i n vesti gat or's re q uest, f or t olera bilit y reas o ns ( e g, se vere  a d verse 
reacti o ns), or at t he s u bject’s  re q u est.  
• W he n t he re q uire me nts of t he pr ot oc ol ar e n ot  f oll o we d.  
• W he n a c o nc o mita nt t her a p y li kel y t o i nterfer e wit h t he res ults of t he st u d y is 
re p orte d, or re q uir e d b y t he s u bject (t he i n vesti gat ors will re p ort all s uc h  i nf or mati o n  
Pr ot oc ol V 0 1 -1 2 1 A -3 0 2, I D P -1 2 1  Valea nt Researc h & De vel o p me nt  
Versi o n 4, [ADDRESS_686685] o ber 2 0 1 6  C O N FI D E N TI A L  
2 5   
 o n t he s o urce d o c u me nts/case r e p ort f or ms ( C R Fs) a n d deci de, i n acc or da nce wit h t he 
s p o ns or, w het her t he s u bj ect is t o be wit h dra w n).  
• W he n a s u bject is l ost t o f oll o w -u p. T he i n vesti gat ors will tr y t wice t o reac h t he 
s u bject b y tel e p h o ne a n d will se n d a f oll o w -u p letter b y certifie d mail bef or e  
c o nsi deri n g t hat t he s u bject is l ost t o f oll o w -u p. T hese acti o ns will be r e p orte d o n  t he 
E n d of St u d y C R F a n d a c o p y of t he f oll o w -u p lett er mai ntai ne d i n t he i n vesti gat or's 
file.  
All pre mat ure disc o nti n u ati o ns a n d t heir reas o ns m ust be caref ull y d o c u me nt e d b y t he 
i n vesti gat or o n t he fi nal C R F, a n d, if nee d b e, o n t he A E f or m. I n a n y cas e, n o s u bject w h o has 
bee n i ncl u de d a n d has a st u d y n u m ber assi g n e d ca n be re place d b y a n ot h er if t he y disc o nti n ue 
pre mat urel y f or w hat e ver reas o n. All data gat her e d o n t he  s u bject pri or t o ter mi nati o n will be 
ma de a vaila ble t o t he s p o ns or.  
Reas o ns f or st u d y c o m pl eti o n/ disc o nti n uati o n as liste d o n t he fi nal re p ort f or m are d efi ne d as 
f oll o ws:  
N or m al St u d y C o m pleti o n – S u bject c o m pletes t he st u d y as pla n ne d i n t h e pr ot oc ol.  
A d verse E ve nt – C o m plete A E f or m.  
De at h – C o m plete S A E f or m.  
S u bject Re q uest – C o nse nt wit h dra wal, s u bject m o ve d, sc he d ule c o nflicts. 
Pr ot oc ol Vi ol ati o n – C o ntact t he S p o ns or or desi g nee bef ore ma ki n g d ecisi o n. 
L ost t o F oll o w -U p – D o c u me nt wit h 2  p h o ne calls a n d a certifie d letter.  
Pre g n a nc y – S u bject will disc o nti n ue st u d y dr u g i m me diatel y, b ut will be f oll o we d t o ter m. 
C o m plete pre g na nc y a n d S A E f or ms.  
W orse ni n g C o n diti o n – S u bject re q uires alter nate treat me nt f or ac ne b ef or e t he e n d of t he 
st u d y a n d t he i n vesti gat or deter mi nes it is n ot d ue t o lac k of efficac y.  
L ac k of Effic ac y – S u bject re q uir es alter n ate treat me nt f or ac n e after at least [ADDRESS_686686] a w al b y P are nt/ G u ar di a n – A n i n dicati o n t hat t he st u d y partici pa nt has bee n 
re m o ve d fr o m t he st u d y b y t he p are nt or l e gal g uar dia n. C o nse nt wit h dra w al, s u bject m o ve d, 
sc he d ule c o nflicts.  
St u d y Ter mi n ate d b y S p o ns or – A n i n dicati o n t hat a cli nical st u d y was st o p pe d b y its 
S p o ns or.  
Ot her – S pecif y i n c o m me nts secti o n of fi nal C R F.  
S u bjects w h o ter mi nate treat me nt earl y will be as ke d t o c o m plete all Wee k 1 2 assess me nts a n d 
pr oce d ur es pri or t o  c o m me nce me nt of a n y alter n ati ve t hera p y f or ac ne (if p ossi ble). S u bjects 
w h o disc o nti n ue fr o m t he st u d y d uri n g t he tr eat m e nt peri o d will n ot be re place d.  
Protocol V01 -121A -302, IDP -121 Valeant Research & Development  
Version 4, [ADDRESS_686687] or whenever clinically necessary a s determined by [CONTACT_9682].  
 
9 Treatment  Plan  
9.1 Methods of Assigning Subjects to Treatment Groups  
This is a double -blinded study, in which the identity of the study drug will be unknown to 
investigator/evaluator and subjects, as well as all individuals closely associated with the study.  
Subjects will be randomized to 1 of the 2 study drug groups in a ratio of 1:1 (IDP -121 [tretinoin 
0.05%] Lotion : IDP -121 Vehicle Lotion). Each screened subject will be assigned a unique 6-  
digit study subject number assigned by [CONTACT_118250], which will consist of the 3-  
digit investigational center/site number (pre -assigned by [CONTACT_3211]/designee) and the 3 digit 
chronological screening order number, starting with 001 (eg, 101001, 101002). The study drug kit will be assigned to subjects based on a randomization code and kit will be dispensed to the subjects at Baseline by [CONTACT_500804], and at Week [ADDRESS_686688] all used and unused study drug tubes as scheduled.  
 
9.3 Un-blinding  
The treatment assignments for all enrolled subjects will be unblinded only after the conclusion of the study. Specifically, the blind will be broken only after all data are verified, entered into the database, and validated; subject evaluability assessments are performed and entered into the database; and the database is locked.  
In the case of a medical emergency, the investigator can break the blind for the subject involved preferably by [CONTACT_220142] (or designe e) immediately. After confirmation, the investigator will be contact[CONTACT_500805] V01 -121A -302, IDP -121 Valeant Research & Development  
Version 4, [ADDRESS_686689]’s source documents. 
 
9.[ADDRESS_686690] for acne vulgaris:  
 
Topi[INVESTIGATOR_85128]  [ADDRESS_686691] requires topi[INVESTIGATOR_85129] (eg, chest or back), the investigator may prescribe a product that does not contain tretinoin and noted in source documents and eCRF.  
In addition there is a mandatory wash out period and restrictions during t he study for the 
following systemic drugs: 
 
Corticosteroids (including intramuscular injections,  
inhaled corticosteroids are allowed)   
4 weeks  
Antibiotics  4 weeks  
Other systemic acne treatments  4 weeks  
Systemic retinoids  6 months  
 
Subjects using concomitant medications or therapi[INVESTIGATOR_220112] (including but not limited to those listed 
above) should not be withdrawn, but the use of the concomitant product should be discontinued. 
No other topi[INVESTIGATOR_35786] (except as noted above) other than the study drug will be permitted for 
acne.  
Information on concomitant medications or therapi[INVESTIGATOR_528815]. Any therapy used by [CONTACT_220143] (e.g., Facial procedures, surgical procedures, 
investigations and operations) and any medication both over the counter (OTC) or prescription used by [CONTACT_528822] (eg, aspi[INVESTIGATOR_248], Tylenol, birth control 
pi[INVESTIGATOR_3353], vitamins, moisturizers, sunscreens). Every attempt should be made to keep concomitant  
Protocol V01 -121A -302, IDP -121 Valeant Research & Development  
Version 4, [ADDRESS_686692] does not return his or her study drug, he or she will be 
instructed to return it as soon as possible. The subjects will bring the tubes dispensed at each treatment visit to the next subsequent study visit. Each tube will be weighed (with the cap on) to the nearest 0.[ADDRESS_686693]’s compliance with applying the study drug. A subject who deviates significantly from the prescribed application amount will be  
counseled. Any missed applications of study drug will be noted by [CONTACT_85196], which will be collected and placed in the appropriate source document. Missed applications will be documented in the eCRF. The subject will also be sent home with a Subject Self Assessment (SSA) survey at the Baseline visit, with instructions to complete it at home at two (2) weeks after their baseline visit, and return it at the Week [ADDRESS_686694] follow the instructions exactly.  
A deviation from the protocol is an unintended and/or unanticipated departure from the procedures and/or processes approved by [CONTACT_135785]/IEC and agreed to by [CONTACT_093]. Deviations usually have an impact on individual patients or a small group of patients and do not involve inclusion/exclusion or primary endpoint criteria. 
A protocol violation occurs when there is nonadherence to the protocol that results in a 
significant, ad ditional risk to the patient, when the patient or investigator has failed to adhere to 
significant protocol requirements (inclusion/exclusion criteria) and the patient was enrolled without prior sponsor approval, or when there is nonadherence to FDA regula tions and/or ICH 
GCP guideline.  
Protocol V01 -121A -302, IDP -121 Valeant Research & Development  
Version 4, [ADDRESS_686695] document and explain in the patients’ source documentation 
any deviation from the approved protocol. The investigator may implement a deviation from, or 
a change of, the protoc ol to eliminate an immediate hazard to study patients without prior 
IRB/IEC approval. As soon as possible after such an occurrence, the implemented deviation or change, the reasons for it, and any proposed protocol amendment(s) should be submitted to the IRB/IEC for review and approval, to the sponsor for agreement, and to the regulatory  authorities, 
if required.  
 
10 Study Drug Materials and  Management  
The study drug will be dispensed by [CONTACT_85197].  
 
10.1 IDP-121 Lotion and IDP -121 Vehicle  Lotion  
Chemical structure and formula for the active ingredients in IDP -121 Lotion and vehicle are 
listed in the tables below: 
Table  2. Drug Substances Identification  
 
Active Ingredient  Tretinoin 0.05%  
Chemical Name  (2E,4E,6E,8E) -3,7-dimethyl -9-(2,6,6 -trimethylcyclohexen -1-yl)nona - 
2,4,6,8- tetraenoic acid  
Chemical Class  Retinoid  
Molecular Formula  C20H28O2 
CAS Registry Number  302-79-[ADDRESS_686696]  Vehicle  
Name [CONTACT_500833], EP / USP  N/A 
Drug Name/Formulation/  
Concentration  IDP-121 Lotion [Tretinoin 0.05%]  IDP-[ADDRESS_686697] 
Laval (Quebec), Canada H7L 4A8  
Packaging  45 g tube  45 g tube  
Storage Requirements  Store at 20°C to 25°C (68°F to 
77°F)  Store at 20°C to 25°C (68°F 
to 77°F)  
Appearance  Opaque pale yellow lotion  Opaque pale yellow lotion  
Dosing Schedule  Once daily x 12 weeks  Once daily x 12 weeks  
Route of Administration  Topi[INVESTIGATOR_500796] V 0 1 -1 2 1 A -3 0 2, I D P -1 2 1  Valea nt Researc h & De vel o p me nt  
Versi o n 4, [ADDRESS_686698] at eac h visit: Baseli ne, Wee k 4 a n d Wee k 8. T he 
s u bjects will be dis pe nse d o ne kit at Bas eli ne as assi g ne d i n t he I W R s yste m. T he t u be wi ll be 
wei g h e d ( wit h t he ca p o n) t o t he near est 0. [ADDRESS_686699] u d y visit ( Wee k 4), w her e it will be c ollecte d a n d wei g h e d ( wit h t he ca p o n) t o 
t he near est 0. 1 gra m; o ne ne w t u be will be dis pe ns e d a gai n b y t he I W R s yst e m at Wee k 4, 
wei g h e d ( wit h t he ca p o n) t o t he near est 0. [ADDRESS_686700] l oses a t u b e (l ost or da ma ge d t u b e), a n ot her kit will be 
dis pe nse d via I W R S. Eac h t u be  dis pe nsi n g will be d oc u me nte d o n t he dr u g acc o u nta bilit y l o g.  
Eac h s u bject kit (a n d t u b e) will ha ve a si n gle p a nel la bel. La bels will c o ntai n t he f oll o wi n g 
i nf or mati o n:  
• Pr ot oc ol  N u m ber  
• Kit N u m ber  
• C o nte nts  
• S pace f or e ntr y of t he s u bject  i nitials  
• S pace f or e ntr y of d ate  dis pe nse d  
• T he s p o ns or na me, D o w P har mace utical Scie nces, a di visi o n of  Valea nt 
P har mace uticals N. A., L L C  
• T he q ua ntit y of pr o d uct ( 4 5  gra ms)  
• A state me nt rea di n g, “ F or e xter nal use o nl y. A v oi d c o ntact wit h e yes a n d  li ps”  
• A state me nt rea di n g , “ St ore at c o ntr olle d r o o m te m perat ure 2 0° C t o 2 5° C ( 6 8° F t o 
7 7° F) wit h e x c ursi o ns per mitte d bet wee n 1 5° C t o 3 0° C ( 5 9° F t o  8 6° F) .”  
• A state me nt rea di n g, “ Ca uti o n: Ne w Dr u g Li mite d b y Fe deral La w t o  I n vesti gati o nal 
Use”  
• A state me nt rea di n g, “ Ret ur n t his pr o d uct t o y o ur i n vesti gati o nal site at y o ur ne xt 
visit.”  
[ADDRESS_686701] ore d at c o ntr olle d r o o m te m perat ure 2 0° C t o 2 5° C ( 6 8° F t o 7 7° F) wit h 
e xc ursi o ns per mitte d bet wee n 1 5° C t o 3 0° C ( 5 9° F t o 8 6° F) , a n d s h o ul d n ot be refri gerate d. All 
u n use d st u d y dr u g will be se nt bac k t o t he S p o ns or or S p o ns or desi g nee u p o n st u d y c o m pleti o n 
f or d oc u me nte d dis p osal.  
Protocol V01 -121A -302, IDP -121 Valeant Research & Development  
Version 4, [ADDRESS_686702] 
material will be applied as a thin coating (a dab the size of a large pea) that is gently rubbed in to 
the skin. The test material use should be limited to the face.  
The Investigator and/or trained investigational center staff m ember will instruct the subject on 
the proper application procedure of the study drug to the treatment area at the Baseline visit (see Appendix 17.1). All subjects will be instructed to apply the test material at approximately the same time every day for 1 2 weeks (up to week 12 visit) after cleansing. On study visit days 
subjects should be instructed to wait until after their study visit to apply study medication. No time interval between dosing and meals or any other activity is specified. Subjects will be  
instructed to gently wash their face with a Sponsor approved cleanser and warm (not hot) water. After washing, the subjects will be asked to thoroughly rinse and gently pat their face dry. The subjects should use the tube to dispense a pea -sized amount of  study drug to their fingertip. This 
dose should then be dotted on to 6 areas (chin, left cheek, right cheek, nose, left forehead, right forehead) on the face. After distributing the dose in this manner the subject should gently rub the 
lotion into the ski n. This amount of drug should be sufficient to cover the entire face excluding 
the mouth, eyes, inside the nose, and lips. It is important for the subject to treat their entire face 
(excluding the mouth, eyes and lips) and they should be instructed NOT to treat only specific lesions. They should gently smooth the test material over the face evenly. The test material should become invisible almost immediately following application with gentle rubbing. If this does not happen, the Investigator should instruct  the subject on the use of a smaller dosage. The 
subject should wash his/her hands after applying the investigational product to the face.  
The subjects will be instructed to continue using the same Sponsor approved facial cleanser, 
moisturizer, and sunscre en, and not to change products during the study. At each visit, subjects 
are to be asked if they have changed their cleansing routine. Facial makeup may be applied 
according to the subject’s normal daily routine; however, subjects should be instructed not to wear make- up during study visits as it may interfere with the evaluator’s assessments. Subjects 
must also agree to use non -comedogenic makeup during the study if they use makeup. No other 
products should be used on the face.  
Subjects should be instructe d to store the test material at room temperature.  
 
10.[ADDRESS_686703]  
Protocol V01 -121A -302, IDP -121 Valeant Research & Development  
Version 4, 7 October 2016  CONFIDENTIAL  
32  
 will be made available to the sponsor’s monitor for the purpose of accounting for all clinical 
supplies. Any significant discrepancy and/or deficiency must be recorded with an expla nation. 
All supplies sent to the Investigators will be accounted for and, in no case, used in any 
unauthorized situation. Tubes will be weighed (with the cap on) to the nearest 0.[ADDRESS_686704] 0.1 gram will be recorded on the pharmacy log and appropriate CRF. All used and unused supplies will be returned to sponsor/designee for destruction at the conclusion of the study.  
 
[ADDRESS_686705] appropriate, documented experience and training, or obtain approval from 
the sponsor based on experience (or through additional training organized by [CONTACT_456]).  
At each study visit, every attempt should be made to ensure that the same investigator / evaluator 
assesses the same subject.  
 
11.1 Schedule of Evaluations and  Procedures  
11.1.1  Visit 1: Screening  Visit  
The following procedures will be conducted at this visit:  
1. Obtain written informed consent prior to performing any study procedures. Subjects  less 
than [ADDRESS_686706] of the 
3-digit site number (pre -assigned to your site) and the 3- digit chronological order 
screening number, assigned by [CONTACT_500808] 101 (eg, 101 001, 101 002, etc; in this example site number is  101). 
3. Record the subject’s demographic  information.  
4. Record the subject’s medical  history.  
5. Record all previous medications (including acne medications) for the past 4 weeks (past  6 
months for systemic retinoids). Record any therapi[INVESTIGATOR_500780].  
6. Perform Evaluator’s Global Assessment followed by [CONTACT_220148]-  
inflammatory lesion count to determine  eligibility.  
7. Perform a Urine Pregnancy Test for a ll females that are pre- menses and females of 
childbearing potential. The urine pregnancy tests will be supplied by [CONTACT_500809].  
8. Discuss allowed cleansers, moisturizers and sunscreens and record any  cleanser, 
moisturizer and sunscreen use. (Appendix  17.2).  
Protocol V01 -121A -302, IDP -121 Valeant Research & Development  
Version 4, [ADDRESS_686707] meets the applicable inclusion/exclusion criteria as outlined  in 
Sections 8.[ADDRESS_686708] to return for the Baseline/Day [ADDRESS_686709] requires a washout, 
schedule the Baseline/Day 0 visit to occur after the washout is  complete.  
NOTE : A urine pregnancy test must be completed at Screening and at the Baseline visit prio r to 
randomization, and at Weeks 4, 8 and 12. The decision may be made by [CONTACT_528823].  
11.1.2  Visit 2: Baseline Visit (Day  0) 
If a washout is not needed, this visit may occur on the same day as the Screening Visit (Visit 1). If a washout is needed, Visit [ADDRESS_686710] occur after the appropriate washout period based on the criteria provided in Section 8.2. 
The following procedures will be conducted at this visit:  
1. The baseline Subject Self Assessment (SSA), Patient Satisfaction Survey (PSS) and the 
Acne- Specific Quality of Life Questionnaire (Acne- QoL) will be completed by [CONTACT_528819] -related procedures. The Week [ADDRESS_686711] continues to meet the applicable inclusion/exclusion criteria  as 
outlined in Sections 8.[ADDRESS_686712] for all females that are pre- menses and females of 
childbearing potential. The urine pregnancy tests will be supplied by [CONTACT_500809].  
5. Perform an abbreviated physical exam, including measurements of height and  weight, 
and vital signs (blood pressure, heart rate, respi[INVESTIGATOR_1487], and oral temperature). Any abnormal physical exam findings will b e recorded.  
6. Collect blood samples for routine laboratory analysis (CBC/Diff, serum chemistry  and 
urinalysis).  
7. The Evaluator will query the subject regarding how oily/shiny their facial skin has  been 
in the past  week.  
Protocol V01 -121A -302, IDP -121 Valeant Research & Development  
Version 4, 7 October 2016  CONFIDENTIAL  
34  
 8. The Evaluator will perfor m Baseline efficacy evaluations including the Evaluator’s 
Global Severity Score (EGSS), inflammatory lesion counts and non- inflammatory lesion 
counts. The EGSS is performed prior to the lesion counting. Every effort should be made 
for the same qualified, v alidated Evaluator to perform the efficacy evaluations at all  visits 
from Baseline to Week [ADDRESS_686713] the presented kit number (this number will be generated from  the 
Interactive Web Response system,  (IWRS)).  
11. The study coordinator or designee will weigh the tube (with the cap on) to the nearest  0.[ADDRESS_686714] (Appendix 17.1). For the first application, the subject will apply the study drug at the investigational center under the direction of the study coordinator or designee. The study drug should be applied after all clinical assessments. 
The study coordinator or designee will instruct the subjects to apply the study drug once 
daily at  home.  
13. Record any AEs or changes in AEs since the screening visit and/or reported 
spontaneously by [CONTACT_19578].  
14. Selected Sites only - Obtain representative photographs of the  face.  
15. Schedule the next study visit at Week 4 (Day 28 ± 3 days). Remind the subject to not 
apply test medication on day of next study visit, prior to the clinic  visit.  
11.1.3  Visit 3 and 4: Week 4 (Day 28 ± 3 Days) and Week 8 (Day 56 ± 3 Days)  Visits  
The following procedures will be conducted at this visit (if a subject terminates early, all final 
visit (Week 12/Final Visit) pr ocedures must be performed):  
1. The take- home Week 2 SSA will be collected during the Week 4 study  visit.  
2. The Week 4 or Week 8 SSA will be conducted and collected.  
3. The Evaluator will perform the efficacy evaluations including the Evaluator’s Global 
Severity S core (EGSS), inflammatory lesion counts and non- inflammatory lesion counts. 
The EGSS is performed prior to the lesion counting. Every effort should be made for the same qualified and validated evaluator to perform the efficacy evaluations at all visits from Baseline to Week [ADDRESS_686715] or changes in any  ongoing 
AEs.  
Protocol V01 -121A -302, IDP -121 Valeant Research & Development  
Version 4, [ADDRESS_686716] another kit number (this number will be generated from the Interactive Web Response system, (IWRS) and dispense a new subject kit of test material. The tube will be weighed on a calibrated scale. Record the weight (with the cap on) to the nearest 0.[ADDRESS_686717] 
medication on the day of the next study visit, prior to the clinic  visit.  
11.1.4  Visit 5: Week 12 (Day 84 - 3/+5 Days) Visit – End of Study  Visit  
The following procedures will be conducted at this visit:  
1. The Week [ADDRESS_686718] and  collected 
prior to any other study -related  procedures.  
2. Perform an abbreviated physical exam, including measurements of height and  weight, 
and vital signs (blood pressure, heart rate, respi[INVESTIGATOR_1487], and oral temperature). Any 
abnormal physical exam findings will be recorded.  
3. Collect blood samples for routine laboratory analysis (CBC/Diff, serum chemistry  and 
urinalysis).  
4. The Evaluator will query the subject regarding how oily/shiny their facial skin has  been 
in the past  week.  
5. The Evaluator will perform the efficacy evaluations including the Evaluator’s Global 
Severity Score (EGSS), inflammatory lesion counts and non- inflammatory lesion counts. 
The EGSS is performed prior to the lesion counting. Every effort should be made for the same qualified and validated Evaluator to perform the efficacy evaluations at all visits 
from Baseline to Week [ADDRESS_686719] the weight (with the cap on) to the nearest 0.1 
gram.  
Protocol V01 -121A -302, IDP -121 Valeant Research & Development  
Version 4, [ADDRESS_686720]- certified/board -eligible dermatologist or 
have appropriate documented experience and training, and be present for formal study training 
and validation at the Investigator Meeting (and/or Site Initiation  Visit), or obtain a waiver from 
the Sponsor based on experience (or through additional training organized by [CONTACT_1034]).  
The EGSS scores and lesion counts will be performed at each study visit. The EGSS scores will 
be collected before the Lesion Counts. All Subject assessments will be performed by a trained and validated Evaluator. Every effort should be made to have the same evaluator assess the same Subject at each visit. If this is not possible, the same Evaluator must assess the Subject at both the b aseline and Week 12 visits.  
11.2.1  Evaluator’s Global Severity Score  (EGSS)  
The Evaluator’s Global Severity Score will be a static assessment that is independent of the baseline score. The investigator will make the assessment without referring to the baseline va lue. 
Every effort should be made for the same evaluator to perform each study assessment for the same study subject, for consistency in evaluations. 
Subjects are eligible if they have acne with a global severity of a 3 (moderate) or a 4 (severe) on 
the EGS S at the baseline visit. The following scores will be used to describe the severity grade 
and subsequent score:  
Table  4. Evaluator’s Global Severity Score  
Score  Grade  Description  
[ADDRESS_686721] 
Clear  Rare non -inflammatory lesions present, with rare non -inflamed papules (papules must 
be resolving and may be hyperpi[INVESTIGATOR_49194], though not pi[INVESTIGATOR_8745]- red 
2 Mild  Some non -inflammatory lesions are present, with few inflammatory lesions 
(papules/pustules only; no nodulocystic lesions)  
 
3  
Moderate  Non-inflammatory lesions predominate, with multiple inflammatory lesions evident: 
several to many comedones and papules/pustules, and there may or may not be one 
nodulocystic lesion  
4 Severe  Inflammatory lesions are more apparent, many comedones and papules/pustules, there 
may or may not be up to 2 nodulocystic lesions  
Protocol V01 -121A -302, IDP -121 Valeant Research & Development  
Version 4, [ADDRESS_686722]’s face. The lesion count groups will 
be inflammatory and non -inflammatory. Facial inflammatory lesions (pustules, papules, and 
nodules) will be counted as follows: pustules and papules will be counted and recorded together, 
not separately; nodular lesions will be counted and recor ded separately. Non -inflammatory 
lesions (open and closed comedones) will be counted and recorded together. The lesions counts will be collected at each visit and/or upon discontinuation. The following are definitions of each lesion type counted:  
Inflammat ory lesions are defined as follows:  
 
Papule – a solid, elevated lesion less than 5 mm  
Pustule – an elevated lesion containing pus less than 5 mm  
Nodule – palpable subcutaneous lesion greater than 5 mm; has depth, not necessarily elevated  
Non- inflammatory l esions are defined as follows:  
 
Open comedones (blackhead) – plugged hair follicle with dilated/open orifice; black in color  
Closed comedones (whitehead) – plugged hair follicle: small opening at skin surface  
 
11.2.3  Other Assessments  
Oily/Shiny Face Assessment  
The subject will be asked at Baseline and Week [ADDRESS_686723] week by [CONTACT_500810]:  
Oily/Shiny skin assessment  
0 – None  No oily or shiny skin on face  
1 – Mild  Mild oily or shiny skin on face 
2 – Moderate D efinite oily or shiny skin on face 
3 – Severe  Extremely oily or shiny skin on face 
If subject answers 1, [ADDRESS_686724] week with scale below:  
0 – Not bothered at al l 
1 – A little bothered  
2 – Moderately bothered 3 – Very bothered  
4 – Extremely bothered  
Photography  
At select sites, photographs of the face will be taken at Baseline and Week 12, at a minimum. 
Only subjects who provide written photographic consent for facial photographs will be included in photography.  
Protocol V01 -121A -302, IDP -121 Valeant Research & Development  
Version 4, 7 October 2016  CONFIDENTIAL  
38  
 11.3 Evaluation of  Safety  
Safety assessments will be conducted at baseline and each subsequent visit.  
 
11.3.1  Cutaneous Safety  Evaluations  
Cutaneous safety will be evaluated through assessment of scalin g, erythema, hypo -pi[INVESTIGATOR_220120] -pi[INVESTIGATOR_220121] -application site at the time of the visit. Cutaneous tolerability 
will be evaluated through assessment of selected local signs and symptoms at the drug - 
application site: itching, burning and stinging at the time of the visit.  
Cutaneous tolerability signs and symptoms that result in the subject’s requiring a concomitant 
therapy, interruption of treatment, or discontinuation from the study, will be reported as an AE.  
(Note: To be assessed by t he evaluator at the time of the study visit.)  
Scaling:  
0 – None  No scaling  
1 – Mild  Barely perceptible, fine scales present on limited areas of the face 
2 – Moderate Fine scale generalized to all areas of the face 
3 – Severe  Scaling and peeling of skin over all areas of the face 
 
 
Erythema:  
0 – None  No evidence of erythema present 
1 – Mild  Slight pi[INVESTIGATOR_22766] 
2 – Moderate Definite redness  
3 – Severe  Marked erythema, bright red to dusky dark red in color  
 
Hypo -pi[INVESTIGATOR_371]:  
0 – None  No evidence  
1 – Mild  Slight, barely perceptible 
2 – Moderate Definite,  evident  
3 – Severe  Marked, prominent  
 
Hyper -pi[INVESTIGATOR_371]:  
0 – None  No evidence  
1 – Mild  Slight, barely perceptible 
2 – Moderate Definite,  evident  
3 – Severe  Marked, prominent  
 
11.3.[ADDRESS_686725] at the study visit as average over the period since the previous visit.  
Protocol V01 -121A -302, IDP -121 Valeant Research & Development  
Version 4, 7 October 2016  CONFIDENTIAL  
39  
 Itching:  
0 – None  No itching 
1-  Mild  Slight itching, not really  bothersome  
2 – Moderate Definite itching that is somewhat bothersome  
3 – Severe  Intense itching that may interrupt daily activities and/or  sleep  
 
Burning:  
0 – None  No burning 
1 – Mild  Slight burning sensation; not really  bothersome  
2 – Moderate Definite warm, burning sensation that is somewhat bothersome 
3 – Severe  Hot burning sensation that causes definite discomfort and  may 
interrupt daily activities and/or sleep  
 
Stinging:  
0 – None  No stinging  
1 – Mild  Slight stinging sensation, not really  bothersome  
2 – Moderate Definite stinging sensation that is somewhat bothersome  
3 – Severe  Stinging sensation that causes definite discomfort and may interrupt daily 
activities and/or  sleep  
11.3.[ADDRESS_686726] of measurements of height and weight, and vital signs (blood pressure, heart rate, respi[INVESTIGATOR_1487], and oral temperature) and will be 
performed at Baseline and Week 12 (end of treatment/study). Any abnormal physical exam findings will be recorded. 
11.3.4  Laboratory Tests  
Clinical laboratory analyses (CBC/Diff, serum chemistry, and urinal ysis) will be conducted on 
blood samples collected from subjects at Baseline and Week [ADDRESS_686727]’s documentation.  
11.3.5  Pregnancy  Tests  
All female subjects of childbearing potential will undergo urine pregnancy testing a t Screening 
and prior to randomization at Baseline, and at Week 4, 8 and Week 12 visits. The urine 
pregnancy tests will be supplied by [CONTACT_2024].  
Pr ot oc ol V 0 1 -1 2 1 A -3 0 2, I D P -1 2 1  Valea nt Researc h & De vel o p me nt  
Versi o n 4, [ADDRESS_686728] u g(s) u n der st u d y. A Es i ncl u d e a n y ill ness, si g n, s y m pt o m, 
or o ut -of -r a n ge a n d cli nicall y si g nifica nt la b orat or y fi n di n g t hat h as a p pear e d or w ors e ne d d uri n g 
t he c o urse of t h e cli nical trial, re gar dl ess of ca usal relati o ns hi p t o t he st u d y. T he c ollecti o n of 
n o n -seri o us A Es a n d s eri o us a d verse e ve nts ( S A Es) will be gi n f oll o wi n g t h e s u bject's 
c o m pleti o n of t he c o nse nt pr ocess t o partici pat e i n t he  st u d y.  
[ADDRESS_686729] u d y. T he A Es s h o ul d be d oc u me nte d as a si n gle me dical dia g n osis. W he n t his is n ot p ossi ble, 
t he A E s h o ul d be d oc u m e nte d i n ter ms of si g ns a n d/ or s y m pt o ms o bser ve d b y t he i n vesti gat or or 
re p orte d b y t he s u bject at eac h st u d y visit. Eac h A E w hic h a p pears t o be i n de pe n de nt of a n y p ri or 
e ve nt will be re p orte d se paratel y.  
All A Es occ urri n g after t he s u bject si g ns t he i nf or me d c o nse nt t hr o u g h t he last st u d y visit m ust 
be re p ort e d, re gar dless of w het her or n ot t he A Es are c o nsi der e d dr u g -relat e d. All A Es, w het her 
i n res p o nse t o a q uer y, o bser ve d b y t he st u d y site pers o n nel, or r e p orte d s p o nta ne o usl y b y t he 
s u bject, will be rec or de d. A n y A Es dee me d relate d t o treat me nt re p ort e d or o bser ve d at t he fi nal 
st u d y/treat me nt visit will be f oll o we d u ntil sta bilizati o n or res ol uti o n ( or u p t o [ADDRESS_686730] u d y visit).  
At eac h visit d uri n g t he st u d y, t he s u bject will be assesse d f or t h e occ urre n ce of ne w a n d o n g oi n g 
A Es. C uta ne o us t olera bilit y si g ns a n d s y m pt o ms t hat res ult i n t he s u bject’s re q uiri n g a 
c o nc o mita nt t hera p y or disc o nti n u ati o n fr o m t he st u d y will be re p orte d as a n A E. T he f oll o wi n g 
data will be c ollecte d o n all A Es a n d rec or de d o n t he a p pr o pri ate C R F:  
• E ve nt na me ( dia g n osis pr eferre d, if u n k n o w n, rec or d t he  si g ns/s y m pt o ms)  
• O nset date a n d e n d date  
• Ma xi m u m i nte nsit y  (s e verit y ) 
• Seri o us ness  
• Acti o n ta ke n re gar di n g st u d y  dr u g  
• C orrecti ve tr eat me nt, if  gi ve n  
Pr ot oc ol V 0 1 -1 2 1 A -3 0 2, I D P -1 2 1  Valea nt Researc h & De vel o p me nt  
Versi o n 4, [ADDRESS_686731] o ber 2 0 1 6  C O N FI D E N TI A L  
4 1   
 • O utc o me  
I n a d diti o n, t he i n vesti gat or’s assess me nt of ca usalit y will be rec or de d.  
Vital si g n a b n or m alities are t o be rec or de d as A Es o nl y if t he y are cli nicall y si g nifica nt (f or 
e x a m ple: are s y m pt o mati c, re q uiri n g c orrecti ve treat me nt, lea di n g t o disc o nti n uati o n or f ulfilli n g 
a seri o us ness criteri o n).  
1 1. 4. 3  Seri o us A d verse  E ve nts  
All A Es will be assesse d as eit her seri o us or n o n -s eri o us.  
A n S A E or seri o us a d v erse e ve nt is defi ne d as a n y u nt o war d me dical o cc urre nce t h at at a n y 
d ose:  
• Res ults i n  deat h  
• Is i m me diatel y life t hr eat e ni n g, (t h e ter m "life t hr eate ni n g" i n t he d efi niti o n of 
"seri o us" r efers t o a n e v e nt i n w hic h t he s u bject is at ris k of deat h at t he ti m e of t he 
e ve nt; it d oes n ot refer t o a n e ve nt w hic h h y p ot h eticall y mi g ht ha ve ca use d deat h if  it 
were m or e  se v er e)  
• Re q uires i n patie nt h os pi[INVESTIGATOR_1314] o n or pr ol o n gati o n of e xisti n g h os pi[INVESTIGATOR_1314] o n 
( h os pi[INVESTIGATOR_1314] o n f or electi ve s ur ger y f or a b aseli ne c o n diti o n is n ot c o nsi dere d a n  A E)  
• Res ults i n persiste nt or si g nifica nt disa bilit y/i n ca p acit y ( per m a ne nt or  s u bst a ntial 
disr u pti o n of a pers o n’s a bilit y t o c o n d u ct n or mal life  f u ncti o ns)  
• Is a c o n ge nital a n o mal y/ birt h  defect  
• Is a me dicall y i m p orta nt e ve nt t hat ma y n ot be i m me diatel y lif e t hreat e ni n g or res ult 
i n deat h or h os pi[INVESTIGATOR_1314] o n, b ut ma y je o p ar dize t he s u bject a n d ma y r e q uire me dical  or 
s ur gical i nter ve nti o n t o pre ve nt o ne of t he a b o v e liste d o utc o mes. E x a m ples of s uc h 
e ve nts i ncl u de, b ut ar e n ot li mite d t o, all er gic br o nc h os pas m re q uiri n g i nte nsi ve 
treat me nt i n a n e mer ge nc y r o o m or at h o me; bl o o d d yscrasias or c o n v ulsi o ns t hat d o 
n ot res ult i n i n patie nt  h os pi[INVESTIGATOR_1314] o n.  
N ote: A s p o nta ne o us a b orti o n will be c o nsi dere d a n S A E, a n d m ust be re p orte d per Re p orti n g of 
S A Es u n der Secti o n 1 1. 4. 6.  
1 1. 4. 4  Assess me nt of  Se verit y  
T he se verit y assi g ne d t o a n A E s h o ul d be deter mi ne d b y t h e ma xi m u m se verit y of t he A E. T h e 
cate g ories d escri b e d bel o w s h o ul d be use d t o esti mate t he se verit y of A Es:  
• Mil d: Tra nsie nt or mil d dis c o mf ort; n o li mitati o n i n acti vit y; n o  me dical 
i nter ve nti o n/t hera p y  re q uire d  
Pr ot oc ol V 0 1 -1 2 1 A -3 0 2, I D P -1 2 1  Valea nt Researc h & De vel o p me nt  
Versi o n 4, [ADDRESS_686732] o ber 2 0 1 6  C O N FI D E N TI A L  
4 2   
 • M o derate: Mil d t o m o der ate li mitati o n i n acti vit y; s o me assista nce ma y b e nee de d;  n o 
or mi ni mal me dical i nter ve nti o n/t hera p y  re q uire d  
• Se vere: Mar k e d li mitati o n i n acti vit y; s o me assista nce us uall y r e q uire d;  me dical 
i nter ve nti o n/t hera p y r e q uire d; h os pi[INVESTIGATOR_1314] o n or pr ol o n gati o n of c urre nt 
h os pi[INVESTIGATOR_1314] o n p ossi ble; ma y b e i nca p acitati n g or life  t hreate ni n g  
[ADDRESS_686733] u g as eit her 
“ Relate d” or “ N ot Relate d”. T he f oll o wi n g s h o ul d be ta ke n i nt o acc o u nt w he n assessi n g S A E 
ca usalit y:  
Relate d: T here is at least a reas o n a ble p ossi bilit y t hat t he A E/ S A E is relate d t o t he st u d y dr u g. 
Re as o na ble p ossi bilit y m ea ns t hat t her e is e vi de nce t o s u g gest a ca us al relati o ns hi p bet wee n t he 
dr u g a n d t he A E. 
 
N ot Relate d: T here is little or n o reas o na ble p ossi bilit y t hat t he A E/ S A E is relate d t o t he st u d y 
dr u g. T his assess me nt i m plies t hat t he A E/ S A E has little or n o te m p oral relati o ns hi p t o t he st u d y 
dr u g a n d/ or a m or e li kel y or cert ai n alter nati ve eti ol o g y e xists.  
 
1 1. 4. 6  Re p orti n g of Seri o us A d verse E ve nts  
A d verse e ve nts classifie d as “seri o us” re q uir e e x pe diti o us ha n dli n g a n d r e p orti n g t o s p o ns or o r 
desi g nee wit hi n [ADDRESS_686734] be i m me diatel y re p orte d t o t he 
me dical m o nit or wit hi n 2 4 h o urs of t he i n vesti gat or’s a w are n ess of t he e v e nt. All S A Es m ust be 
re p orte d via c o nfir me d facsi mile a n d e mail tra ns missi o n a n d m ust be s u b mitte d o n a writte n S A E 
re p ort f or m si g ne d b y t he i n vesti gat or wit hi n 2 4 h o urs of t he i n vesti gat or’s a war e ness of t he 
e ve nt.  
T he c o ntact(s) f or re p ort i n g a n S A E are: 
 Me dical M o nit or 
 
 
  
& 
 
 Pr oject Ma na ger [ T K L Res ear c h, I n c.] 
 
Fa x:  N/ A  
Protocol V01 -121A -302, IDP -121 Valeant Research & Development  
Version 4, 7 October 2016  CONFIDENTIAL  
43  
 Investigators should not wait to receive additional information to fully document the event 
before notifying Medical Monitor and Sponsor of an SAE. If only limited information is initially 
available, follow -up reports are required. Additional relevant information such as hospi[INVESTIGATOR_528816] t o the Sponsor as soon as they are available.  
Should the investigator become aware of an SAE (regardless of its relationship to investigational 
product) that occurs within [ADDRESS_686735] be reported in 
accordance with pr ocedures specified in this protocol. 
All deaths of subjects, regardless of cause, and which are known to the Investigator will be reported on the appropriate CRF for up to 30 days after the administration of study drug, regardless of the Investigator's opi [INVESTIGATOR_85155]. Documentation of the 
subject’s cause of death and a copy of the autopsy or hospi[INVESTIGATOR_85156]. The Medical Monitor must be notified within 24 hours of knowledge of the event by [CONTACT_756] (and/or facsimile/email) of all subject deaths. Written follow -up must be received by [CONTACT_500811] (5) calendar days of initial notification.  
 
The investigator should take all appropriate measures to ensure the safety of the subjects, notably 
he/she should follow a subject with an SAE until the event has resolved or the condition has stabilized. This may imply that follow -up will continue after the subject has left the study, and 
that additional investigations may be re quested by [CONTACT_1034], and that additional investigations 
may be requested by [CONTACT_1034]. When a SAE persists at the end of the study, the Investigator will conduct follow -up contacts with the subject until the Investigator/Sponsor agree the event is 
satisfactorily resolved and/or stabilized. If at any time after 30 days after administration of study 
drug, the investigator becomes aware of an SAE which he/she feels is related to study drug or procedure, this must also be reported immediately (within 24 hours of knowledge of occurrence) by [CONTACT_220155]/email to the Medical Monitor and  Sponsor. 
11.4.7  Expedited Serious Adverse Event  Reports  
An AE, whether serious or non- serious, is designated unexpected (unlabeled) if it is not reported 
in the clinical safety section of the Investigator Brochure or if the event is of greater frequency, specificity or severity.  
Expedited SAE reports are those that are both unexpected based on the reference document (Investigator Brochure or Package I nsert) and are related (ie, the relationship cannot be ruled 
out) to the study drug. These expedited reports are subject to reporting timelines of 7 and/or 15 calendar days to the regulatory reporting agency(ies). The Sponsor will notify regulatory authori ties of these AEs and all participating investigational centers in writing for submission by 
[CONTACT_85213]/IEC. This notification will be in the form of a Safety Update to the Investigator Brochure (ie, “15- day letter”).  
Pr ot oc ol V 0 1 -1 2 1 A -3 0 2, I D P -1 2 1  Valea nt Researc h & De vel o p me nt  
Versi o n 4, [ADDRESS_686736] re vie w a n d retai n t he n otice wit h t he 
I n v esti gat or Br oc h ur e a n d i m me diatel y s u b mit a c o p y of t his i nf or mati o n t o t he res p o nsi ble 
I R B/I E C acc or di n g t o l ocal re g ulati o ns. T he i n v esti gat or a n d I R B/I E C will deter mi ne  if t he 
i nf or me d c o nse nt r e q uires re visi o n. T he i n vesti gat or s h o ul d als o c o m pl y wit h t he I R B/I E C 
pr oce d ur es f or re p orti n g a n y ot h er saf et y i nf or mati o n.  
[ADDRESS_686737] u d y partici pati o n:  
• I nf or me d c o ns e nt  re q uire me nts  
• C o ntrace pti ves i n c urre nt  use  
F oll o wi n g re vie w of t his i nf or mati o n a n d a p pr o priate s u bject c o u ns eli n g, t h e i n vesti gat or or 
desi g nee a n d t he s u bj ect m ust si g n t he i nf or me d c o nse nt bef ore st u d y e nr oll me nt.  
D uri n g t h e st u d y, all fe m ale s u bjects of c hil d beari n g p ote ntial s h o ul d be i nstr ucte d t o c o ntact t he 
i n vesti gat or i m me diatel y if t he y s us p ect t he y mi g ht be pre g na nt ( e g, misse d or late me nstr ual 
peri o d).  
If a s u bject or i n vesti gat or s us pects t hat t he s u bject ma y b e pre g n a nt pri or t o st u d y e nr oll me nt, 
t he st u d y dr u g m ust be wit h hel d u ntil t he res ults of la b orat or y pre g na n c y testi n g ar e a vaila ble. If 
pre g na nc y is c o nfir me d, t he s u bject m ust n ot recei ve st u d y dr u g a n d m ust n ot be e nr olle d i n t he 
st u d y. If pre g na n c y is s us pecte d w hile t he s u bject is recei vi n g st u d y treat me nt, t he st u d y dr u g 
m ust i m me diatel y b e wit h hel d u ntil t he res ult of pre g na nc y t esti n g is k n o w n. If pre g n a nc y is 
c o nfir me d, t he st u d y dr u g will be pe r ma ne ntl y dis c o nti n ue d a n d t he s u bject will be f oll o we d 
u ntil t he pre g n a nc y c o m es t o ter m. A Pre g na nc y R e p ort f or m will be s u b mitte d t o t he s p o ns or, 
i nitiall y a n d at t he e n d of t he pre g na n c y, w hic h i n cl u des t he o utc o me of t h e pre g na n c y a n d a n y 
c o m plicati o n s occ urri n g d uri n g t he pre g na n c y or t he deli ver y.  
All c o nfir me d pre g n a nci es m ust be i m me diatel y r e p orte d t o t he me dical m o nit or wit hi n 2 4 h o urs 
of t he i n vesti gat or’s a w ar e ness of t he pr e g na n c y. All c o nfir me d pre g n a nci es m ust be re p orte d vi a 
c o nfir me d f acsi mile/e mail tra ns missi o n a n d m ust be s u b mitte d o n a S A E a n d pre g na nc y re p ort 
f or ms wit hi n 2 4 h o urs of t he i n vesti gat or’s a w are n ess of t he pre g n a nc y usi n g t he sa m e re p orti n g 
as pr oce d ure f or a n S A E u n der Secti o n 1 1. 4. 6.  
Protocol V01 -121A -302, IDP -121 Valeant Research & Development  
Version 4, 7 October 2016  CONFIDENTIAL  
45  
 12 Statistics  
All statistical processing will be performed using SAS® version 9.3 or later unless otherwise 
stated. Statistical significance will be based on two -tailed tests of the null hypothesis resulting in 
p-values of 0.05 or less. 
The primary method of handling missing efficacy data will be based on estimation using the 
method of Markov Chain Monte Carlo (MCMC) imputation. This method provides robust 
estimation when the pattern of missingness is arbitrary. Additionally, the estimation will be done 
for each treatment gr oup separately so that the pattern of missingness for one group does not 
influence the estimation of missing data for another group. Groups of complete datasets 
following the estimation will be concatenated to form analysis datasets for the comparative 
analyses and subsequent imputation result inference with SAS PROC MIANALYZE. 
Descriptive statistics will also be derived from the multiply imputed  datasets.  
Additionally, a model -based multiple imputation process will be used as a sensitivity analysis to 
the MCMC imputation. Finally, the absolute change in lesion count will be analyzed using a 
repeated measures ANCOVA for lesion count data or a repeated measures logistic regression model (generalized estimating equations) for the dichotomized EGSS.  
A statistic al analysis plan (SAP), describing all statistical analyses will be provided as a separate 
document. The SAP will be finalized prior to unblinding of the study treatments. 
Evaluations and Analyses  
Inflammatory lesions and non- inflammatory lesions will be r ecorded for each subject at Baseline 
and at Weeks 4, 8, and 12. The absolute and percent change from baseline of inflammatory lesions and non- inflammatory lesions will be derived for each subject at Weeks 4, 8, and 12.  
The EGSS will be recorded for each Su bject. The EGSS will be dichotomized into “success” and 
“failure” at Week 4, [ADDRESS_686738] week.  
All assessments will be conducted for both ITT and PP.  
 
12.1 Assessment of  Efficacy  
All efficacy analyses will be conducted on the ITT (primary) and PP (supportive) populations. 
 
12.1.1  Primary  Efficacy  
There are three co -primary efficacy endpoints:  
Pr ot oc ol V 0 1 -1 2 1 A -3 0 2, I D P -1 2 1  Valea nt Researc h & De vel o p me nt  
Versi o n 4, [ADDRESS_686739] o ber 2 0 1 6  C O N FI D E N TI A L  
4 6   
 • A bs ol ute c ha n ge i n i nfla m mat or y lesi o n c o u nt fr o m baseli ne t o Wee k  1 2  
• A bs ol ute c ha n ge i n n o n -i nfla m mat or y lesi o n c o u nt fr o m baseli ne t o Wee k  1 2  
• Pr o p orti o n of s u bjects w h o ha ve a least a 2 gr a de re d ucti o n at Wee k 1 2 fr o m baseli ne 
i n t he E val uat or's Gl o bal Se verit y Sc ore a n d wer e Clear or Al m ost  Clear  
1 2. 1. 2  Sec o n d ar y  Effic ac y  
T here are t w o Wee k 1 2 s ec o n dar y effi cac y e n d p oi nts:  
• Perce nt c h a n ge i n i nfla m mat or y lesi o n c o u nt fr o m baseli ne t o Wee k  1 2  
• Perce nt c h a n ge i n n o n -i nfla m mat or y lesi o n c o u nt fr o m baseli ne t o Wee k  1 2  
1 2. 1. 3  S u p p orti ve  Effic ac y  
T here is o ne Wee k 1 2 s u p p orti ve efficac y e n d p oi nt:  
• Pr o p orti o n of s u bjects w h o ha ve at least a 2 gra d e re d ucti o n at Wee k 1 2 fr o m baseli ne 
i n t he E val uat or's Gl o bal Se verit y  Sc ore  
T here are t hr ee Wee k 8 s u p p orti ve efficac y e n d p oi nts:  
• Perc e nt c h a n ge i n i nfla m mat or y lesi o n c o u nt fr o m baseli ne t o Wee k  8 
• Perce nt c h a n ge i n n o n -i nfla m mat or y lesi o n c o u nt fr o m baseli ne t o Wee k  8 
• Pr o p orti o n of s u bjects w h o ha ve at least a 2 gra d e re d ucti o n at Wee k 8 fr o m baseli ne 
i n t he E val uat or's Gl o bal Se verit y  S c ore  
T here are t hr ee Wee k 4 s u p p orti ve efficac y e n d p oi nts:  
• Perce nt c h a n ge i n i nfla m mat or y lesi o n c o u nt fr o m baseli ne t o Wee k  4 
• Perce nt c h a n ge i n n o n -i nfla m mat or y lesi o n c o u nt fr o m baseli ne t o Wee k  4 
• Pr o p orti o n of s u bjects w h o ha ve at least a 2 gra d e re d ucti o n at Wee k 4 fr o m baseli ne 
i n t he E val uat or's Gl o bal Se verit y  Sc ore  
[ADDRESS_686740] will be i ncl u de d i n t he m o del; 
ot her wise it will be re m o ve d.  
A s ke w ness test, bas e d o n t he met h o ds prese nte d b y J. H. Zar ( 1 9 8 4) [ 1 0 ], will be a p plie d t o t he 
resi d uals res ulti n g fr o m a n A N C O V A. A t w o -si de d p -val ue f or t h e s ke w n ess test si g nifica nt at  
Protocol V01 -121A -302, IDP -121 Valeant Research & Development  
Version 4, 7 October 2016  CONFIDENTIAL  
47  
 0.01 will imply the use of the non- parametric method. If a param etric analysis is indicated, the 
results of the parametric analysis will be considered the primary analysis. Should a non-  
parametric analysis be indicated, the absolute or percent changes in inflammatory and non - 
inflammatory lesions will be rank transfor med prior to submitting them to the ANCOVA. 
Results of the rank- transformed analyses then will be considered the primary analysis; however, 
results of the non- ranked transformed analyses will also be presented.  
12.1.5  Statistical Hypothesis Testing and Control of  Multiplicity  
Statistical hypothesis testing for lesion count analyses will use the statistical model introduced in 
Section 12.1.3 and employs the methods of Section regarding missing values. The analysis of the dichotomized Evaluator's Global Se verity Score will be based on the logistic regression test 
stratified by [CONTACT_500825] 12.1.[ADDRESS_686741] for a step is not significant. All subsequent tests for the remaining steps will be considered not significant. The order of testing is: 
 
Step Number  Secondary Endpoint  
[ADDRESS_686742] for a step is not significant. All subsequent tests for the remaining steps will be co nsidered not significant. The order of testing is:  
 
Step 
Number   
Supportive Endpoint  
[ADDRESS_686743] a 2 grade reduction at Week 12 from  
Pr ot oc ol V 0 1 -1 2 1 A -3 0 2, I D P -1 2 1  Valea nt Researc h & De vel o p me nt  
Versi o n 4, [ADDRESS_686744] o ber 2 0 1 6  C O N FI D E N TI A L  
4 8   
  
 baseli ne i n t he E val uat or's Gl o bal Se verit y Sc ore  
[ADDRESS_686745] a 2 gra d e re d ucti o n at Wee k 8 fr o m  
baseli ne i n t he E val uat or's Gl o bal Se verit y Sc ore  
[ADDRESS_686746] a 2 gra d e re d ucti o n at Wee k 4 fr o m  
baseli ne i n t he E val uat or's Gl o bal Se verit y Sc ore  
 
 
[ADDRESS_686747] atistics  
Descri pti ve statistics will be prese nt e d f or t he f oll o wi n g para meters b y treat me nt gr o u p f or b ot h 
t he I T T a n d P P p o p ulati o ns:  
• Fre q u e nc y a n d per ce nt distri b uti o ns of t he E val uat or’s Gl o bal Se verit y Sc or e at 
Baseli ne a n d Wee ks 4, 8, a n d  1 2.  
• Fre q u e nc y a n d per ce nt distri b uti o ns of t he dic h ot o mize d E val uat or’s Gl o bal Se verit y 
Sc ore at Baseli ne a n d Wee ks 4, 8, a n d 1 2.  
• Descri pti ve statistics i ncl u di n g mea n, me dia n, sta n dar d de vi ati o n, mi ni m u m, a n d 
ma xi m u m will be use d t o s u m marize i nfla m mat or y a n d n o n -i nfla m mat or y lesi o n 
c o u nts at baseli ne a n d wee ks 4, 8, a n d 1 2.  
• Descri pti ve statistics i ncl u di n g mea n, m e dia n, sta n dar d de viati o n, mi ni m u m,  a n d 
ma xi m u m will be use d t o s u m marize t he a bs ol ute a n d perce nt c ha n ge i n 
i nfla m mat or y a n d n o n -i nfla m mat or y lesi o n c o u nts at Wee ks 4, 8, a n d  1 2.  
• Fre q u e nc y a n d per ce nt distri b uti o ns f or t he Oil y/ S hi n y assess me nts at Wee k  1 2  
Mea ns, sta n dar d d e viati o ns a n d fre q u e nc y c o u nts (r o u n de d t o t he nearest w h ol e n u m ber) will be 
c o m p ute d fr o m t he m ulti pl y i m p ute d M C M C data f or t he vari a ble.  
[ADDRESS_686748] u d y is i nte n de d t o be c o n d ucte d i n a ma n n er 
s uc h t hat a mi ni m u m of 5 s u bjects will be e nr olle d i n eac h treat me nt ar m f or a n y i n vesti gat or.  I n 
t he e ve nt t hat t her e ar e t o o fe w s u bjects i n a tr eat me nt ar m f or a n i n v esti gat or, t he n t his 
i n vesti gat or's dat a will be c o m bi ne d t o ac hie v e t he desire d sa m ple size mi ni m u m per ar m. T he 
c o m bi ni n g of i n vesti gat or's d ata will be acc o m plis he d b y t a ki n g t h e i n vesti gat or wit h t he 
s mallest e nr oll me nt a n d c o m bi ni n g it wit h t he i n vesti gat or wit h t he lar gest. If t here is a f urt her 
nee d t o c o m bi ne dat a, t he n t he data of t h e i n vesti gat or wit h t he sec o n d s m allest e nr oll me nt will 
be c o m bi ne d wit h t he i n v esti gat or's d ata w hic h h a d t he se c o n d lar gest e nr oll me nt, a n d s o  o n.  
T his pr ocess will c o nti n ue f or all i n vesti gat ors w h o di d n ot ha ve a mi ni m u m of 5 s u bjects per 
acti ve treat me nt ar m. T h e pr ocess of c o m bi ni n g i n vesti gat or d ata t hat ha v e i ns ufficie nt s u bjects 
per treat me nt ar m will res ult  i n re defi ni n g t he gr o u ps of i n vesti gat ors f or t he p ur p oses of  
Protocol V01 -121A -302, IDP -121 Valeant Research & Development  
Version 4, 7 October 2016  CONFIDENTIAL  
49  
 statistical analyses. These combined groups will be referred to as "analysis centers" in the 
statistical analyses based on ANCOVA and stratified logistic testing.  
Prior to investi gating the treatment effect within the analysis centers, the magnitude of the site 
mail effect will be investigated to determine if the main site -to-site variability is such that it 
could mask the analysis center effects. Thus, if computationally possible, a one -way ANCOVA 
(for lesion count variables) or a logistic regression analysis (for EGSS) with a factor of site will 
be conducted prior to pooling. If the data structure interferes with the logistic regression, a descriptive analysis of the site effect w ill be undertaken. Conclusions appropriate to the findings 
of this step will be presented. 
The consistency of treatment response will be investigated across the analysis centers  subsequent 
to combining the data as described above. Statistical tests will be  conducted to identify if there 
are extreme analysis centers that could affect the interpretation of common statistical and clinical 
conclusions. An analysis center by [CONTACT_500826] 0.10. Change 
from baseline in inflammatory lesions and non- inflammatory lesions will be analyzed with an 
ANCOVA (unranked or ranked) with factors of treatment, analysis center, and treatment by [CONTACT_500827] a covariate. For 
the purpose of testing consistency of treatment response, the dichotomized EGSS will be analyzed with a logistic regression procedure. Further examination will fol low for any variables 
that have a significant ANCOVA or logistic regression interaction term. In the event that the ANCOVA or logistic regression interaction (referred to henceforth as the "appropriate test") p-  
value is less than or equal to 0.10, a sensi tivity analysis that excludes analysis centers with the 
extreme efficacy result will be performed to determine the robustness of the treatment effect.  On 
the other hand, if the outcome of the appropriate test has a p- value greater than 0.10, then the 
concl usions from the pooled data will be considered to be free of the impact of extreme analysis 
centers.  
The first step in conducting a sensitivity analysis is to identify the extreme analysis center or 
centers that contribute to the statistical significance o f the appropriate test. The process involves 
submitting subsets of analysis centers to the appropriate test and observing the appropriate test p-  
value for the subset. Subsets with p- values greater than 0.[ADDRESS_686749] for all subsets that can be created by [CONTACT_500828]. If one  
Protocol V01 -121A -302, IDP -121 Valeant Research & Development  
Version 4, [ADDRESS_686750] -hoc aspects of the process will be given when the results are interpreted. Conclusions 
will be presented by [CONTACT_85220].  
12.1.8  Missing Efficacy Data Imputations  
Lesion Count Variable Missing Data Imputation  
Missing 12 week data will be estimated by [CONTACT_85221]. Missing lesion count data will be derived for the analysis using the method of Markov Chain Monte Carlo (MCMC) multiple imputation which does not rely on the assumption of data missing at random. Additionally, the pattern of missing observations in each treatment group cannot influence the missing value estimation in the other because the imputation is being conducted independently for each treatment group. 
Multiple imputation and subsequent analysis will involve [ADDRESS_686751] phases with these principal 
tasks:  
 
1. Calculated the number of missing values to be estimated by [CONTACT_85222] (nmiss ) for 12  week 
value.  
2. Create a data set of subjects, one for each treatment group, with observed values and 
those needing estimation by [CONTACT_85222]. The missing lesion count values in each data set will be filled in using the MCMC method ‘5 x nmiss’ times to gener ate ‘5 x nmiss’ data 
sets. The resulting data sets for each treatment arm will be combined into one  complete 
data set for each imputation.  
Syntax:  
proc mi data=datain out=dataout seed=&seed. nimpute=5xnmiss <options>; 
where trtpn=(1, or 2);  
mcmc chain=multiple;  
var baseline week4 week8 week12; run; 
Protocol V01 -121A -302, IDP -121 Valeant Research & Development  
Version 4, [ADDRESS_686752] been pre - 
specified by [CONTACT_2329] a random number generator:  
• Inflammatory Lesion Counts; IDP -121 Lotion: Seed=  [PHONE_10385]  
• Inflammatory Lesion Counts; IDP -121 Vehicle: Seed= 356782065  
• Non-Inflammatory Lesion Counts; IDP -121 Lotion: S eed= [PHONE_10386] 
• Non-Inflammatory Lesion Counts; IDP -121 Vehicle: Seed=  436373460  
EGSS Missing Data Imputation  
A similar procedure will be used for the analyses based on proportion of EGSS successes wherein the ANCOVA analysis is replaced with a logistic regression analysis. Specifically, missing 12 week EGSS values from which the dichotomized EGSS is derived will be estimated by (MCMC) which does not rely on the assumption of data missing at random. Additionally, the pattern of missing observations in each treatment group cannot influence the missing value estimation in the other because the imputation is being conducted independently for each treatment group.  
The missing 12 week EGSS values will be derived for the analysis using the method of Markov Chain Monte Carlo (MCMC) multiple imputation. Multiple imputation and subsequent analysis will involve 4 principal ta sks: 
1. Calculate the number of missing values to be estimated by [CONTACT_85222] (nmiss) for 12  week 
value.  
2. Create a data set, one for each treatment group, of subjects with observed values and those needing estimation by [CONTACT_85222]. The missing EGSS values in each data set will be filled in using the MCMC method ‘5 x nmiss’ times to generate ‘5 x nmiss’ data sets.  The 
resulting data sets for each treatment arm will be combined into one complete data set by [CONTACT_47915].  
Syntax:  
proc mi data=datain out=dataout seed=&seed. nimpu te=5xnmiss <options>; 
where trtpn=(1, or 2);  
mcmc chain=multiple;  
var baseline week4 week8 week12;  
Protocol V01 -121A -302, IDP -121 Valeant Research & Development  
Version 4, 7 October 2016  CONFIDENTIAL  
52  
 run; 
 
3. For each complete data set, the dichotomous success rate (clear or almost clear with a 2 - 
point change from baseline) will be computed. The 12- week estimated global values  will 
be rounded to the nearest integer value prior to evaluating the success rate. Each 
complete data set will be analyzed with a logistic regression with factors of treatment group and analysis center. 
4. The res ults from these analyses will be combined into a single inference using  SAS 
PROC  MIANALYZE.  
A total of [ADDRESS_686753] been pre -specified by [CONTACT_2329] a random number generator:  
• EGSS; IDP -121 Lotion: Seed=  [PHONE_10387]  
• EGSS; IDP -121 Vehicle: Seed= [ADDRESS_686754] sensitivity analysis for absolute change in lesion count use a repeated measures ANCOVA, with treatment, analysis center, and visit (ie, Week 4, Week 8) as independent  factors 
and a covariate of baseline lesion count.  In this analysis, data from all post -baseline visits will 
be included with no imputation for missing  data.  
The second sensitivity analysis will use the model based multiple imputation method to impute missing data for the absolute change in lesion counts at Week 12. Although the full details will be presented in the Statistical Analysis Plan (SAP), the m ultiple imputation will involve 4 
principal tasks:  
1. Calculate the number of missing values (nmiss) for absolute change in lesion count. 
2. Missing values will be filled in ‘5 x nmiss’ times to generate ‘5 x nmiss’ complete data sets. The imputation model used will be an ANCOVA with factors of treatment group and analysis center, and a covariate of baseline lesion count (ie, the imputation model will be the same as the analysis model). Appropriate modifications will be made should the analysis be based on a  non- parameteric method. 
3. Each complete data set will be analyzed with an ANCOVA with factors of  treatment 
group, and analysis center, and a covariate of baseline lesion count. 
4. Results from these analyses will be combined into a single  inference.  
Sensitivity analyses for EGSS 
Protocol V01 -121A -302, IDP -121 Valeant Research & Development  
Version 4, [ADDRESS_686755] sensitivity analysis for the dichotomized EGSS success will use a repeated measures 
logistic regression model (generalized estimating equations), with dichotomized EGSS success 
as the dependent variable and treat ment, analysis center, and visit (ie, Week 4, Week 8) as 
independent factors. In this analysis, data from all post -baseline visits will be included with no 
imputation for missing data.  
The second sensitivity analysis will use the model based multiple imputation method to impute 
missing data for the dichotomized EGSS data. Although the full details will be presented in the 
SAP, the multiple imputation will involve 4 principal tasks: 
1. Calculate the number of missing values (nmiss) for absolute change in lesion count. 
2. Missing values will be filled in ‘5 x nmiss’ times to generate ‘5 x nmiss’ complete data 
sets. The imputation model used logistic regression with factors of treatment group  and 
analysis center (ie, the imputation model will be the same as the analy sis model). 
3. Each complete data set will be analyzed with a logistic regression a factors of  treatment 
group and analysis center. 
4. Results from these analyses will be combined into a single  inference.  
 
12.1.10  Subgroup Analyses  
Subset analyses will be conducted for the ITT populations for the subgroups baseline global 
severity, gender, age, ethnicity, race, and geographic location. Age will be dichotomized to less than the median age of subjects and greater than or equal to the median age of subjects. A n 
additional analysis will be include with categories of less than 18, 18 to less than the median age and greater than or equal to the median age. Geographic region will be dichotomized to US and outside US (OUS). Subset analyses will be conducted on the variables absolute change from baseline in inflammatory lesions and non- inflammatory lesions at Week 12 as well as the 
dichotomized global severity score at Week 12. These analyses will contain only descriptive statistics.  
 
12.2 Assessment of  Safety  
Safety will be evaluated by [CONTACT_220131] (AEs), Cutaneous Safety Evaluation, 
and Tolerability Evaluations. Cutaneous Safety Evaluation scores (erythema, scaling, and hypo/hyper -pi[INVESTIGATOR_371]) and Tolerability (itching, burning, and stinging) will be pr esented with 
descriptive statistics at Baseline and at Weeks 4, 8, and 12 for each treatment group. Frequencies and percentages for each outcome category will be included in these statistics. Mean values will be presented graphically by [CONTACT_85223]. 
12.2.1  Adverse Events  
All adverse events occurring during the study will be recorded and classified on the basis of MedDRA terminology. Descriptions of AEs will include the date of onset, the date the AE  
Protocol V01 -121A -302, IDP -121 Valeant Research & Development  
Version 4, 7 October 2016  CONFIDENTIAL  
54  
 ended, the severity of the AE, the rel ationship to study medication, the action taken regarding 
study medication usage, the action taken regarding to treat the AE, and the outcome. All reported 
treatment -emergent AEs (TEAEs) will be summarized by [CONTACT_365473], 
system or gan class, severity, seriousness, and relationship to study medication. TEAEs are those 
AEs with an onset on or after the date of the first study drug application. 
Adverse events will be summarized by [CONTACT_85225]. Each subject will be 
counted only once within a system organ class or a preferred term by [CONTACT_365474].  
Adverse events will be summarized by [CONTACT_220160]. Each subject will be counted only once within a system organ class or a preferred term by [CONTACT_220161].  
Comparisons among treatment groups will be made by [CONTACT_220162] (class ified into MedDRA terms) during the study. The Fisher’s Exact test will 
be used to compare the proportion of subjects in each treatment group who report any adverse event at a significance level of 0.05. The specific system organ classes and preferred term s 
analyzed will be those that are reported by [CONTACT_220133].  
All information pertaining to AEs noted during the study will be listed by [CONTACT_1130], detailing verbatim given by [CONTACT_093], preferred term, system organ class, start date, stop date, severity, actions taken, and drug relatedness. The AE onset will also be shown relative (in 
number of days) to the day of initial dose of the randomized study medication. 
Serious adverse events (SAEs) will b e tabulated by [CONTACT_85177].  
In addition, a list of subjects who discontinued from the study and a list of subjects who 
experienced SAEs will also be provided.  
12.2.[ADDRESS_686756] results will be provided.  
12.2.3  Vital Sign Measurements  
Changes from Baseline in vital sign measurements will be summarized with descriptive statistics for each treatment group at all applicable study visits.  
Protocol V01 -121A -302, IDP -121 Valeant Research & Development  
Version 4, [ADDRESS_686757]  Self-Assessments 
Subjects will be asked to complete three questionnaires during the study: the Subject Self Assessment scale, the Patient Satisfaction Survey and the Acne- Specific Quality of Life 
Questionnaire (Appendices 17.3, 17.4 and 17.5). Descriptive statistics will be used to summ arize 
the data reported for each questionnaire. No Inferential analyses will be conducted.  
 
12.[ADDRESS_686758] demographic and baseline characteristics will be summarized by [CONTACT_500829]. For continuous variables (e.g. age) comparisons among the two treatment groups will be conducted using a two- way analysis of variance 
(ANOVA) with factors of treatment group and analysis center. Ethnicity and race will be analyzed with a Cochran -Mantel -Haenszel test stratified by [CONTACT_85229]. Past and current 
medical conditions, as well as history of disease will not be compared statistically.  
 
12.[ADDRESS_686759] 9 years of age and older with moderate or severe acne (a score of 3 or 4 [moderate to severe] on the EGSS scale) will be enrolled and randomized in the study. With a 1:1 randomization ratio, it is anticipated that: 
Pr ot oc ol V 0 1 -1 2 1 A -3 0 2, I D P -1 2 1  Valea nt Researc h & De vel o p me nt  
Versi o n 4, [ADDRESS_686760] o ber 2 0 1 6  C O N FI D E N TI A L  
5 6   
 • 4 0 0 s u bjects will be ra n d o mize d t o recei ve I D P -1 2 1 L oti o n, o nce d ail y  a p plicati o n  
• [ADDRESS_686761] -b aseli ne e val uati o n.  
A n i nte nt -t o -treat (I T T) a nal ys is will be c o n d u cte d o n all st u d y s u bjects. A per -pr ot oc ol ( P P) 
a nal ysis will als o be c o n d ucte d. S u bjects will be eli gi ble f or t he P P a nal ysis if t he y c o m plet e t he 
[ADDRESS_686762] u d y pr ot oc ol vi olati o ns (i.e., a n y s u bject or 
i n vest i gat or acti vit y t hat c o ul d ha ve p ossi bl y i nterfere d wit h t he t hera p e utic a d mi nistrati o n of  t he 
treat me nt or t he pr ecise e val uati o n of treat me nt efficac y). T h e P P p o p ulati o n will i ncl u de 
s u bjects i n t he safet y p o p ulati o n w h o d o n ot meet a n y of t he f oll o wi n g  criteria:  
• Faile d a n y of t he i ncl usi o n/e x cl usi o n  criteria;  
• Ha ve ta k e n a n y i nterferi n g c o n c o mita nt  me dicati o ns;  
• Di d n ot atte n d t he Wee k [ADDRESS_686763];  
• Misse d b ot h t he wee k 4 a n d wee k 8  visits;  
• Ha ve n ot bee n c o m plia nt wit h t he d osi n g re gi me n (i.e. S u bjects ma y n ot miss m ore 
t ha n fi ve c o nsec uti ve da ys of d osi n g a n d m ust ta ke 8 0 -1 2 0 % of e x pecte d d oses. T he 
n u m ber of e x pecte d d oses will be deter mi ne d f or eac h s u bject base d o n t he le n gt h  of 
t heir partici pati o n i n t he  st u d y);  
• O ut of visit wi n d o w at t he [ADDRESS_686764] u d y 2  i n 
Atrali n ™ (treti n oi n) Gel, 0. 0 5 % N D A [ADDRESS_686765] u d y was a t w o -ar m trial o f 
Atrali n ™ vers us its ve hicle a n d is felt t o be a rele v a nt st u d y i n N D A [ADDRESS_686766] 9 6 % p o wer t o d et ect a st atisticall y  si g nifica nt 
differe n ce wit h a si g nifica nce le v el of 0. 0 5. T he esti mate d a bs ol ute c ha n ge fr o m baseli ne  i n  
Protocol V01 -121A -302, IDP -121 Valeant Research & Development  
Version 4, 7 October 2016  CONFIDENTIAL  
57  
 treatment means were 6.5 and 3.5 for Atralin™ versus its vehicle, respectively, with a standard 
deviation of 11.3. 
A sample size of 400 per treatment arm has greater than 99% power to detect a statistically 
significant difference with a significance level of 0.05 using the estimated absolute change from 
baseline in treatment means of 17.8 and 9.9 for Atralin™ versus it s vehicle, respectively, with a 
standard deviation of 24.7. 
The sample size estimates for the dichotomized EGSS require a substantially larger enrollment in 
order to achieve a power of at least 90%. The success rates observed in the second Atralin™ 
study was 23% for Atralin™ and 14% for its vehicle which is a difference of 9%. Approximately 
90% power is achieved with sample sizes of 400 per treatment group, respectively, using a 1:1 
randomization. 
It is noted that the same differential in success ra tes was observed in Study 1 (Atralin™ 
(tretinoin) Gel, 0.05% NDA 022070 application). The success rates observed in the first 
Atralin™ study was 13% for Atralin™ and 4% for its vehicle which is also a difference of 9%. 
Using these estimates, more than 99% percent power is achieved with sample sizes of 400 per treatment group.  
The clinical study will be conducted under a common protocol at each investigational site and every effort will be made to promote consistency in study execution at each investigationa l site 
as well as uniform evaluation of the EGSS evaluation for subjects at the various study visits. The experience in clinical trial execution gained during the execution of several acne studies conducted under the guidance of the Sponsor raises the expe ctation that the differential between 
the success rates of the two arms will be greater than 9%. Thus, the power of the EGSS is expected to be at least 95% for sample sizes of 400 subjects in each arm.  
Individually and collectively the considerations lead to a choice of randomizing 400 subjects per treatment group.  
12.8.3  Handling of Missing Data 
The method of multiple imputation will be used (see Section 12.1.8).  
 
12.8.4  Multicenter  Issues 
The study will be conducted at multiple investigational centers in North America and Latin 
America with the intention of pooling the results for analysis.  
12.8.5  Multiplicity  Issues  
Not applicable.  
Protocol V01 -121A -302, IDP -121 Valeant Research & Development  
Version 4, 7 October 2016  CONFIDENTIAL  
58  
 12.8.6  Windowing  Rules  
The timing of all study visits is relative to Baseline (Day 0). The Week 4 and Week 8 visits 
should occur within ± 3 days of the scheduled times, the Week 12 visit should occur within - 3 / 
+5 days of the scheduled time. 
 
13 Quality Control and Quality Assurance  
13.1 Study  Monitoring  
An Investigator Meeting and/or an initiation visit will be conducted with the principal investigator [INVESTIGATOR_220124]/or its designee. During this meeting, an 
extensive review and discussion of the protocol, the role of the study techn ician, all study 
procedures, source documents, and eCRFs will be conducted. Evaluation scales will be reviewed extensively and documentation of training will be recorded for training of sponsor -approved 
evaluators.  
The study monitors/clinical research asso ciates will be trained prior to study initiation. Following 
this training, an overview of the study disease and study material background will be understood. Specific monitoring guidelines and procedures to be followed during monitoring visits will also be utilized. During the course of the study, all data will be 100% source document verified by [CONTACT_220164]. All subject source records must be made available to the monitors. 
The conduct of the study will be closely monitored by [CONTACT_85232]. 
The reports of these verifications will also be archived with the study report. In addition, inspections or on site audits may be carried out by [CONTACT_220165]'s Quality Assurance Department. The investigators will allow the sponsor's representatives and any regulatory agency to examine all study records, corresponding subject medical records, clinical dispensing records and storage area, and any other documents considered source documentation. The investigators agree to assis t the representative, if required.  
 
13.2 Audits and  Inspections  
The study will be conducted under the sponsorship of Valeant in conformation with all appropriate local and federal regulations, as well as ICH guidelines. Interim and end of study audits of raw da ta, study files, and final report may be conducted by [CONTACT_220166]’s Quality Assurance 
Department or designee.  
The sponsor is responsible for implementing and maintaining quality assurance and quality control systems to ensure that studies are conducted and dat a are generated, documented, and 
reported in compliance with the protocol, GCP, and applicable regulatory requirements. In addition, the sponsor will be responsible for securing agreement from all involved parties to ensure direct access to all study relat ed investigational centers, source data/documents, CRFs, 
Protocol V01 -121A -302, IDP -121 Valeant Research & Development  
Version 4, [ADDRESS_686767]’s source documents and 
CRFs. The investigator or designee will enter the information required by [CONTACT_500815]. Subjects will be identified in the CRFs by [CONTACT_119123].  
The investigators must read the protocol thoroughly and must follow the instructions exactly. Any deviations should be agreed to by [CONTACT_528824], 
with appropriate written protocol amendments made prior to implementing the agreed changes. Any amendment containing major modifications (particularly if it may involve an increased risk to the subjects) will be approved by [CONTACT_528825]. No change in the 
conduct of the study can be instituted without written approval from the sponsor. 
 
[ADDRESS_686768] (IRB) or Independent Ethics Committee (I EC). A signed and dated notification of the 
IRB/IEC approval will be provided to the sponsor and investigator prior to study initiation. The name [CONTACT_85251]/IEC will be supplied to the sponsor. The investigator wi ll provide required progress reports and report all SAEs to the 
IRB/IEC as required by [CONTACT_1201]/IEC.  
 
14.3 Written Informed  Consent  
Written informed consent/assent, in accordance with local clinical investigation regulations, must be obtained prior to participation in the study. The investigator or designee will discuss the purpose of the study with each subject, and provide a description of the study drug (including any potential and possible side effects) and the study procedures. Information must be given both in oral and written form. Subject information will be provided in a language understandable to the subject and may not include any language that appears to waive any of the subject‘s  legal  
Protocol V01 -121A -302, IDP -121 Valeant Research & Development  
Version 4, [ADDRESS_686769] any study related procedures performed before his/her written informed consent has  been obtained. The original signed and dated informed consent 
form will be retained with the study records, and a copy of the signed form will be given to the subject.  
An informed consent template will be supplied by [CONTACT_456]. Any changes to the inform ed 
consent form must be agreed to by [CONTACT_500816]/IEC, and a copy of the approved version must be provided to the sponsor or designee after IRB/IEC approval.  
 
14.[ADDRESS_686770] initials, demographics (including birthdates), 
medical his tories, and prior concomitant medication uses, along with the name [CONTACT_500834]. Other than where necessary to meet regulatory requirements, all data collected in this  study will be 
presented in tabulated (ie, aggregate) form and listings containing information that could be used to identify an individual subject will not be included in any public disclosures of the study data or the study  results.  
 
14.[ADDRESS_686771].  
Pr ot oc ol V 0 1 -1 2 1 A -3 0 2, I D P -1 2 1  Valea nt Researc h & De vel o p me nt  
Versi o n 4, [ADDRESS_686772] o ber 2 0 1 6  C O N FI D E N TI A L  
6 1   
 14 .7  I n vesti g at or  O bli g ati o ns  
T he i n vesti gat or a gr ees, w he n si g ni n g t he pr ot oc ol, t o a d here t o t he i nstr ucti o ns a n d pr oce d ures 
descri be d i n it a n d t her e b y t o a d h ere t o t he pri nci ples of G o o d Cli nical Practice ( G C P).  
 
[ADDRESS_686773] f oll o w t he i nstr ucti o ns e x actl y. 
W he ne ver p ossi ble, a n y pla n ne d de viati o ns s h o ul d be a gree d t o b y pri or disc ussi o n bet wee n t he 
s p o ns or a n d t he i n vesti gat or, wit h a p pr o priate d o c u me ntati o n of s p o ns or a p pr o val pri or t o 
effecti n g t h e c ha n ges a gr ee d u p o n. A n y a m e n d me nt t o t he pr ot oc ol c o ntai ni n g maj or 
m o dificati o ns ( partic ularl y if it ma y i n v ol ve a n i ncrease d ris k t o t he s u bjects) will be a p pr o ve d 
b y t he I R B bef ore it ma y be i m ple me nte d. N o c h a n ge i n t he c o n d uct of t he st u d y ca n be 
i nstit ute d wi t h o ut writte n a p pr o val fr o m t he s p o ns or.  
 
14 .9  C o nfi de nti alit y/ P u blic ati o n of t he St u d y  
All t he data f ur nis he d t o t he i n vesti gat or a n d his/ her staff a n d all data o bt ai ne d t hr o u g h t his 
pr ot oc ol will be re gar de d as c o nfi de ntial a n d pr o prietar y i n nat ure a n d will n ot be discl ose d t o 
a n y t hir d p art y, e x ce pt f or t he F D A or ot her re g ulat or y b o d y, wit h o ut writte n c o nse nt fr o m t he 
s p o ns or.  
 
[ADDRESS_686774]’s s o urce d oc u me nts a n d i n a p plica ble 
st u d y l o gs pr o vi de d b y t h e s p o ns or. S o urce d o c u me nts i ncl u de s u bject me di cal rec or ds, h os pi[INVESTIGATOR_307] 
c harts, cli nic c h arts, i n vesti gat or s u bject st u d y files, as well as t he r es ults of dia g n ostic tests  
(e g, la b or at or y tests). All re q uire d d ata s h o ul d be r ec or de d i n t he st u d y d o c u me ntati o n 
c o m pletel y f or pr o m pt data re vie w. U p o n st u d y c o m pleti o n or at a n y ot h er ti me s pecifie d b y t he 
s p o ns or or desi g nee, t h e a p pr o priate st u d y d oc u m e nts m ust be s u b mitte d.  
T he i n vesti gat or m ust kee p acc urate s e par ate r ec or ds (s o urce d oc u me ntati o n) of all s u bject visits, 
bei n g s ur e t o i ncl u de all perti ne nt st u d y r elate d i nf or mati o n. At a mi ni m u m, t his i ncl u des t he 
foll o wi n g i nf or mati o n:  
• A state me nt i n dicati n g t h at t he s u bject has bee n e nr olle d i n t he st u d y a n d t h e  s u bject 
n u m ber  
• Date t hat i nf or me d c o nse nt was o btai ne d  
• E vi de nce t hat t he s u bject meets st u d y eli gi bilit y r e q uire me nts (e g, me dical hist or y, 
scree ni n g  e val u ati o ns)  
Pr ot oc ol V 0 1 -1 2 1 A -3 0 2, I D P -1 2 1  Valea nt Researc h & De vel o p me nt  
Versi o n 4, [ADDRESS_686775] o ber 2 0 1 6  C O N FI D E N TI A L  
6 2   
 • Dates of all st u d y rel ate d visits a n d res ults of a n y e val uati o ns/ pr oce d ures  p erf or me d, 
i ncl u di n g w h o perf or me d eac h assess me nt at eac h  visit  
• Use of a n y c o nc urre nt m e dicati o ns d uri n g t he  st u d y  
• D oc u me ntati o n of st u d y dr u g  acc o u nt a bilit y  
• A n y a n d all si de effects a n d A Es m ust be t h or o u g hl y d oc u me nt e d t o  c o ncl usi o n  
• Res ults of a n y dia g n ostic tests c o n d ucte d d uri n g t he  st u d y  
• T he date t he s u bject e xite d t he st u d y a n d a state me nt i n dicati n g t hat t he  s u bj ect 
c o m plete d t he st u d y or w as disc o nti n ue d earl y, i ncl u di n g t he reas o n f or 
disc o nti n uati o n  
N otes descri bi n g tele p h o ne c o n vers ati o ns a n d all electr o nic mail wit h t he s u bject or t he s p o ns or 
(s p o ns or’s desi g nee) c o n cer ni n g t he st u d y m ust be rec or de d or k e pt o n file. All s o urc e 
d oc u me nts m ust be ma de a vaila ble t o t he s p o ns or a n d t he s p o ns or’s desi g n ate d m o nit or u p o n 
re q uest.  
 
[ADDRESS_686776] u d y ar e t o be ret ai ne d b y t he i n vesti gat or 
u ntil n otifie d b y t h e s p o ns or i n writi n g t hat t he r ec or ds ma y b e destr o ye d.  
T he i n vesti gat or will all o w re pr ese ntati ves of t he s p o ns or’s m o nit ori n g tea m, t he g o ver ni n g 
I R B/I E C, t he F D A, a n d o t her a p plica ble re g ulat or y a ge ncies t o i ns pect all st u d y rec or ds, C R Fs, 
a n d c orr es p o n di n g p orti o ns of t he s u bject’s cli nic a n d/ or h os pi[INVESTIGATOR_500782] r ec or ds at r e g ular 
i nter vals t hr o u g h o ut t he st u d y. T hes e i ns pecti o ns are f or t he p ur p ose of v erif yi n g a d h er e n ce t o 
t he pr ot oc ol, c o m plete ness a n d acc urac y of t he data bei n g e nter e d o nt o t he C R F, a n d c o m plia nce 
wit h F D A or ot her re g ul at or y a ge nc y re g ulati o ns.  
Protocol V01 -121A -302, IDP -121 Valeant Research & Development  
Version 4, 7 October 2016  CONFIDENTIAL  
63  
 16 References  
1. Leyden JJ, Shalita AR. Rational therapy for acne vulgaris: an update on topi[INVESTIGATOR_71831]. 
J Am Acad Dermatol. 1986;15(4 Pt  2):907- 15. 
 
2. Webster GF. Acne vulgaris. BMJ. 2002;325(7362):475- 9. 
 
3. Eady EA. Bacterial resistance in acne. Dermatology.  1998;196(1):59- 66. 
 
4. Eady EA, Farmery MR, Ross JI, Cove JH, Cunliffe WJ. Effects of benzoyl peroxide  and 
erythromycin alone and in combination against antibiotic -sensitive and - resistant skin 
bacteria from acne patients. Br J Dermatol.  1994;131(3):331- 6. 
 
5. Leyden JJ, McGinley KJ, Cavalieri S, Webster GF, Mills OH, Kligman AM. 
Propi[INVESTIGATOR_528817].  J Am Acad  Dermatol. 
1983;8(1):41- 5. 
 
6. Shalita A. The integral role of topi[INVESTIGATOR_85163].  J 
Eur Acad Dermatol Venereol. 2001;[ADDRESS_686777]  3:43- 9. 
 
7. McLane  J. Analysis  of common  side effects  of isotretinoin.  J Am Acad  Dermatol. 
2001;45(5):S188- 94. 
 
8. Orfanos  CE, Ehlert  R, Gollnick  H. The retinoids. A review  of their clinical pharmacology 
and therapeutic use. Drugs.  1987;34(4):459- 503. 
 
9. Lucky AW, Cullen SI, Funicella T, Jarratt MT, Jones T, Reddick ME. Double -blind, 
vehicle- controlled, multicenter comparison of two 0.025% tretinoin creams in patients 
with acne vulgaris. J Am Acad Dermatol.  1998;38(4):S24- 30. 
 
10. Zar, JH. Biostatistical analysis. 2nd Edition. Englewood Cliffs, NJ: Prentice -Hall. P. 118- 
119. 1984.  
Protocol V01 -121A -302, IDP -121 Valeant Research & Development  
Version 4, [ADDRESS_686778] Instruction Sheet  
 
Wash your face gently with a mild cleanser approved by [CONTACT_85243] (not hot) 
water. Rinse thoroughly and gently pat dry with a cotton towel. Wait until skin is completely dry before applying the test material.  
 
A thin coating of test material should be applied once daily (about the same time every day)  to 
the entire face for twelve weeks. Use the tube to disp ense a pea- sized amount of study drug to 
your fingertip.  
 
This dose should then be dotted on to 6 areas (chin, left cheek, right cheek, nose, left forehead, right forehead) on the face. After distributing the dose in this manner, gently rub the lotion into  
the skin. This amount should be used to evenly cover the entire face excluding the mouth, eyes and lips. It is important to treat your entire face.  
 
Do NOT treat only specific lesions. DO NOT APPLY MORE THAN THE  PRESCRIBED 
AMOUNT.  
Be sure to wash your han ds after you apply the  product. 
Reminders:  
- On study visit days please wait until after your study visit to apply the study  medication.  
- Avoid contact [CONTACT_68572], inside the nose, mouth and all mucous  membranes.  
- Do not cover the affected areas with any type of dressing, such as  gauze.  
- THE TEST MATERIAL SHOULD BE USED ONLY BY [CONTACT_528826].  
- Store at controlled room temperature 20°C to 25°C (68°F to 77°F) with excursions permitted 
between 15°C to 30°C (59°F to 86°F) . Do not freeze. Avoid excessive heat or  cold. 
- Tubes of test material must be returned to the study facility, even if they are  empty.  
- If you miss any doses, at your next visit inform the study doctor of the date(s) of the  missed 
dose(s).  
- Continue to use the same, study doctor approved, cleanser, moisturizer and sunscreen 
throughout the  study.  
- You must not use any other treatment for your facial acne while you are participating i n this 
study.  
- Avoid unnecessary sun exposure and tanning  booths. 
Protocol V01 -121A -302, IDP -121 Valeant Research & Development  
Version 4, 7 October 2016  CONFIDENTIAL  
65  
 - It is important that you inform the study site about any medications (i.e., prescriptions, over- 
the-counter medications, street drugs, or herbal medications) that you have take n during the 
study.  
 
If you have any questions or have a potential research- related side effect or injury you may 
contact   [INVESTIGATOR_136]  . 
Pr ot oc ol V 0 1 -1 2 1 A -3 0 2, I D P -1 2 1  Valea nt Researc h & De vel o p me nt  
Versi o n 4, [ADDRESS_686779] u d y. S u bjects ma y use t he bel o w set of e x a m ples or ot her I n vesti gat or a p pr o ve d n o n - 
me dicate d pr o d u cts o n t he treat me nt ar ea. I nf or m ati o n re gar di n g pr o d ucts use d s h o ul d be 
ca pt ure d i n t he s o ur ce d o c u me nt a n d rec or d e d o n t he faci al s ki n car e secti o n of t he e C R F.  
 
A p pr o ve d Clea ns er E x a m ples:  
Cera Ve clea ns er  
Ceta p hil dail y clea ner a n d ge ntle clea nsi n g bar 
P ur p ose ge ntle clea nsi n g was h  
 
A p pr o ve d M oist urizer  E x a m ples:  
Cera Ve Crea m or L oti o n 
M oist urel crea m or l oti o n 
N utra der m  
Ceta p hil l oti o n or crea m 
D M L  
E uceri n l oti o n or cr ea m 
P ur p ose  
 
A p pr o ve d M oist urizer/ S u nscree n C o m bi nati o n Pr o d uct E x a m ples: 
Cera Ve L oti o n A. M.  
Ola y C o m plete ( S P F 1 5)  
Ne utr o ge na Healt h D efe nse Dail y M oist urizer ( S P F 3 0) 
Ceta p hil Dail y Faci al M oist urizer ( S P F 1 5)  
 
A p pr o ve d S u nscr ee n E x a m ples:  
Ba na n a B oat S p ort S u n bl oc k L oti o n ( S P F 1 5, 3 0 + or 5 0) 
Ne utr o ge na U V A/ U V B ( S P F 3 0 or 4 5)  
Ne utr o ge na S e nsiti ve S ki n S u n bl oc k L oti o n ( S P F 1 7)  
Ne utr o ge na Healt h y D ef e nse Oil -Free S u n bl oc k L oti o n ( S P F 3 0 or 4 5) 
C o p pert o ne Water Ba bies U V A/ U V B S u n bl oc k L oti o n ( S P F 4 5)  
Pr ot oc ol V 0 1 -1 2 1 A -3 0 2, I D P -1 2 1  Valea nt Researc h & De vel o p me nt  
Versi o n 4, [ADDRESS_686780] Q uesti o n  
H o w w o ul d rate t h e c urre nt se verit y of y o ur f acial ac ne c o n diti o n o n a scale of 1 -7?  
( C hec k o nl y o ne b o x)  
1, Clear or al m ost clear s ki n ( > 9 0 %);  
2, M o deratel y cl ear s ki n ( > 8 0 % b ut ≤ 9 0 %);  
3, Fairl y clear s ki n ( > 7 0 % b ut ≤ 8 0 %); 
4, Ac ne c o v ere d a b o ut 5 0 % of t he face;  
5, Fairl y se v ere ac ne ( > 7 0 % b ut ≤ 8 0 % c o ver a ge);  
6, M o deratel y se v ere ac n e ( > 8 0 % b ut ≤ 9 0 % c o vera ge); 
7, Se vere ac ne, wit h al m ost t otal c o vera ge ( > 9 0 %).  
 
Wee k 2 ( at -h o me), 4, 8, a n d [ADDRESS_686781] Q uesti o n  
H o w w o ul d rate t h e c urre nt se verit y of y o ur f acial ac ne c o n diti o n o n a scale of 1 -7?  
( C hec k o nl y o ne b o x)  
1, clear ( 1 0 0 %);  
2, al m ost clear ( 9 0 % t o < 1 0 0 %);  
3, mar ke d i m pr o ve me nt ( 7 5 % t o < 9 0 %);  
4, m o derate i m pr o ve m e nt ( 5 0 % t o < 7 5 %);  
5, fair i m pr o ve me nt ( 2 5 % t o < 5 0 %);  
6, n o c ha n ge;  
7, w orse  
Protocol V01 -121A -302, IDP -121 Valeant Research & Development  
Version 4, 7 October 2016  CONFIDENTIAL  
68  
 17.4 Patient Satisfaction Survey (PSS)  
 
 
Baseline Question 
 
On a scale of [ADDRESS_686782] satisfied please rate your 
level of satisfaction with your current facial acne study treatment.  
 
 
 
Pr ot oc ol V 0 1 -1 2 1 A -3 0 2, I D P -1 2 1  Valea nt Researc h & De vel o p me nt  
Versi o n 4, [ADDRESS_686783] o ber 2 0 1 6  C O N FI D E N TI A L  
6 9   
 17 .5  Ac ne -S pecific Q u alit y of Lif e Q uesti o n n aire  ( Ac ne -Q o L)  
1.  I n t he p ast W E E K, h o w u nattracti ve di d y o u f eel beca use of y o ur f acial  ac ne?  
 e xtre mel y  ver y  m uc h  q uite  a bit  a g o o d  bit  s o me w hat  a little bit n ot at  all  
2.  I n t he p ast W E E K, h o w e m barrasse d di d y o u feel beca use of y o ur f acial  ac ne?  
 e xtre mel y  ver y  m uc h  q uite  a bit  a g o o d  bit  s o me w hat  a little bit n ot at  all  
3.  I n t he p ast W E E K, h o w s elf -c o nsci o us ( u neas y a b o ut o neself) di d y o u feel a b o ut y o ur facial 
ac ne?  
 e xtre mel y  ver y  m uc h  q uite  a bit  a g o o d  bit  s o me w hat  a lit tle bit n ot at  all  
4.  I n t he p ast W E E K, h o w u pset were y o u a b o ut ha vi n g facial ac ne?  
 e xtre mel y  ver y  m uc h  q uite  a bit  a g o o d  bit  s o me w hat  a little bit n ot at  all  
5.  I n t he p ast W E E K, h o w a n n o ye d di d y o u feel at h a vi n g t o s pe n d ti me e ver y da y clea ni n g a n d 
treati n g y o ur face b eca us e of y o ur f acial  ac n e?  
 e xtre mel y  ver y  m uc h  q uite  a bit  a g o o d  bit  s o me w hat  a little bit n ot at  all  
6.  I n t he p ast W E E K, h o w dissatisfie d wit h y o ur self -a p peara n ce di d y o u f eel beca use of y o ur 
facial  ac n e?  
 e xtre mel y   ver y  m uc h  q uite  a bit  a g o o d  bit  s o me w hat  a little bit n ot at  all  
7.  I n t he p ast W E E K, h o w c o ncer ne d or w orrie d wer e y o u a b o ut n ot l o o ki n g y o ur b est  beca use 
of y o ur facial ac n e?  
 e xtre mel y  ver y  m uc h  q uite  a bit  a g o o d  bit  s o me w hat  a little bit n ot at  all  
8.  I n t he p ast W E E K, h o w c o ncer ne d or w orrie d wer e y o u t h at y o ur ac n e me dicati o n  pr o d ucts 
were w or ki n g fast e n o u g h i n cleari n g u p t he ac ne o n y o ur  face?  
 e xtre mel y  ver y  m uc h  q uite  a bit  a g o o d  bit  s o me w hat  a little bit n ot at  al l 
9.  I n t he p ast W E E K, h o w b ot here d di d y o u feel a b o ut t he nee d t o al wa ys h a v e me dicati o n  or 
c o ver -u p a vaila ble f or t h e ac n e o n y o ur  face?  
 e xtre mel y  ver y  m uc h  q uite  a bit  a g o o d  bit  s o me w hat  a little bit n ot at  all  
[ADDRESS_686784] W E E K, h o w m uc h was y o ur self -c o nfi de nce (s ure of y o urself) ne gati vel y  aff ecte d 
beca use of y o ur f acial  ac ne?  
 e xtre mel y  ver y  m uc h  q uite  a bit  a g o o d  bit  s o me w hat  a little bit n ot at  all  
[ADDRESS_686785] W E E K, h o w c o ncer ne d or w orrie d wer e y o u a b o ut meeti n g ne w pe o ple  beca use  
of y o ur facial ac n e?  
 e xtre mel y  ver y  m uc h  q uite  a bit  a g o o d  bit  s o me w hat  a little bit n ot at  all  
[ADDRESS_686786] W E E K, h o w c o ncer ne d or w orrie d wer e y o u a b o ut g oi n g o ut i n p u blic beca use  of 
y o ur faci al ac n e?  
 e xtre mel y  ver y  m uc h  q uite  a bit  a g o o d  bit  s o me w hat  a little bit n ot at  all  
Pr ot oc ol V 0 1 -1 2 1 A -3 0 2, I D P -1 2 1  Valea nt Researc h & De vel o p me nt  
Versi o n 4, [ADDRESS_686787] W E E K, h o w m uc h was s ocializi n g wit h pe o ple a pr o ble m f or y o u beca use of  y o ur 
facial  ac n e?  
 e xtre mel y  ver y  m uc h  q uite  a bit  a g o o d  bit  s o me w hat  a little bit n ot at  all  
[ADDRESS_686788] W E E K, h o w m uc h was i nteracti n g wit h t he o p p osite se x ( or sa me se x if ga y  or 
les bia n) a pr o ble m f or y o u beca use of y o ur f acial  ac ne?  
 e xtre mel y  ver y  m uc h  q uite  a bit  a g o o d  bit  s o me w hat  a little bit n ot at  all  
[ADDRESS_686789] W E E K, h o w ma n y b u m ps di d y o u ha v e o n y o ur  face?  
 E xte nsi ve   A w h ole  l ot  A l ot  A m o derate  a m o u nt  S o me Ver y fe w  N o ne  
[ADDRESS_686790] W E E K, h o w ma n y b u m ps f ull of p us di d y o u ha v e o n y o ur  f ace?  
 E xte nsi ve   A w h ole  l ot  A l ot  A m o derate  a m o u nt  S o me Ver y fe w  N o ne  
[ADDRESS_686791] W E E K, h o w m uc h sca b bi n g fr o m y o ur faci al ac n e di d y o u  ha v e?  
 E xte nsi ve   A w h ole  l ot  A l ot  A m o derate  a m o u nt  S o me Ver y fe w  N o ne  
[ADDRESS_686792] W E E K, h o w c o ncer ne d or w orrie d wer e y o u a b o ut scarri n g fr o m y o ur f acial  ac ne?  
 e xtre mel y  ver y  m uc h  q uite  a bit  a g o o d  bit  s o me w hat  a little bit n ot at  all  
[ADDRESS_686793] W E E K, h o w oil y was y o ur facial s ki n?  
 e xtre mel y  ver y  m uc h  q uite  a bit  a g o o d  bit  s o me w hat  a little bit n ot at  all  
 
 
 
 
C o p yri g ht © 1 9 9 7 Merc k & C o., I nc.  
W hite h o use Stati o n, NJ, U S A 
Use d wit h P er missi o n  
Pr ot oc ol V 0 1 -1 2 1 A -3 0 2, I D P -1 2 1  Valea nt Researc h & De vel o p me nt  
Versi o n 4, [ADDRESS_686794] o ber 2 0 1 6  C O N FI D E N TI A L  
7 1   
 Fec h a:     
 
C uesti o n ari o s o bre l a c ali d a d de vi d a, es pecífic o al ac né  
 
  N o. de  I de ntific aci ó n:   
 
( F av or de m arc ar u n a c asill a p ar a c a d a pre g u nt a)  
 
 
de masia d o  m uc h o  m u y  basta nte  al g o  u n p oc o  na da  
       
 
 
de masia d o  m uc h o  m u y  basta nte  al g o  u n p oc o  na da  
       
 
 
de masia d o  m uc h o  m u y  basta nte  al g o  u n p oc o  na da  
       
 
 
de masia d o  m uc h o  m u y  basta nte  al g o  u n p oc o  na da  
       
 
 
de masia d o  m uc h o  m u y  basta nte  al g o  u n p oc o  na da  
       
 
 
de masia d o  m uc h o  m u y  basta nte  al g o  u n p oc o  na da  
       
 
 
de masia d o  m uc h o  m u y  basta nte  al g o  u n p oc o  na da  
       1. D ura nte la S E M A N A pasa da, ¿ q ué ta n p oc o at r acti v o( a) t e se ntiste  de bi d o al ac né d e la 
cara?  
2. D ura nte la S E M A N A pasa da, ¿ q ué ta n a ver g o nz a d o( a) te se ntiste de bi d o al ac né d e la cara?  
3. D ura nte la S E M A N A pasa da, ¿ q ué ta n ac o m pl ej a d o( a), [i nc ó m o d o(a) c o nti g o mis m o(a)], te 
se ntiste de bi d o al ac n é de la car a?  
4. D ura nte la S E M A N A pasa da, ¿ q ué ta n dis g ust a d o( a) te se ntiste p or te n er ac n é de la cara?  
5. D ura nte la S E M A N A pasa da, ¿ q ué ta n m ol est o( a) te se ntiste p or t o mar t a nt o tie m p o 
diaria me nte li m piá n d ote y trat á n d ote la cara, d e bi d o al ac né d e la cara?  
6. D ura nte la S E M A N A pasa da, ¿ q ué ta n i ns atisf ec h o( a) te se ntiste c o n t u as pect o pers o nal, 
de bi d o al ac n é de la car a?  
7. D ura nte la S E M A N A pasa da, ¿ q ué ta n i ntr a n q uil o( a) o pre oc u p a d o( a) est u viste de n o verte 
l o mej or p osi ble, de bi d o al ac né d e la cara?  
Pr ot oc ol V 0 1 -1 2 1 A -3 0 2, I D P -1 2 1  Valea nt Researc h & De vel o p me nt  
Versi o n 4, [ADDRESS_686795] o ber 2 0 1 6  C O N FI D E N TI A L  
7 2   
 ( F av or de m arc ar u n a c asill a p ar a c a d a pre g u nt a)  
 
 
de masia d o  m uc h o  m u y  basta nte  al g o  u n p oc o  na da  
       
 
 
de masia d o  m uc h o  m u y  basta nte  al g o  u n p oc o  na da  
       
 
 
de masia d o  m uc h o  m u y  basta nte  al g o  u n p oc o  na da  
       
 
 
de masia d o  m uc h o  m u y  basta nte  al g o  u n p oc o  na da  
       
 
 
de masia d o  m uc h o  m u y  basta nte  al g o  u n p oc o  na da  
       
 
 
de masia d o  m uc h o  m u y  basta nte  al g o  u n p oc o  na da  
       
 
 
 
de masia d o  m uc h o  m u y  basta nte  al g o  u n p oc o  na da  
       8. D ura nte la S E M A N A pasa da, ¿ q ué ta n i ntr a n q uil o( a) o pre oc u p a d o( a) est u viste de q ue l os 
me dica me nt os y pr o d uct os para el ac né est u viese n f u nci o na n d o l o s uficie nte me nte rá pi d o 
para eli mi nar el ac n é de l a car a?  
9. D ura nte la S E M A N A pasa da, ¿ q ué ta n m ol est o( a) te se ntiste p or la n ecesi da d de te ner 
sie m pre dis p o ni bles me dica me nt os o cr e mas para c u brir el ac né d e la cara?  
1 0. D ura nte la S E M A N A pasa da, ¿ q ué ta n ne g ati v o f ue el efect o d el ac né e n t u c o nfia nza e n ti 
mis m o(a)?  
1 1. D ura nte la S E M A N A pasa da, ¿ q ué ta n i ntr a n q uil o( a) o pre oc u p a d o( a) te se ntiste al 
c o n ocer a n ue v as pers o n as, de bi d o al ac n é de la cara?  
1 2. D ura nte la S E M A N A pasa da, ¿ q ué ta n i ntr a n q uil o( a) o pre oc u p a d o( a) te se ntiste al salir y 
estar e ntr e la ge nte, d e bi d o al ac né d e la cara?  
1 3. D ura nte la S E M A N A pasa da, ¿ q ué t a n pr o ble m átic o f ue p ar a ti s oci aliz ar c o n l as 
pers o n as, de bi d o al ac né de la cara?  
1 4. D ura nte la S E M A N A pasa da, ¿ q ué t a n pr o ble m átic o f ue p ar a ti rel aci o n arte c o n 
pers o n as del se x o o p uest o ( o del mis m o se x o, para h o m ose x uales), de bi d o al ac né d e la 
cara?  
Pr ot oc ol V 0 1 -1 2 1 A -3 0 2, I D P -1 2 1  Valea nt Researc h & De vel o p me nt  
Versi o n 4, [ADDRESS_686796] o ber 2 0 1 6  C O N FI D E N TI A L  
7 3   
 ( F av or de m arc ar u n a c asill a p ar a c a d a pre g u nt a)  
 
 
 
a b u n da ntes  u na gra n  
ca nti da d   
m uc h os  u na ca nti da d  
m o dera da   
al g u n os  m u y  
p oc os   
ni n g u n o  
       
 
 
 
a b u n da ntes  u na gra n  
ca nti da d   
m uc h os  u na ca nti da d  
m o dera da   
al g u n os  m u y  
p oc os   
ni n g u n o  
       
 
 
 
a b u n da ntes  u na gra n  
ca nti da d   
m uc has  u na ca nti da d  
m o dera da   
al g u nas  m u y  
p ocas   
ni n g u na  
       
 
 
de masia d o  m uc h o  m u y  basta nte  al g o  u n p oc o  na da  
       
 
 
de masia d o  m uc h o  m u y  basta nte  al g o  u n p oc o  na da  
       
 1 5. D ura nte la S E M A N A pasa da, ¿c uá nt os gr a n os te nías e n la cara?  
1 6. D ura nte la S E M A N A pasa da, ¿c uá nt os gr a n os i nf ect a d os te nías e n la cara?  
1 7. D ura nte la S E M A N A pasa da, ¿c uá ntas c ostr as o p ostill as (es pi [INVESTIGATOR_500784]) te nías, de bi d o al 
ac né d e la cara?  
1 8. D ura nte la S E M A N A pasa da, ¿ q ué ta n i ntr a n q uil o( a) o pre oc u p a d o( a) est u viste p or las 
marcas y o cicatrices, q u e q ue dar o n d el ac n é de la cara?  
1 9. D ura nte la S E M A N A pasa da, ¿ q ué ta n gr as os o esta ba el c utis?  